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Abstract 
Cutaneous melanoma (CM) is an aggressive neoplastic disorder of melanocytes 
accounting for 4% of skin cancers, but over 75% of skin cancer-related deaths. The 
outlook for advanced melanoma is typically poor, particularly for patients with distant 
and/or visceral metastatic disease. Although new melanoma therapies including 
vemurafenib and ipilimumab confer significant clinical benefit, accumulating evidence 
suggests that they are less effective when tumour load is high and patient 
performance status poor, as is often the case in advanced disease. New strategies 
for the early detection of sub-clinical relapsed and/or metastatic disease are 
therefore urgently required. Development of such biomarkers, combining sensitivity 
and specificity, would allow the deployment of these treatments when tumour volume 
is low thereby maximising anti-melanoma efficacy. Cancer-associated gene 
promoter methylation is recognized as an important mechanism in tumour initiation 
and progression. Exploring the epigenetic profiles of melanoma will lead to the 
generation of new strategies for molecular subtyping, discovery of diagnostic and 
prognostic biomarkers and development of novel therapeutic targets.  
 
In the present study, I have identified a panel of promising epigenetic melanoma 
biomarkers by exploiting both a systematic approach and candidate gene approach. 
Biomarkers TFPI2 and P4HA3 showed a high frequency and high level of 
methylation in melanoma cell lines. Significantly increased methylation in melanoma 
suggests a role for TFPI2 and P4HA3 as epigenetic biomarkers that can potentially 
predict poor prognosis of melanoma. Furthermore, in my work a highly significant 
correlation has been established between detection of methylated genomic DNA of 
 XV | P a g e  
 
TFPI2 and P4HA3 in melanoma patients’ sera and metastatic disease. This implies 
potential clinical utility for TFPI2 and P4HA3 as serum biomarkers for the detection 
of metastatic melanoma. In contrast, the presence of NT5E and DUSP2 methylation 
is likely to be a good prognostic biomarker for both primary melanoma and 
metastatic disease. NT5E methylation was associated with early stage melanoma 
but became undetectable when melanoma metastasis progressed to visceral sites. 
Similarly, the significantly higher methylation level of DUSP2 in primary melanomas 
than in metastatic disease implies that DUSP2 methylation may also be a biomarker 
of good prognosis in melanoma.  
  
In summary, my study proposes that epigenetic dysregulation by CpG island 
methylation of tumour-related genes TFPI2, P4HA3, NT5E and DUSP2 is important 
in melanoma development and progression and that detection of methylated DNA 
from these genes may provide novel biomarkers for predicting tumour progression 
and patient outcome. Molecular functions of these biomarkers in melanoma should 
be investigated in future work for the purpose of better understanding the biology of 
this highly aggressive tumour. Such studies may also lead to new therapeutic 
strategies for advanced melanoma. For example, antibodies to NT5E show efficacy 
in animal models of metastatic breast cancer and merit assessment in melanoma. 
Moreover, detection of circulating methylated genomic DNA from TFPI2 and P4HA3 
in patient sera may be useful for predicting prognosis and for the early diagnosis of 
metastatic disease. Given the emerging evidence that new melanoma therapeutics, 
particularly ipilimumab, are most effective when used in low volume metastatic 
disease, such epigenetic biomarkers are likely to be of value in informing the clinical 
deployment of such agents. 
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Aims 
 
The major aim of this project is to build up a portfolio of novel candidate biomarkers 
that are epigenetically dysregulated in melanoma. A systematic approach and 
candidate gene approach will be performed for identification and investigation of 
potential melanoma biomarkers. For selected genes, the following investigation will 
be performed:  
(1) Analysis of CpG island methylation status for selected genes in human 
melanoma cell lines and normal melanocytes. 
(2) Methylation profiling of selected genes in melanoma clinical samples and 
benign melanocytic naevi to examine the association between DNA 
methylation and melanoma progression. 
(3) Analysis of circulating methylated DNA in melanoma patients’ sera to 
determine the potential utility of detection of methylated genes in detection of 
metastatic melanoma. 
(4) Investigation of molecular function for candidate genes in the initiation and 
progression of melanoma. 
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Chapter 1 Introduction 
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1.1 Cutaneous Melanoma (CM) 
 
Cutaneous melanoma (CM) is an aggressive neoplastic disorder of melanocytes 
accounting for 4% of skin cancers, but over 75% of skin cancer-related deaths 
(Miller and Mihm 2006). Melanoma was probably first described in the fifth 
century B.C. by Hippocrates. The term of melanoma was first adopted in 1838 by 
Robert Carswell (Urteaga and Pack 1966). In 1840, Samuel Cooper stated 
melanoma is untreatable without early removal (Cooper 1840). This remains true 
today, with early diagnosis and surgical excision the cornerstone of treatment. 
Melanoma has a high propensity to disseminate and form metastasis at which 
point surgery is not curative. The outlook for metastatic melanoma is poor, 
particularly for patients with distant organ involvement, including liver, lung, brain 
and bones, with a median survival time of less than 12 months (Balch et al. 2009). 
This poor outcome is in large part because metastatic melanoma is intrinsically 
resistant to conventional cytotoxic agents which are the mainstay of the medical 
management of other solid tumours. The recent clinical launch of targeted anti-
melanoma agents, including Vemurafenib that targets a subset of patients 
harboring BRAF mutation and the anti-CTLA4 (Cytotoxic T-Lymphocyte Antigen 
4) antibody, ipilimumab, has improved the management of unresectable or 
metastatic melanomas (Hodi et al. 2010; Chapman et al. 2011; Robert et al. 
2011). However, despite a response rate to Vemurafenib of > 50%, the great 
majority of patients develop resistant disease within a few months and die rapidly. 
Development of new strategies for early diagnosis and more effective therapies 
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for metastatic melanomas are therefore urgently needed and are priorities in 
melanoma research.  
 
1.1.1 Epidemiology of melanoma 
 
It is estimated that the incidence of CM has doubled in the past 20 years, and the 
highest incidence is reported in Queensland, Australia (Lens and Dawes 2004; 
MacKie et al. 2009). The incidence of CM is increasing rapidly in Caucasian 
populations with approximately 13,000 new diagnoses in the UK each year 
(CRUK 2013). It was the 6th most common cancer in British males and females 
in 2010 (CRUK 2013). In Scotland, the overall incidence of CM has significantly 
increased in the last two decade, from 491 cases in 1991 to 1,202 cases in 2011 
(ISD 2011) (Figure 1-1). A disproportionately high incidence of CM is seen in 
young adults and it is now the 5th commonest cancer in persons aged 15-24 
years in the UK (North West Cancer Intelligence Service 2011). A predictive 
model has forecast that the CM rate will continue to rise to 2-3 times the current 
incidence over the next 30 years (Diffey 2004). Despite most melanoma patients 
having a favourable prognosis, those with metastatic disease especially to 
visceral sites have a poor prognosis (Balch et al. 2009). More than 2,000 patients 
died from melanoma annually in the UK between 2008 to 2010, of which 5% 
were under 40 years and more than half were less than 70 years (CRUK 2013).  
In Scotland, the mortality rate has nearly doubled in the last two decades (ISD 
2011). 
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1.1.2 Histological progression of melanoma  
 
Melanocytes are dendritic cells derived from neural crest and mostly located in 
the basal layer of epidermis, accounting for 1-2% of the total epidermal cell 
population (Jhappan et al. 2003). Being capable of producing melanin pigment, 
melanocytes influence skin and hair colour and interact with neighbouring 
keratinocytes via dendritic processes (Elder 1992). A cluster of normal 
melanocytes is called a benign naevus. Some melanocyte naevi may transform 
to the potential precursor of melanoma, the dysplastic naevi. These naevi show a 
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Figure 1-1: Incidence of melanoma diagnosed in Scotland from 1991 to 
2011, including all age groups and both sexes. 
Based on database from ISD Scotland cancer statistics (ISD 2011).
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phenotype of irregular shape, increased horizontal size and multiple colours with 
premalignant histological features (Pacheco et al. 2011). Melanomas can be 
simply categorized into radial growth phase (RGP) or vertical growth phase (VGP) 
according to their growth pattern (Rigel 2005). RGP melanoma is characterized 
by the presence of scattered melanoma cells within the epidermis (MacKie 2000). 
Inexorable proliferation discriminates RGP melanoma from benign naevi, 
although melanoma cells at this phase still show a low proliferation rate (Elder 
1992). The simultaneous presence of melanoma cells in the epidermis and 
dermis indicates VGP melanoma. During this stage, melanoma cells grow and 
invade vertically downwards to within the dermis, and have greater potential to 
disseminate to other areas of the skin or to distant organs (Miller and Mihm 2006). 
Thus, mortality rates increase significantly as melanomas progress from RGP to 
VGP. The last step of the malignant process is metastasis. Metastatic 
melanomas have a generally very poor prognosis. Melanoma with local and 
resectable disease, particular for lymph node only disease, may have an 
extended survival rate. Metastatic melanoma disseminated to distant visceral 
organs has the worst prognosis (Balch et al. 2009). 
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Figure 1-2: Melanoma progression from benign naevus to melanoma 
based on the Clark model. (Miller and Mihm 2006) 
Figure 1-3: Histopathological subtypes of primary melanoma.  
(A): Superficial spreading melanoma (SSM) (Dermatology information system). 
(B): Nodular melanoma (NM) (Dermatology information system). (C): Lentigo 
maligna melanoma (LMM) (NZ). (D) Acral lentiginous melanoma (ALM) (JANCIN 
2009).  
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1.1.3 Subtypes of CM 
 
There are four major histopathological types of cutaneous melanoma. These are 
superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma 
and acral lentiginous melanoma (MacKie 2000) (Figure 1-3). Superficial 
spreading melanoma accounts for approximately 70% of melanoma incidence in 
white race melanoma populations and correlates with the number and size of 
pre-existing melanocytic naevi. Nodular melanoma and lentigo maligna 
melanoma occur preferentially in middle and old age, respectively. The peak 
incidence of acral lentiginous melanoma is seen in dark-skinned populations 
(Lens 2008), and the predominant sites for this type of melanoma are on toes 
and fingers.  
1.1.4 Staging system of melanoma 
 
Current melanoma staging is based on the American Joint Committee on Cancer 
(AJCC) staging system which uses the TNM (Tumour Node Metastasis) 
classification. The AJCC melanoma staging system, revised in 2008, includes a 
number of clinico-pathological parameters for melanoma classification: Breslow 
thickness (tumour depth), presence of ulceration, mitotic rate, lymph node 
metastasis, and the site of distant metastases (Balch et al. 2004) (Figure 1-4 and 
Table 1-1). The revised AJCC database was based on an expansion of the 
patient sample size to 50,000 from 17 major melanoma centres on three 
continents (Soong et al. 2010). 
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Breslow thickness, ulceration and the mitotic rate are the dominant determinants 
of risk of metastasis for localized melanomas. Breslow thickness refers to the 
absolute depth of melanoma from the uppermost layer of epidermis to the 
deepest adjacent melanoma cells at the base of the tumour (Breslow 1979). 
Whilst thin lesions (Breslow thickness <1mm, T1) are almost always cured by 
surgical excision (5-year survival of over 95%), thicker tumours (Breslow >4mm, 
T4) have a significant risk of metastatic spread and a 5-year survival of less than 
50% (Balch et al. 2009). Most invasive melanomas presenting in the UK are less 
than 2mm and can be excised completely without further treatment. Ulceration 
describes a histological situation where there is an absence of intact dermis 
overlying the primary melanoma, and is associated with a worse prognosis for 
melanomas of an equivalent thickness without ulceration (Dickson and 
Gershenwald 2011). It is mostly present in thick melanomas, despite being an 
independent predictor of melanoma patient outcome. Interestingly, T3 non-
ulcerated melanomas and T2 ulcerated melanomas have shown a similar 5 year 
survival, suggesting that the presence of ulceration upgrades the melanoma 
prognosis to a more advanced stage. Mitotic rate was intensively studied before 
being incorporated into the latest version of AJCC as a new independent 
prognostic factor for primary melanoma (Balch et al. 2009). Mitotic rate is a 
measure of proliferation, and is particularly useful for predicting outcome of 
vertical growth phase melanomas (Elder et al. 2005). Being equally useful as 
Breslow thickness and ulceration in predicting melanoma patient survival and 
clinical outcome, the mitotic rate has replaced Clark’s level of invasion in the new 
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staging system. In fact, it is one of the most reliable prognostic predictors of 
melanoma, and its assessment can be easily performed during routine 
histopathological examination (Mervic 2012). Two cohort studies involving 3,661 
and 1,284 melanoma patients carried out in Australia and UK, respectively, have 
shown evidence for the higher prognostic significance of the mitotic rate over 
many other variables (Retsas et al. 2002; Azzola et al. 2003). 
 
Approximately 20% of patients will develop spread of melanoma beyond the skin 
(metastasis). For melanomas with a higher potential to metastasize, sentinel 
lymph node biopsy (SLNB) is undertaken to investigate whether there is 
dissemination of melanoma into lymph nodes. SLNB safely and reliably stages 
regional lymph nodes with minimal invasiveness (Sondak et al. 2013). Five year 
survival rates decrease from 70% to 39% when the number of lymph node 
metastases increases to three. SLNB is an important prognostic tool in 
melanoma staging, but it’s therapeutic value remains controversial (Thompson 
and Shaw 2007).   
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Figure 1-4: Staging system of melanoma based on 2008 AJCC staging system.  
(Nading et al. 2010) 
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Patients with disseminated melanoma have poor survival and outcome. 
Anatomical site and number of metastases are the most informative prognostic 
factors for this patient population. For those with stage IV melanoma, non-
pulmonary visceral metastasis has the poorest one year survival of 33%, 
whereas distant skin, subcutaneous and lymph node metastasis has a relatively 
better one year survival of 62% (Dickson and Gershenwald 2011). In addition to 
metastasis, elevated serum lactate dehydrogenase (LDH) also acts as a most 
unfavourable prognostic parameter that predicts poor patient outcome. It is an 
independent indicator for patients at Stage IV when their serum LDH level rises 
above the upper limits of normal, regardless of the sites and the numbers of 
distant metastases (Neuman et al. 2008). The mechanism of increased LDH 
levels in serum is still unclear. The hypoxic environment of tumour cells may be a 
cause, as melanoma cell necrosis and LDH release occur when insufficient blood 
is supplied to the tumour (Agarwala et al. 2009).   
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Table 1-1: Melanoma TNM classification based on 2008 AJCC staging system 
(Nading et al. 2010). 
 
Regional 
Lymph Nodes 
(N) 
No. of Metastatic Nodes Nodal Metastatic Mass 
N classification 
 N1 1  a. Micrometastasis       b. Macrometastasis  
 N2 2-3  
a. Micrometastasis       b. Macrometastasis   
c. In transit met(s)/ satellite(s) without 
metastatic nodes 
 N3 
4 or more metastatic nodes, or matted nodes,  or in transit met(s)/satellite(s) 
with metastatic node(s) 
 NX 
Patients in whom the regional nodes cannot be assessed  
(eg, previously removed for another reason) 
 N0 No regional metastases detected 
Distant 
Metastasis (M) 
Site Serum LDH 
M classification 
 M1a 
Distant skin, subcutaneous, or 
nodal metastasis 
Normal 
 M1b Lung metastases Normal 
 M1c All other visceral metastases Normal 
 Any distant metastases Elevated 
 M0 No detectable evidence of distant metastases 
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1.1.5 Risk factors for melanoma 
 
The carcinogenesis of cancers is multifactorial, with a contribution from both 
environmental and intrinsic factors. Likewise, cutaneous melanoma in 
Caucasians is predominantly caused by environmental factors, particularly 
ultraviolet radiation (UVR) exposure causing genetic and epigenetic changes, 
and familial predisposition (Jhappan et al. 2003).  
 
1.1.5.1 Environmental risk factor  
 
It is widely accepted that UV radiation is the leading environmental factor for 
melanomagenesis, and is responsible for 80% of melanoma cases arising on 
skin areas with intermittent sun exposure (Garbe and Leiter 2009). A meta-
analysis of 57 epidemiological studies has identified intermittent exposure and 
sunburn history as essential risk factors for melanoma, despite the heterogeneity 
across the studies. Chronic sun exposure, on the other hand, is associated with 
the elderly patient population who developed lentigo maligna melanomas on the 
head and neck (Whiteman et al. 2006). Additionally, the most common mutation 
in melanoma, BRAFV600E mutation, is correlated with intermittent sun exposure 
history (Davies et al. 2002; Maldonado et al. 2003). Chronic sun exposure, in 
contrast, has not shown a significant correlation with melanoma incidence, or the 
most common melanoma mutation of BRAFV600E (Curtin et al. 2005). The other 
forms of UV radiation, such as artificial sunbeds, may also contribute to the 
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melanomagenesis (Swerdlow and Weinstock 1998; MacKie et al. 2009). A 
significant contribution of cosmetic sunbeds to melanoma risk has been 
confirmed by the International Agency for Research on Cancer (IARC) in a meta-
analysis of 19 studies involving 7,355 melanoma patients (Erratum 2007). 
 
Based on wavelength, UVR is comprised of three bands: UVA (315-400nm), 
UVB (280-315nm), and UVC (100-280nm) (Hockberger 2002). As the ozone 
layer in the atmosphere absorbs wavelengths shorter than 310nm, 90% of UVA 
and only 5-10% of UVB will reach the surface of the earth, with UVC and most of 
the UVB being absorbed (Kanavy and Gerstenblith 2011). UVA and UVB have 
been shown to induce melanomas in different animal models, respectively 
(Setlow et al. 1993; Ley 1997; Bennett 2008). However, the contribution of UVA 
and UVB in melanoma development is difficult to quantify, and their individual 
molecular contributions to melanoma progression are still not fully understood.  
 
UVA was initially considered harmless because it is poorly absorbed by DNA. 
However, accumulating evidence suggests that UVA may indirectly cause DNA 
changes through oxidative damage. One piece of evidence is that use of artificial 
sunbeds, which predominantly emit UVA, results in increased risk of developing 
melanoma (Erratum 2007). Epidemiological studies have also revealed an 
association with UVA exposure and melanoma mortality rates (Garland et al. 
2003). Larger wavelength UVA can penetrate deep into the dermis interacting 
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with melanocytes within naevi and influencing the tumour microenvironment 
(Swalwell et al. 2012). High UVA doses cause intracellular oxidative stress by 
producing excessive reactive oxygen species (ROS) which generate highly 
mutagenic substances. The production of these mutagenic reactions will 
subsequently induce DNA damage through a variety of mechanisms, including 
base substitutions of G–T and G-C, DNA single-strand break, and carcinogenic 
events in epidermal keratinocytes (Ravanat et al. 2001; Costin and Hearing 2007; 
Wischermann et al. 2008). The association between UVA radiation and BRAF 
mutation V600E is still awaiting to be defined, although there is evidence 
suggesting UVA may activate the BRAF-MAKP pathway (Sekulic et al. 2010). 
 
Despite limited penetration beyond the epidermis (Hoffmann et al. 2000), UVB 
can directly damage DNA via production of pre-mutagenic lesions of cyclobutane 
pyrimidine dimers (CPD) and 6-4 photoproducts (6-4 PPs), and consequently 
cause C to T, or CC to TT transversion mutations (Besaratinia and Pfeifer 2008). 
These ‘UVB signature’ mutations are involved in multiple genetic processes, 
such as cell cycle dysregulation, apoptosis, and DNA repair, as well as 
epigenetic change, however, they are not related to BRAF mutation V600E in 
melanomas (Tommasi et al. 1997; Sarasin 1999). UVB-induced 
immunosuppression may be an additional mechanism in melanomagenesis  
(Schwarz 2008). 
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The mechanisms by which UVA and UVB drive tumourigenesis are still 
incompletely understood. In addition to genetic changes, oxidative stress may 
play a role in modulating DNA methylation in human cancers, including 
melanoma (Campos et al. 2007; Franco et al. 2008; Ziech et al. 2011). Other 
extrinsic risk factors, such as exposure to phototoxic drugs or cosmetic products 
which contain carcinogens, may also impact on the initiation and progression of 
melanomas (Volkovova et al. 2012). 
 
Melanocytes protect skin from extrinsic stress through skin pigmentation. They 
synthesize and transfer melanin pigments to keratinocytes, their partner in the 
‘epidermal melanin unit’ through dendritic processes. Melanin is a redox 
biopolymeric pigment synthesized in organelles called melanosomes and 
composed of eumelanin (black/brown) or phaeomelanin (red/yellow) (Hearing 
1999). The amount and composition of eumelanin and phaeomelanin (red/yellow) 
pigments is variable across different population ethnicity, and their skin colour is 
determined accordingly (Sulaimon and Kitchell 2003). Melanin works as a photo-
protective barrier by scattering and reducing the penetration of UV radiation 
through epidermis (Kaidbey et al. 1979). Phaeomelanin is less functional than 
eumelanin in terms of capability of shielding UVR (Hill and Hill 2000). Therefore, 
dark-skinned people with more eumelanin pigment generally have lower risk of 
CM than fair-skinned people (Gloster and Neal 2006; Brenner and Hearing 2008). 
Comparatively, populations that produce phaeomelanin with the phenotype of 
pale skin, red hair, freckles, are much more prone to melanomagenesis. In 
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addition to poor UV reflection, phaeomelanin could act as a photosensitizer to 
UVR due to ROS induction, thereby increasing tumourigenesis (Korytowski et al. 
1987; Mitra et al. 2012). 
 
1.1.5.2 Genetic risk factors  
 
Family history is a significant genetic risk factor for melanoma. It is estimated that 
5% to 12% of melanoma incidence has a hereditary history of melanoma in 
multiple (≥3) first-degree relatives and as much as a 70 fold increased risk of 
developing a melanoma (Goldstein and Tucker 2001). This type of melanoma is 
often diagnosed at an early age and is often thinner than non-familial melanomas. 
Linkage between familial melanomas and germline mutations of melanoma 
predisposition genes has been well addressed. There are both high penetrance 
melanoma susceptibility genes, such as tumour suppressor gene CDKN2A 
(cyclin-dependent kinase inhibitor 2A) and CDK4 (cyclin-dependent kinase 4), 
and low penetrance melanoma susceptibility alleles, such as melanocortin-1 
receptor (MCIR), agouti stimulating protein (ASIP) and tyrosinase (TYR) 
(Hayward 2003; Gudbjartsson et al. 2008; Raimondi et al. 2008). Genetic 
alterations of CDKN2A have been identified in approximately 40% of melanoma-
prone families (Goldstein et al. 2006). There is evidence that such mutations in 
CDKN2A are influenced by UVR and contribute to the production of ROS 
(Jenkins et al. 2011). Germline mutations of CDK4 are relatively less common 
and only present in 2-3% of melanoma families (Goldstein et al. 2006). Low 
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penetrance melanoma susceptibility genes MCIR, ASIP and TYR are involved in 
the pigmentation pathway. Variants of these genes show a significantly increased 
melanoma risk (Gudbjartsson et al. 2008; Raimondi et al. 2008), and associate 
with melanoma risk factors including fair skin, poor tanning response, red or 
blonde hair and freckles (Bliss et al. 1995). The co-existence of germline variants 
of MC1R with CDKN2A or BRAF mutations have also been reported to increase 
melanoma risk (Landi et al. 2006; Fargnoli et al. 2008; Pastorino et al. 2008). 
Establishment of the significance for these melanoma susceptibility genes should 
enable genetic testing in populations with strong family history of melanoma  
(Kasparian et al. 2007). 
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1.2 Genetic and epigenetic aberrations of melanoma 
 
Progression from normal melanocyte to benign and dysplastic melanocytic 
naevus, to horizontal and vertical growth phase primary CM and, ultimately, to 
metastatic CM, reflects the accumulation of genetic and epigenetic changes in 
critical genes and pathways that control functions such as proliferation, 
differentiation, motility and apoptosis. These critical genes function as oncogenes 
(typically amplified or upregulated in cancer), or as tumour suppressor genes 
(deleted, mutated or downregulated in cancer). Exploring the genetic and 
epigenetic profiles of melanoma will help us to better understand the molecular 
mechanisms underlying the initiation and progression of this lethal malignant 
disease, in turn leading to the generation of new strategies for molecular 
subtyping, discovery of diagnostic and prognostic biomarkers and development 
of novel therapeutic targets.   
 
1.2.1 Genetic dysregulation of melanoma 
 
Multiple genetic events including gene mutation, chromosomal deletion, 
amplifications and translocations, may contribute to the molecular pathogenesis 
of melanoma (van Doorn et al. 2005). Dysregulation of several major signalling 
pathways has been shown to be of particular significance in the development and 
progression of melanoma: RAS-RAF-MEK-ERK-MAP, MITF signalling, CDKN2A 
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signalling, PTEN/AKT pathway, and p53 signalling (Miller and Mihm 2006; Dahl 
and Guldberg 2007; Palmieri et al. 2009).  
 
1.2.1.1 RAS-RAF-MEK-ERK-MAP Kinase Pathway 
 
Somatic mutations harboured by the components of RAS-RAF-MEK-ERK-
Mitogen-activated protein (MAP) kinase pathway occur frequently in human 
cancer. Activating mutation in the gene encoding the serine/threonine protein 
kinase BRAF (v-raf murine sarcoma viral oncogene homolog B1) was carried by 
a high percentage of melanomas (40-60%), including a predominant form of a 
substitution of valine by glutamic at amino acid position of 599 (V600E), which 
accounts for approximately 90% of BRAF mutation (Davies et al. 2002; Dahl and 
Guldberg 2007; Flaherty et al. 2010). Interestingly, BRAFV600E mutation also 
occurs at a high frequency in benign naevi, with induction of senescence and 
triggers the activation of MAPK (Pollock et al. 2003). Additional molecular 
alterations are therefore necessarily required for the malignant switch from 
melanocyte to melanoma. For example, combination of BRAFV600E mutation 
and inactivation of tumour suppressor gene p53 or p16INK4a triggers 
melanomagenesis in vivo (Patton et al. 2005; Dankort et al. 2007). Another 
frequently mutated member of this pathway is NRAS, accounting for 
approximately 10-20% melanomas that are not BRAF mutated (Albino et al. 1989; 
Davies et al. 2002; Curtin et al. 2005). This high frequency of NRAS and BRAF 
mutations underscores the importance of activation of the MAPK pathway for 
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melanomagenesis and reveals their potential clinical utility as therapeutic targets 
for melanoma. The significance of treatments targeting the MAPK pathway will 
be discussed.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1- 5: Schematic of MAPK signalling pathway.  
BRAF600E mutation activates the cell proliferation via increasing activity of MAPK 
pathway. BRAF mutation inhibitor Vemurafenib blocks the signal transduction of MAPK 
pathway. 
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1.2.1.2 MITF 
 
Microphthalmia-associated transcription (MITF) is known as a ‘master regulator’ 
of melanocytic activities, including development, differentiation, cell survival and 
proliferation. Increased level of amplified MITF from melanocytes to primary 
melanomas and again to metastases identified by a microarray analysis has 
characterised MITF to be an oncogene (Hemesath et al. 1994; McGill et al. 2002; 
Du et al. 2004; Carreira et al. 2005; Loercher et al. 2005). A novel germline 
mutation of MITF recently identified in two independent studies suggested the 
association of MITF with familial melanoma (Bertolotto et al. 2011; Yokoyama et 
al. 2011). However, MITF acts as both a promoter and suppressor of cell 
proliferation when crosstalking with different pathways. It can drive cell 
proliferation by interacting with cell cycle regulator CDK2 (Du et al. 2004)  or  
cause cell growth arrest by activating p14ARF (Loercher et al. 2005) or p21 
(Carreira et al. 2005). MITF also associates with the apoptosis pathway by 
regulating apoptosis inhibitor BCL2 (McGill et al. 2002). MITF is a potential 
clinical target for assessing chemoresistance because reduced MITF activity 
increase the sensitivity of melanoma cells to chemotherapy (Garraway et al. 
2005). 
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1.2.1.3 CDKN2A signalling 
 
The CDKN2A locus, which encodes two tumour suppressor genes p16INK4A 
and p14ARF on chromosome 9p21 (Quelle et al. 1995) is frequently inactivated 
in melanoma (Curtin et al. 2005; Hodis et al. 2012). p16INK4A regulates the cell 
cycle transition at G1-S checkpoints by inhibiting activity of cyclin-dependent 
kinase 4 (CDK4) (Serrano et al. 1996). Dysregulation of p16INK4A by genetic 
alteration including somatic mutations (Hayward 2003) and epigenetic alteration 
of aberrant methylation have been reported in melanoma (Jonsson et al. 2010). 
Inactivation of p16INK4A by these alterations causes genetic instability of 
melanocytes (Fung et al. 2013) and leads to susceptibility of melanocytes to 
cellular oxidative stress (Jenkins et al. 2011), implying a critical role for 
p16INK4A in the initiation of melanomagenesis. Inactivation of p16INK4A will 
potentially abrogate senescence in cancer (Bennett 2008) and increased 
telomerase activity induced by inactive p16INK4A. Telomere shortening is a 
crucial mechanism for induction of replicative senescence. Being present in 
tumours, the enzyme telomerase catalyses the extension of telomeres and 
prevents cellular senescence. Telomerase activity increases with  tumour 
progression from early stage primary melanoma to metastatic melanomas 
(Ramirez et al. 1999). p14ARF facilitates the stabilization of p53 by interacting 
with MDM2. Inactive p14ARF in melanoma therefore may be a mechanism that 
indirectly downregulates p53 (Freedberg et al. 2008). 
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1.2.1.4 PTEN/AKT signalling  
 
PTEN (phosphatase and tensin homolog) is a putative tumour suppressor gene 
dysregulated in human cancers. In melanoma, expression of PTEN is often 
reduced or lost due to genetic deletions or mutations (Tsao et al. 1998; Celebi et 
al. 2000; Reifenberger et al. 2000; Goel et al. 2006). More than 100 genetic 
alterations of PTEN have been identified in melanomas, including three genetic 
changes discovered in both melanoma cell lines and melanoma tissues 
(Aguissa-Toure and Li 2012). Along with these genetic changes, other molecular 
mechanisms such as DNA methylation also contribute to the inactivation of 
PTEN in melanoma (Mirmohammadsadegh et al. 2006; Lahtz et al. 2010). 
Increased expression of AKT, the negative downstream mediator of PTEN has 
also been reported in melanoma (Dai et al. 2005). PTEN/AKT pathway together 
with downstream targets such as BAD (Li et al. 2003) and NFKB (Dhawan et al. 
2002) regulates a number of critical cancerous activities including cell 
proliferation, apoptosis, migration, and metastasis in melanoma 
(Madhunapantula and Robertson 2009). Moreover, PTEN in the context of MAPK 
pathway upregulation clearly makes a contribution to the development and 
progression of melanoma, as well as drug sensitivity and efficacy of MAPK 
pathway components inhibitors (Tsao et al. 2004; Nogueira et al. 2010; Byron et 
al. 2012; Vredeveld et al. 2012; Nathanson et al. 2013).  
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1.2.1.5 p53 signalling 
 
p53 has been described as the ‘guardian of the genome’ that regulates multiple 
tumour-related signalling pathways in response to stress, including apoptosis, 
DNA repair and cell cycle arrest (Vousden 2006). It is frequently mutated in 
human cancers, and has been pivotal to our understanding of the mechanisms of 
tumourigenesis. It is also an attractive target for new anticancer strategies. 
However, p53 is rarely mutated in melanoma and most melanomas sustain a 
high expression level of the wild-type form (Bartek et al. 1991; Albino et al. 1994; 
Sparrow et al. 1995; Gwosdz et al. 2006). Nonetheless, accumulating evidence 
suggests an important role for p53 and the p53 pathway in melanomagenesis. 
For example, co-existence of inactive p53 and RAS or RAF mutations in animal 
models can trigger melanoma formation (Bardeesy et al. 2001; Dovey et al. 2009; 
Goel et al. 2009). Diverse mechanisms of p53 pathway disruption in melanomas 
have also been reported, including overexpression of MDM2 (Muthusamy et al. 
2006) and MDM4 (Gembarska et al. 2012) which degrades p53 via ubiquitination, 
as well as dysregulation of p53 responsive targets in apoptosis and cell cycle 
pathways (Avery-Kiejda et al. 2011), such as PTEN (Karst et al. 2005) and 
APARF-1 (Soengas et al. 2001). Additionally, two antagonistic isoforms of p53 
and p53 regulated microRNA may also contribute to the regulation of the whole 
pathway, respectively (Hermeking 2007; Avery-Kiejda et al. 2008). 
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1.2.2 Targeted therapies for melanoma 
 
Minimal improvement in the medical management of advanced melanoma has 
been made until very recently, with only the U.S. Food and Drug Administration 
(FDA) approved dacarbazine and interleukin 2 (IL-2) available as conventional 
therapy, both of which have unsatisfactory efficacy, with low patient response 
rates (Jang and Atkins 2013). However, this situation has changed remarkably 
with the introduction of targeted treatments in the last few years (Flaherty et al. 
2010; Chapman et al. 2011; Flaherty et al. 2012; Hauschild et al. 2012; Long et 
al. 2012; administration 2013). Vemurafenib (PLX-4032), an inhibitor targeting 
the most common mutant form of BRAF in melanoma (V600E) (Figure 1-5), has 
significantly improved the management of stage 3C and stage 4 melanomas that 
harbour BRAFV600E mutation (Flaherty et al. 2010; Chapman et al. 2011). 
BRAFV600E alters the orientation of the αC helix and this enables vemurafenib 
to bind to V600E mutation, but not to wild type BRAF (Tsai et al. 2008). In a 
phase III BRIM (BRAF inhibitor in Melanoma) study (Chapman et al. 2011), 
Vemurafenib-treated patients with disseminated melanoma showed significantly 
improved 6-month overall survival (84%) compared with those treated with 
standard chemotherapy dacarbazine (64%). However, this new treatment only 
increased progression-free survival (PFS) by a few months (median PFS 5.3 
months for vemurafenib versus 1.6 months for dacarbazine). Notwithstanding this 
evidence of clinical efficacy, it is clear that the majority of patients develop 
relapsed disease after a few months of therapy and the prognosis for patients 
with a large tumour burden remains poor (Flaherty et al. 2010). Relapsed 
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disease is probably because melanoma cells bypass inhibition of BRAF mutation 
and pursue proliferation through other associated pathways such as PI3K/AKT 
pathway and mTOR pathway (Britten 2013). Therefore, vemurafenib may show 
superior efficacy if metastatic disease could be detected earlier and therapy 
initiated with lower tumour volumes, because smaller volume tumours have less 
genetic and epigenetic diversity and is therefore less able to evolve drug 
resistance. In attempts to improve the efficacy of targeted therapy, dual therapy 
with the second generation BRAFV600E inhibitor, dabrafenib (Hauschild et al. 
2012; Long et al. 2012) and the MEK inhibitor, trametinib (Flaherty et al. 2012)  
(both agents have recently been approved by FDA in 2013 for metastatic and 
unresectable melanoma) has been trialled and the combination shows markedly 
increased efficacy compared to dabrafenib alone (Ballantyne and Garnock-Jones 
2013).  
 
Ipilimumab is an immune-modulatory treatment for advanced melanoma that was 
approved by the FDA in 2011. It is a monoclonal antibody (Britten 2013) that 
specifically inhibits the activity of a negative regulator of T cells, cytotoxic T-
lymphocyte-associated antigen 4 (CTLA-4) (Pardoll 2012). Ipilimumab 
significantly improved overall survival (OS) in comparison to the cancer vaccine 
glycoprotein (gp) 100 and when combined with dacarbazine compared to 
dacarbazine alone (Hodi et al. 2010; Robert et al. 2011). Autoimmune toxicities 
of ipilimumab remain a major concern, but these can be managed medically to 
allow maintenance of dose density and dose intensity. 
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1.2.3 Epigenetic dysregulation of melanoma 
       
‘Epigenetics’ refers to heritable changes in gene expression without alterations in 
the primary DNA sequence, providing an additional layer of gene regulation 
through transcriptional control (Holliday 1987). Epigenetic regulation is 
functionally pivotal for numerous biological processes, including embryonic 
development, cell growth, chromosome stability maintenance and human 
diseases, including cancer (Lopez-Serra and Esteller 2008). The pathogenic 
effects of abnormal epigenetic changes have been extensively investigated, 
particularly in neoplasia. These come about by biochemical modifications such 
as methylation and acetylation, either of the DNA itself, or of the associated 
histone proteins (Gal-Yam et al. 2008). DNA methylation is the best-
characterized epigenetic signature and has been extensively studied in human 
cancer.      
 
1.2.3.1 DNA methylation  
 
DNA methylation occurs exclusively on cytosine residues within cytosine-guanine 
dinucleotides (CpG dinucleotides) (Lopez et al. 2009). This biological process is 
catalysed by a family of methyltransferases which transfer a methyl group from S-
adenosyl-methionine (SAM) to the 5-carbon of the cytosine ring (Herman and 
Baylin 2003; Foulks et al. 2012) (Figure 1-5). CpG dinucleotides are 
concentrated in short CpG rich regions, named CpG islands, which are 
preferentially located at the 5’ end of genes and occupy 50%-70% of human 
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gene promoters (Bird 1986). Whilst most CpG sites outside of CpG islands in the 
genome are methylated, the majority of CpGs in CpG islands usually remain 
unmethylated during development and in normal human tissues (Eckhardt et al. 
2006). CpG island methylation in normal cells is the main mechanism for gene 
silencing on the inactive X chromosome and for a process called genomic 
imprinting (Wong et al. 1999). Genomic imprinting can involve either DNA 
methylation or histone modulation with resultant monoallelic inheritance in a 
parent-of-origin-specific manner (Reik and Walter 2001). These methylation 
phenomena in normal tissues are essential for normal development and 
reprogramming of embryogenesis (Reik et al. 2001; Kim et al. 2009). Genomic 
imprinting may also ensure transposable elements remain epigenetically silenced 
to maintain genome integrity and one hypothesis for the origin of imprinting 
centres on the need to silence genes inserted into the genome by viruses 
(Barlow 1993). Aberrant DNA methylation is frequently detected in human 
cancers, particularly for those cancer-associated genes that are ubiquitously 
genetically altered in cancers, implying that DNA methylation is a hallmark of 
cancer, equally as important as genetic modifications of DNA (Esteller 2007). 
Human cancers undergo two major mechanisms of aberrant DNA methylation: 
hypermethylation and hypomethylation. Hypermethylation is a process to gain 
methylation which usually takes place within the promoter region of tumour 
suppressor genes leading to gene inactivation and promotion of tumourigenesis. 
Two suggested mechanisms explaining gene silencing by DNA methylation are 
inhibition of transcription factor binding to its recognised cognate sequence, and 
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recruitment of co-suppressors after methyl-binding proteins anchor to methylated 
DNA (Klose and Bird 2006). Methylation-dependent gene silencing is a major 
event in the onset of many cancers interacting with the cell cycle, apoptosis, cell 
adhesion, and angiogenesis (Herman and Baylin 2003). The contribution of DNA 
hypermethylation to metastasis is not fully understood, but a possible correlation 
has been suggested by increasing DNA methylation in parallel with tumour 
progression to metastasis (Rodenhiser 2009). DNA hypermethylation is not 
restricted to gene promoters, but can also occur in other areas including the gene 
body or the CpG shore (Maunakea et al. 2010; Hansen et al. 2011). Besides 
protein coding genes, tumour suppressors like non-coding RNA (micro-RNA) are 
also influenced by expression-associated DNA methylation in cancers with 
functional significance (Lujambio et al. 2008; Berdasco and Esteller 2010). On 
the other hand, the presence of global hypomethylation (loss of methylation) in 
DNA repetitive sequences may contribute to the re-expression of normally silent 
harmful viral genes and oncogenes, with loss of methylation promoting hyper-
proliferation and chromosomal instability (Esteller 2008). Consequently, hyper- or 
hypomethylation of DNA, or both are likely to drive tumour development (Lopez 
et al. 2009). Recent discovery of a new modified form of methylation, 5-
hydroxymethyl cytosine (5hmc), has added further complexity. However, despite 
its presence in embryonic stem cells (Kriaucionis and Heintz 2009), 5hmc is likely 
to be absent in several human cancers (Haffner et al. 2011; Yang et al. 2013), 
including melanoma (Lian et al. 2012), suggesting in this investigation it is not 
necessary to distinguish the two forms of 5’ methylcytosine (5mc) and 5hmc. 
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Figure 1-6: Schematic of DNA methylation and regulation of gene expression by 
DNA methylation.  
(A): Biological conversion of cytosine to 5mc by methyltransferase. (B): DNA methylation 
transcriptionally regulates gene expression. Hypermethylation (gain of methylation) should 
correlate with reduced gene expression whilst hypomethylation (loss of methylation) 
correlates with increased gene expression. 
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1.2.3.2 DNA methylation in melanoma 
 
Similar to most other human cancers, melanoma is subject to considerable 
epigenetic dysregulation, with a large number of genes being transcriptionally 
downregulated by DNA hypermethylation. Approximately 100 such genes have 
been found to be hypermethylated in melanoma (listed in Table 1-2) 
(Rothhammer and Bosserhoff 2007; Liu et al. 2008; Howell et al. 2009; Liu et al. 
2009; van den Hurk et al. 2012), including putative tumour suppressors that are 
also genetically modified in melanoma, such as p16INK4, p14ARF and PTEN, 
suggesting that DNA methylation can cooperate with genetic changes, such as 
gene mutations, and further promote tumourigenicity. In addition, genes such as 
MGMT, RASSF1A and E-cadherin which have a high frequency of methylation in 
other human cancers are also methylated in melanoma (Esteller 2008). 
Importantly, many hypermethylated genes in melanoma are components of 
critical cancer-related pathways, with representative examples being APC in the 
WNT pathway, DAPK and APAF1 in the apoptosis pathway and TFPI2 in tumour 
invasion and metastasis (Soengas et al. 2001; van den Hurk et al. 2012), 
illustrating the indispensable role played by epigenetic dysregulation in concert 
with genetic changes during tumour development and progression. However, due 
to the unique biology of melanoma, a large number of additional epigenetically 
regulated genes undoubtedly still await identification and characterization.  
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Table 1-2:  Hypermethylated genes identified in melanoma tissues. 
(Rothhammer and Bosserhoff 2007; Liu et al. 2008; Howell et al. 2009; Liu et al. 
2009; van den Hurk et al. 2012) 
Functions Gene symbols 
Apoptosis 
APAF1, ASC, DAPK, CASP8, HSPB1, p73, PIRIN, PYCARD, RARB 
(Haugen et al. 2004), SFN, TIMP3, TRAIL 
Cell proliferation 
CDH1, CDKN1B, CDKN1C, CDKN2A, CSK, DDIT4L, DNAJC15, 
EBP1, ERα, ET2, GDF15, IGFBP7, p14
ARF
, p16
INK4
, p73, PCNA, PI5, 
PRDX2, RARB (Haugen et al. 2004), RASSF1A, S100A1, SFN, 
TIMP1, TSP1 
Migration and invasion BST2, CDH1, CSK, PI5, PIRIN 
Cell adhesion CDH8, IGFBP7, ITGAE, ITGB8, THBS1, TIMP1, TIMP3 
Immune response 
CASP8, CCR7, CD10/MME, DPPIV, CSK, GDF15, IFIT1, LXN, 
MT2A, MX1, PTGS2, PYCARD, QPCT, SFN, SOCS1, SOCS2, 
SOCS3, SYK, TIMP1 
Angiogenesis TFPI2, TIMP1, TIMP3, WFDC1(McAlhany et al. 2003) 
Senescence BST2, p16
INK4
 
Metastasis CDH1, HSPB1, PI5, PTGS2, TCF21(Arab et al. 2011), TM 
Metabolism CASP8, CYBA, LDHB, MTAP，PRDX2, 3-OST-2 
Wnt pathway APC, FRZB, WIF1 
TGF-beta pathway CSNK1G2, GDF15, RUNX3, THBS1, WFDC1(McAlhany et al. 2003) 
MAPK pathway ISGF3G, RGS3, TSP1 
p53 signalling MGMT, THBS1, TRAIL 
PTEN/AKT pathway PTEN 
Unknown in cancers 
HOXB13, KR18, LRRC1, NPM2, RARRES1, PDLIM4, RPL37A, TM, 
TRP1 
Gene function was searched from Gene Cards Website (Database)   
 34 | P a g e  
 
1.2.3.3 Methodologies for DNA methylation analysis 
 
Accompanying the fast moving field of DNA methylation, with ever expanding 
complexities involving isoforms, transcription-specific CpG sites within promoter 
regions and other areas, and methylation in microRNA, the development and 
improvement of DNA methylation investigative methodologies has also rapidly 
evolved (Laird 2010). Methylation analysis is mainly based on three strategies: 
sodium bisulfilte conversion, affinity enrichment and methylation-Sensitive 
Restriction Enzymes (MSREs) digestion (Ndlovu et al. 2011). Bisulfite conversion 
is a particularly useful technique enabling 5mc to be distinguished from cytosine 
by converting unmethylated cytosine to uracil whilst methylated cytosine remains 
unchanged. This provides a platform for many other techniques, including PCR-
based, methylation-specific PCR (MSP), bisulfite sequencing and 
pyrosequencing, and large-scale, extensive coverage methods like deep 
sequencing, Illumina methylation microarray and genome-wide bisulfite 
sequencing (Laird 2010).  
 
Simpler techniques such as MSP and pyrosequencing are relatively more 
practical in terms of time, cost and analysis. Pyrosequencing quantitatively 
measures DNA methylation at single CpG dinucleotide resolution with high 
accuracy, sensitivity and reproducibility (Dupont et al. 2004). The basic principle 
of this protocol is detection of the release of pyrophosphate generated during the 
synthesis of double stranded DNA when using single stranded DNA as template 
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(Ronaghi 2001). This sequencing technique has shown promising results in the 
detection of multiple methylated CpG islands in some tumour types, including 
melanoma and head and neck cancer (Gal-Yam et al. 2008; Shaw et al. 2008; 
Ugurel et al. 2009). MSP is based on gel electrophoresis by which methylated 
cytosines in a defined DNA fragment are directly displayed (Hamilton 2011). For 
the purpose of easy performance, analysis and interpretation, pyrosequencing 
and MSP will be explored in this thesis, with the aim of identifying potential 
epigenetically silenced biomarkers of melanoma. However, both these two 
protocols only allow evaluation of methylation within a limited length of DNA 
sequence, suggesting they are more applicable for methylation validation than for 
primary identification of methylated candidates. For unbiased analysis, a large-
scale methylation analysis such as genome-wide methylation microarray is 
required. Currently, the widely used Illumina methylation microarray provides 
high-throughout, high-resolution, and more comprehensive methylation profiles, 
but simultaneously requires good quality starting materials, and significant 
bioinformatics expertise for the analysis (Bibikova et al. 2011).  
 
Affinity enrichment and MSRE are also currently adapted for many downstream 
DNA methylation analyses (Laird 2010). The fundamental principles 
underpinning these two methods are enrichment of methyl-DNA by 
immunoprecipitation using a 5mc specific antibody and enzymatic digestion of 
methylated or unmethylated DNA sections by methylation-sensitive restriction 
enzyme, respectively (Acevedo et al. 2011). An important strength of these two 
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methods over bisulfite conversion based methods is the capability for 
discriminating 5mc from 5hmc (Gupta et al. 2010). 
 
1.2.3.4 Clinical applications of DNA methylation in cancer  
 
Identification of methylation-dependent silencing of tumour-related genes has 
extended our understanding of the initiation and progression of cancer and 
suggests a number of potential translational applications for aberrant DNA 
methylation, with particular interest in discovery of epigenetic biomarkers and 
development of epigenetic therapeutic strategies. 
 
1.2.3.4.1 DNA methylation as a biomarker 
 
Cancer related genes are likely to be epigenetically altered at a higher frequency 
than genetical mutations (Baylin and Jones 2011). Therefore, use of epigenetic 
biomarkers may be particularly helpful for early detection of metastatic disease. 
Identification of methylated DNA could also be useful for early diagnosis, 
molecular profiling of tumour progression, predicting treatment response and 
allowing selection of patients for specific targeted therapies (Hegi et al. 2005; 
Conway et al. 2011; Fukushige and Horii 2013). Promising example is the use of 
methylated GSTP1 for early diagnosis and prognosis of prostate cancer. Van 
Van Neste et al. have reported an overall sensitivity of 82% and specificity of 95% 
of GSTP1 methylation to discriminate prostate cancer from non-neoplastic 
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prostate tissue based on 35 studies (Van Neste et al. 2012). Another potential 
use for epigenetic biomarkers is for predicting the primary tumour in those 
patients diagnosed with metastatic disease of unknown primary origin 
(Fernandez et al. 2012). Methylated DNA is also attractive as a serum biomarker 
for tumour progression and prognosis. Recent studies have reported the 
application of serum epigenetic biomarkers for detecting metastases in human 
cancers (Li et al. 2012). In fact, measurement of biomarkers in patients’ 
circulating blood is increasingly recommended because of its simplicity and 
minimal invasiveness (Tandler et al. 2012).  
 
Metastatic melanoma is accompanied by increased serum levels of biochemical 
biomarkers. Currently available melanoma serum biomarkers LDH (as described 
in 1.1.4) and melanocyte lineage/differentiation antigens S100-beta are very 
insensitive and only detect disseminated melanoma when there is significant 
tumour burden with little chance of curative treatment (Ugurel et al. 2009). 
Therefore, serum biomarkers for early detection of metastases with high 
sensitivity are urgently required. Investigation of aberrantly hypermethylated 
tumour related genomic DNA circulating in the peripheral blood of cancer 
patients could allow pre-symptomatic detection of metastases with higher 
sensitivity and specificity, since tumour DNA is likely to be released from the 
circulating tumour cells, from lysis of necrotic tumour cells or from tumour cell-
free DNA (Board et al. 2008; Heyn and Esteller 2012). The presence of 
detectable free tumour DNA is known to be correlated with a poor prognosis 
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(Silva et al. 1999; Dominguez et al. 2002; Lecomte et al. 2002). Thus, detection 
of circulating methylated DNA holds promise for improving the accuracy and 
early diagnosis of melanoma, including subclinical relapse and metastasis. 
Correlations of methylated ER-α (Mori et al. 2006) and RASFF1A (Mbulaiteye et 
al. 2006) in melanoma patients’ blood with melanoma progression have been 
previously reported. However, the sample size for these studies was rather small 
and clinical validation of these serum biomarkers in bigger patient cohorts plus 
investigation of more promising epigenetic serum biomarkers are clearly needed.  
 
1.2.3.4.2 Therapeutic strategy targeting DNA methylation 
 
The methylation process is pharmacologically reversible and this may be 
exploitable to develop new therapeutic strategies for cancer. Demethylating 
agents, such as 5’-azacytidine and 5’-aza-2-deoxycytidine have shown efficacy in 
reactivating and up-regulating previously silenced tumour suppressor genes 
(Esteller 2006). 5’-azacytidine and 5’-aza-2-deoxycytidine have also been 
approved by FDA for the treatment of haematopoietic malignancies, particularly 
for patients with myelodysplastic syndrome (Kantarjian et al. 2007). By 
preferentially targeting replicating cells these demethylating agents trigger re-
expression of tumour suppressor genes in tumour cells (Lopez et al. 2009). They 
could also be combined with chemotherapy to improve the clinical response, as 
chemotherapy resistance is often induced by transcriptionally silenced tumour-
related genes. 
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2.1 Cell lines and culture conditions 
 
2.1.1 Human melanocyte and melanoma cell culture 
 
Two benign immortalised melanocytes and 23 human melanoma cell lines have 
been collected for this study. These cell lines were purchased from Invitrogen, 
American Type Culture Collection (ATCC), or kindly provided by Dr Gareth 
Inman (Jacqui Wood Cancer Centre, Ninewells Hospital & Medical School, 
University of Dundee), Dr.  Daniele Bergamaschi (Barts and London, School of 
Medicine and Dentistry, Queen Mary, University of London) and Dr Monica 
Rodolfo (Department of Experimental Oncology, Istituto Nazionale Tumori, Italy). 
Primary melanoma cell lines are categorized into radial growth phase, RGP, and 
vertical growth phase, VGP. Table 2-1 shows the name, disease stage, source 
and culture media of each cell line. All cell lines were grown at 37 °C and 5% 
CO2, with regular mycoplasma contamination testing. 
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Table 2-1: Description, source and culture media of the cell lines used 
in this study. 
Cell line Source Medium Supplements 
Normal Human Melanocytes 
HEMa-LP Dr Daniele Bergamaschi   254I HMGS2II 
HEMn-LP Invitrogen 254 HMGS2 
Primary Melanoma, Radial Growth Phase (RGP) 
SBCL2 Dr Gareth Inman RPMIIII 
10% FBS 
PMWK Dr Gareth Inman DMEMIV 10% FBS 
WM35 Dr Gareth Inman RPMI 10% FBS 
Primary Melanoma, Vertical Growth Phase (VGP) 
WM983A ATCC DMEM 5% FBS 
WM115 ATCC DMEM 5% FBS 
LM2 Dr Monica Rodolfo DMEM 5% FBS 
WM902B Dr Gareth Inman RPMI 10% FBS 
MEL224 Dr Daniele Bergamaschi   RPMI 10% FBS 
MEL505 Dr Daniele Bergamaschi   RPMI 10% FBS 
Metastatic Melanoma 
SKMEL2 Dr Gareth Inman DMEM 10% FBS 
SKMEL23 Dr Gareth Inman DMEM 10% FBS 
SKMEL147 Dr Gareth Inman DMEM 10% FBS 
SKMEL173 Dr Gareth Inman DMEM 10% FBS 
SKMEL30 Dr Gareth Inman RPMI 10% FBS 
MEL501 Dr Daniele Bergamaschi   RPMI 10% FBS 
A375M Dr Daniele Bergamaschi   RPMI 10% FBS 
C8161 Dr Daniele Bergamaschi   RPMI 10% FBS 
COLO829 Dr Gareth Inman RPMI 10% FBS 
WM266-4 Dr Gareth Inman DMEM 5% FBS 
WM239A Dr Daniele Bergamaschi   DMEM 5% FBS 
WM983B ATCC DMEM 5% FBS 
LM9 Dr Monica Rodolfo DMEM 5% FBS 
LM29 Dr Monica Rodolfo DMEM 5% FBS 
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I
254 Medium is purchased from Invitrogen, 
II
RPMI and 
IV
DMEM are purchased from Gibco. 
 II
 
Human melanocyte growth supplement-2 (HMGS2) contains bovine pituitary extract, fetal 
bovine serum (FBS), bovine insulin, bovine transferrin, basic fibroblast growth factor, 
hydrocortisone, heparin, and endothelin-1 (Invitrogen). 
 
 
2.1.2 Human melanoma cell line culture for microarray  
 
The following 3 sets of paired cell lines that are derived from the same patients 
were selected for gene HumanHT12 expression microarray and 
HumanMethylation450 microarray: 
Set 1: WM983A and WM983B 
Set 2: WM115, WM266.4 and WM239A 
Set 3: LM2, LM9 and LM29 
In order to minimize the variation cross the panel, the culture conditions, 
including the culture medium and the percentage (%) of FBS have been 
optimized. DMEM medium with additional 5% FBS was selected to culture all 8 
cell lines, due to the maintenance of similar phenotypes and proliferation rates 
with the original medium on demand. Figure 2-1 shows the morphology of two 
representative cell lines grown in the original medium and optimized culture 
medium. 
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2.1.3 Disassociation, freezing and recovery of cells 
 
Cells were washed in phosphate buffered saline (PBS) before disassociation in 
0.05% Trypsin-EDTA (Ethylenediaminetetraacetic Acid) (Gibco). Harvested cells 
were pelleted by centrifugation and resuspended in growth medium for 
passaging, or in a solution of 90% FBS and 10% dimethyl Sulphoxide (DMSO) 
for freezing. For recovery of frozen cells, cryovials containing the frozen cells that 
have been stored in liquid nitrogen were quickly thawed in water bath (37°C), and 
resuspended in culture media for recovery. 
Special Medium  
B A 
RPMI + 5% FBS  
D 
DMEM+ 5% 
FBS 
C 
DMEM+ 5% 
FBS 
Figure 2-1: Morphology of WM239A (A, C) and WM115 (B, D) cell lines under different 
culture media.  
(A): WM239A cell grown in RPMI and 5% FBS after one week; (B): WM115 cell lines grown 
in the special medium (MCDB153:L15 4:1, 2%FBS, CaCl2 1.68Mm, Insulin 5ug/ml and 
Collagen IV) recommended by ATCC; (C, D): WM239A (C) and WM115 (D) cell lines show 
similarly cellular phenotype and proliferation rate with A and B after being maintained in a 
solution of DMEM+5% FBS in one week. 
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2.2 Tissue and serum samples 
 
This project was approved by both the East London & City Health Authority Local 
Research Ethics Committee and by the Tayside Medical Research Ethics 
Committee. Formalin-fixed, paraffin-embedded (FFPE) tissue and serum 
samples from melanoma patients collected through Barts and The London were 
kindly provided by Dr Catherine HarwoodI.  FFPE tissues from Dundee were 
selected and provided by Dr Alan EvansII. Serum samples from melanoma 
patients for prospective study (Dundee) were collected by Amanda DegabrieleIII 
and Leaca CrawfordIII. Clinical information of melanoma patients was obtained 
from detailed inspection of clinical records including histopathology reports and 
Multi Disciplinary Team (MDT) entries. 39 samples were chosen for 
microdissection by histopathological examination under supervision by Dr 
Catherine Harwood. 
IBarts and The London, School of Medicine and Dentistry, Queen Mary, University of 
London. 
IIDepartment of Pathology, Ninewells Hospital & Medical School, University of Dundee. 
IIINHS Tayside, Ninewells Hospital & Medical School, University of Dundee. 
 
Table 2-2: Description of clinical cases. 
 
Clinical 
samples 
Description Number Source 
FFPE stick cores of melanomas ~100 
Barts and The London 
 microdissected melanomas 39 
Frozen  benign naevi 10 
Serum melanoma patients  85 
FFPE paired melanoma samples 16 University of Dundee 
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2.3 Molecular biology methods 
 
2.3.1 DNA and RNA Purification 
 
2.3.1.1 DNA extraction from cultured cells and patient serum 
 
The cell monolayer was washed by PBS, trypsinized, pelleted by centrifugation, 
and resuspended in 200µl PBS before DNA digestion. Cells in PBS were 
homogenised by vortexing. Genomic DNA was subsquently extracted using the 
QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions. Serum DNA was also extracted using the QIAamp 
DNA Blood Mini Kit. 
 
2.3.1.2 RNA extraction from cultured cells 
 
Cells were lysed in RLT buffer (supplied with the RNeasy mini kit, Qiagen) after 
washing in PBS and collected by cell scraper. The cell lysate in the RLT buffer 
was then processed for RNA extraction using the RNeasy Mini Kit following the 
manufacturer’s protocol, including the on-column DNease digestion step.  
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2.3.1.3 DNA purification from paraffin embedded tissues 
 
Xylene and ethanol was used for deparaffinization. DNA lysis buffer (x1 TNE= 
100 mM NaCl, 10 mM Tris.Cl (pH8), 1 mM EDTA, 0.5%SDS (sodium dodecyl 
sulfate) containing 20 microlitres of proteinase K (Qiagen) was added to the 
samples with a following incubation at 55 °C. After the tissue was thoroughly 
digested, DNA was purified with phenol at room temperature and finally 
precipitated from the aqueous layer by addition of 2.5 volumes of 100% ethanol 
and storage at -80 °C for one hour. The DNA pellet was dried and dissolved in 
Tris EDTA buffer solution (TE, pH8). 
 
2.3.1.4 RNA purification from paraffin embedded tissues 
 
Sections were deparaffinized by xylene and 100% ethanol. The dried pellet was 
re-suspended in RNA lysis buffer (10 mM Tris/HCL (pH 8.0), 0.1 mM EDTA, 2% 
SDS) supplemented with 60 µl proteinase K, and incubated at 55°C until the 
tissue was completely solubilized. RNA was purified with phenol at room 
temperature and precipitated with isopropanol in the presence of 0.1 volume of 3 
M sodium acetate (pH 5.2), and carrier glycogen at -20°C for 2 hours. The RNA 
pellet was washed once in 75% ethanol, and resuspended in RNase-free water. 
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2.3.1.5 Quantification and quality examination of DNA and RNA 
 
DNA and RNA concentration were measured spectrophotometrically by Thermo 
Scientific NanoDrop 2000 (Labtech). The absorbance ratio at 260nm/280nm of 
1.7-1.9 and 1.9-2.1 assured good quality of DNA and RNA, respectively. Integrity 
of RNA was checked by 1% denaturing agarose gel eletrophoresis and ethidium 
bromide staining. As shown in Figure 2-2, the 28S and 18S ribosomal RNA 
bands in the 5 RNA samples are clearly visible, with an approximate ratio of 2:1, 
and indicated good integrity of these RNA samples. 
 
 
  
 
 
 
 
 
 
 
 
 
 
28S 
18S 
Figure 2-2: Visualisation of ribosomal RNA 18S and 28S in five RNA samples 
by 1% of denaturing agarose gel eletrophoresis with ethidium bromide 
staining.  
28S and 18S are approximate 5kb and 2kb in size. The presence of 28S and 18S 
bands at a ratio of 2:1 indicated good integrity of RNA samples. 
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RNA samples prepared for gene expression microarrays were sent to Tayside 
Tissue Bank (University of Dundee) to examine the RNA Integrity Number (RIN) 
algorithm. RIN is a more rigorous parameter in examining RNA integrity than 
denaturing agarose gel electrophoresis, particularly for the downstream 
application of gene expression microarrays. This technique indicates the 
presence or absence of degradation products and automatically interprets the 
results. A RIN score of 10 Indicating full integrity of an RNA sample is shown in 
Figure 2-3.   
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 2-3: An RNA sample prepared for gene expression microarray showed 
full integrity with a RIN of 10.  
The RIN detects RNA integrity, based on a range from 1 to 10, with 10 being the 
best integrity and 1 being the most degraded.   
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2.3.2 Reverse transcription of mRNA to cDNA 
 
Complementary DNA (cDNA) synthesis was performed using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems), with 1 μg of total RNA. 
The reaction was performed in a Tetrad 2 Peltier Thermal Cycler (BioRad). The 
cycling conditions for cDNA synthesis are shown in Table 2-4. Synthesized cDNA 
was diluted in nuclease-free water to a final concentration of 100ng/ µl.  
 
Table 2-3: Composition of reverse transcription reaction 
 
Components Volume (µl) Final concentration 
10× RT Buffer 2.0 1 × 
25× dNTP Mix (100mM) 0.8 1 × 
10× RT Random Primers 2.0 1 × 
MultiScribe Reverse Transcriptase 
(50 Units/µl) 
1.0 2.5 Units/µl 
RNase Inhibitor (20 Units/µl) 1.0 1.0 Units/µl 
Nuclease-free water variable  
Template RNA variable 1 µg/reaction 
Total volume 20  
 
 
 
 
Table 2-4: Reverse transcription thermal programme cycling conditions 
 
 Step 1 Step 2 Step 3 Step 4 
Temperature 25°C 37°C 85°C 4°C 
Duration 10 mins 2 hours 5 mins Hold 
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2.3.3 Quantitative real-time polymerase chain reaction (qPCR) 
 
2.3.3.1 qPCR Reaction 
 
TaqMan® gene expression assays on demand (Table 2-6) were designed for 
each gene by Applied Biosystems. All the assays in this study were labeled with 
a 5’ fluorescent reporter dye 6-carboxyfluorescein (FAM). TaqMan is a probe-
based qCPR approach that quantifies the PCR products by detecting the 
fluorescence emission during the PCR reaction. The fluorescent signal is emitted 
when the probe is cleaved by Taq polymerase as the hybridization progresses, 
which prevents the quencher from suppressing the reporter fluorescence. This 
repetitive process in every cycle does not interfere with the accumulation of PCR 
product (Bustin 2000; Arya et al. 2005). 
Table 2-5:  Three-step cycling programme for qPCR 
 
Step Hold 1 Hold 2 Cycling 
Cycles 1 1 40-45 
Temperature 50°C 95°C 95°C 60°C 
Time 2 mins 10 mins 15 s 1 min 
 
 
The qPCR reaction was pipetted by QIAgility robot (Qiagen) into Rotor-Gene 
strip tubes (Qiagen), and PCR was performed by a Rotor-Gene Q instrument 
(Qiagen). Each reaction mixture is composed of 5µl of TaqMan® Gene 
Expression Master Mix (contains AmpliTaq Gold® DNA Polymerase UP (Ultra 
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Pure), Uracil-DNA Glycosylase, dNTPs with dUTP), cDNA template and 
additional Nuclease-free water to a final volume of 20µl. RNA expression levels 
were normalized against the endogenous control β2-microglobulin (B2M). DNA 
contamination was ruled out by running no-template controls. Each sample was 
analyzed in at least duplicates. 
 
Table 2-6: Symbol, description and ID of TaqMan® gene expression assays 
 
Gene Symbol Gene Description Probe Assay ID 
B2M 
 Beta-2-microglobulin 
 
Hs99999907_m1 
DAB2 
Disabled homolog 2, mitogen-responsive 
phosphoprotein 
Hs01120080_m1 
DKK1 Dickkopf 1 homolog Hs00931312_g1 
DUSP2 Dual specificity phosphatase 2 Hs00358879_m1 
EGLN1 Egl nine homolog 1 Hs00254392_m1 
EGLN2 Egl nine homolog 2 Hs01086086_g1 
EGLN3 Egl nine homolog 3  Hs00222966_m1  
EGR2 Early growth response 2 Hs00166165_m1 
NT5E 5'-Nucleotidase, ecto (CD73) Hs01554888_m1 
SMAD3 SMAD family member 3 Hs00969210_m1 
TFPI2 Tissue factor pathway inhibitor 2 Hs00197918_m1 
TSC22D1 TSC22 domain family, member 1 Hs00394659_m1 
 52 | P a g e  
 
2.3.3.2 qPCR Normalisation and Analysis 
 
The relative expression of target genes was calculated using the formula 2-∆CT. 
Cycle threshold (CT) value is the cycle number at the point where the 
amplification curve passes the threshold line, whilst the threshold was manually 
set above the baseline of no-template control to avoid the background noise 
(Figure 2-4). ∆CT was equal to the average CT for target gene minus the average 
CT of endogenous B2M control in each sample.  
 
 
 
 
 
 
 
 
PCR cycle number 
10 20 30 40 
Threshold 
Baseline 
Plateau 
CT of Sample 1 
Sample 1 Exponential 
Phase 
Figure 2-4: Visualisation of qPCR amplification plot by Rotor-Gene Q 2.0.2 (build 4) 
software.  
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2.3.4 DNA Methylation analysis 
 
2.3.4.1 Bisulfite Modification of genomic DNA 
 
500ng-1µg genomic DNA from cell lines, FFPE samples or 45µl serum DNA was 
subjected to bisulfite modification using the EZ DNA MethylationTM Kit (Zymo, 
California) following the manufacturer’s instructions. The basic principle of this 
protocol is to treat methylated DNA with sodium bisulfite, which converts 
unmethylated cytosine residues to uracil whilst methylated cytosines remain 
unchanged. The methylation profile of modified DNA samples is then examined 
in downstream applications, including MSP (methylation-specific polymerase 
chain reaction (PCR), pyrosequencing, and bisulfite sequencing. 
 
 
2.3.4.2 Primer Design 
 
Genome CpG island sequence was obtained from the UCSC Genome Browser 
(Browser). Primers for MSP and bisulfite sequencing were designed using 
MethPrimer (MethPrimer). The primers were selected in a CpG-rich region with 
close proximity to the transcription start site. Primers for bisulfite sequencing and 
pyrosequencing were designed to avoid CpGs within the primer sequence. 
Conversely, MSP primers were required to include at least 3 CpGs. 
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2.3.4.3 Reconstitution of lyophilized PCR primers 
 
PCR primers were supplied from MWG lyophilized at ambient temperature. The 
vials were briefly centrifuged before dissolving in TE buffer (pH 8.0) to make a 
concentration of 100µM for stock. Once completely dissolved after vortexing and 
incubation at room temperature, the PCR primers were diluted to a final 
concentration of 10µM in small aliquots to avoid repeated freezing and thawing 
cycles, and stored at -20°C. The optimal annealing temperature for each primer 
set was determined by gradient PCR. 
 
 
2.3.4.4 Agarose-gel electrophoresis 
 
2% agarose gels were prepared in 1 × Tris-Acetic Acid-EDTA (TAE) buffer (50 ×, 
Bio-Rad) in a microwave, with additional SYBR® Safe DNA gel stain (10,000 ×, 
Invitrogen) added after cooling down. Samples were mixed with Sample Loading 
Dye (Bioline), along with DNA ladder (Bioline) and loaded onto the gels in 1 × 
TAE buffer and resolved by electrophoresis at 120 V for 60 minutes. DNA 
fragments were visualised by UV illumination or VersaDoc imaging system (Bio-
Rad). 
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2.3.4.5 Methylation specific PCR (MSP) 
 
MSP is a non-quantitative technique that measures DNA methylation based on a 
gel-electrophoresis method. Bisulfite modified genomic DNA was amplified with 
either a methylated-specific (M) or unmethylated-specific (U) primer set using Hot 
Star Taq DNA Polymerase kit (Taqman) in a Tetrad 2 Peltier Thermal Cycler 
(BioRad). Bisulfite modified methylated and unmethylated DNA samples (Qiagen) 
were included in each amplification as methylated and unmethylated controls 
respectively.  
 
Table 2-7: Reaction Composition using Hot Star Taq DNA polymerase 
 
Component Volume/Reaction 
Final 
concentration 
10x PCR Buffer 2.5µl 1X 
dNTP mix (10mM) each 0.5µl 0.2mM 
Forward primer (10µM) 1µl 0.4µM 
Reverse primer (10µM) 1µl 0.4µM 
HotStar Taq polymerase 0.125µl  
DNA template Variable  
Nuclease-free water Variable  
Total 25 µl  
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Primers and annealing temperatures of candidate genes are listed in Table 2-9. 
DNA products were loaded onto 2% denaturing agarose gel eletrophoresis as 
described in 2.3.4.4, and visualized under VersaDoc imaging system. 
 
 
Table 2-8: Cycling protocol for MSP 
 
Step Duration Temperature 
3 step cycling x8   
Initial activation 2min 95°C 
 30sec 60°C 
 30sec 72°C 
3 step cycling x35   
Denaturation 30sec 95°C 
Annealing 30sec variable 
Extension 30sec 72°C 
Final extension 5 min 72°C 
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Table 2-9: MSP Primers and annealing temperature of candidate genes 
 
  
 
 
Gene Primer Forward 5’ Primer Reverse 3’ Primer Type 
Annealing 
Temperature 
Dab2 
GACCGAAAACTTCGAAACCGCGCGA GGGGTTTTTTGCGTCGTTGTAGCGC Methylated 61°C 
ACCAACCAAAAACTTCAAAACCACACAA GTGGGGTTTTTTGTGTTGTTGTAGTGT Unmethylated 54°C 
SMAD3 
CGTCGGTTAAGGGTTTTGAC GAACGACTCGATTAAAATTACGAA Methylated 57°C 
GTGTTGGTTAAGGGTTTTGATG CAAACAACTCAATTAAAATTACAAA Unmethylated 55°C 
TFPI2 
GTTCGTTGGGTAAGGCGTTC AACGACGAAATAACAATCCCCGTA Methylated 55°C 
GGTTTGTTGGGTAAGGTGTTTGA AAAACAACAAAATAACAATCCCCAT Unmethylated 55°C 
EGR2 
TTTTTTTCGATAGTCGCGCGTTTTC GACGACGCCGATTTCCTTAACGAT Methylated 55°C 
TTTTTGATAGTTGTGTGTTTTTGT AACAACACCAATTTCCTTAACAAT Unmethylated 55°C 
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2.3.4.6 Pyrosequencing 
 
Pyrosequencing quantitatively measures methylation of an individual CpG site at 
high sensitivity. This technique is frequently used to indicate the frequency and 
level of methylation for candidate genes. All pyrosequencing analysis referred to 
in this study was performed in collaboration with Miss Laura Lattanzio (Santa 
Croce e Carle Hospital, Cuneo, Italy). Bisulfite modified DNA was amplified for 
subsequent pyrosequencing using a Hot Star Taq DNA Polymerase kit. The 
composition of PCR reactions and cycling conditions are shown in 2.3.4.5. PCR 
products were detected by agarose gel electrophoresis as described in 2.3.4.4, in 
order to ensure adequate PCR product of appropriate size without the presence 
of contamination. Pyrosequencing was performed in the PyroMark ID System 
(Biotage, Sweden). CpGenome Universal Methylated DNA (Millipore) and 
placental sexed male DNA (Sigma) were used as methylation positive and 
negative controls, respectively. 
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Table 2-10: Primers and annealing temperatures of target genes for Pyrosequencing 
Gene Primer Forward 5’ Primer Reverse 3’ 
Annealing 
Temperature °C 
Sequencing 
Primer 
Dab2 ATGGAGTTAGAGGGAAGAAGGGT AAAATCCTCAACTACCAACATCT 55 F 
TFPI2 GGGTTTATGGTGTAGGGGG CAACCACCCCTCAAACTCC 57 F 
SMAD3 GAGAATAAAAATAGTTTAGGGG AATACACCCTAAAAAAAACCC 57 F 
AGTR1 GTTAGGATTTTAGGTAGTAG CTCCAACCACTCCCCAT 53 R 
LEPREL 1 GGGGTTGTTTTATAGTGG AAATACCCCAAAACCCTC  52 F 
LEPREL 2 GTAGATTGTTTGATTTAGTG CCACCTAATAATAAACCCTC 53 F 
P4H A1 GGTTGTTGTGGTAATTTGGG  AACTAAAACCACTAAACAACC 55 R 
P4H A2 GTTTTTTTGTTTAGTTTTTGGG CTCTCCCTACAACCCC 54 F 
P4H A3 GGTATAGTGTATTTTATTGAG ACTACTAAAACTACTAAAAC  49 F 
DUSP2 GTAGATAGGAGTTTTGGAGT CTCTTCCCCTCCTTACAAA 55 F 
TSC22D1_
SET 1 
GGGTTATAAATAGGAAGTTTT ACTATAAAAACCCCCACAC- 52 F 
TSC22D1_
SET 2 
TAATGGTTTAGTGTTTTGAGG CCCCCATTCTCCAAATCC 55 F 
TSC22D1_
SET 3 
GTGGGGGTGGGGGGAGG CAACTCTAAACCAAAACTCCC 57 F 
TSC22D1_
SET 4 
GGTTTAGAGTTGAGTGGAGTT CAACTTCTAAAACTTAATAATCC 56 F 
 60 | P a g e  
 
2.3.4.7 Bisfulfite sequencing 
 
Bisulfite sequencing data was provided by Dr Tim Crook. Briefly, bisulfite 
modified DNA was subject to amplification, and PCR products were detected by 
agarose gel electrophoresis as described in 2.3.4.4. A gel slice containing the 
appropriately sized DNA fragment of interest was excised under UV illumination, 
and extracted for purification. The purified DNA fragment was end-extended, 
cloned, used to transform TOP10 electrocompetent cells (Invitrogen), and plated 
on agar plates containing Kanamycin (1ml/100ml). Selected colonies were added 
to 5ml of liquid broth containing Kanamycin. Plasmid DNA was purified and 
sequenced. 
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2.4 Protein procedures 
 
2.4.1 Western blotting 
 
2.4.1.1 Preparation of protein lysates 
 
Adherent cells seeded in 10mm dishes were washed three times in ice-cold PBS 
before harvest. Protein lysis buffer including Radio-immune Precipitation (RIPA) 
Buffer (1×, Thermo Scientific), HaltTM Protease Inhibitor Cocktail (100×, Pirece®, 
Thermo Scientific), HaltTM Protease and phosphatase Inhibitor Cocktail (100×, 
Pierce®, Thermo Scientific), and 0.5M EDTA (100×, Thermo Scientific) was 
added to the cells. The cells were scraped off and transferred into 1.5ml 
Eppendorf® microcentrifuges tube, followed by 15 minutes of incubation on ice 
and centrifugation at full speed in a cold centrifuge for 10 minutes to pellet 
insoluble cell debris. Supernatant containing the protein was then transferred to a 
1.5ml eppendorf and stored at -80°C. 
 
2.4.1.2 Protein concentration 
 
Protein concentration was analysed by the Bio-Rad DCTM protein assay. Protein 
extract was thawed on ice, and diluted 1 in 10 in a 96 well plate. Reagents were 
added to the plate according to the manufacturer’s protocol. Plate containing 
mixtures of reagents and either standard protein Bovine serum albumin (BSA), or 
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protein samples was incubated at room temperature for 15 minutes and read by 
ModulusTM II microplate multimode reader at a wavelength of 750nm. 
 
2.4.1.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
 
20-50 µg of each protein sample was mixed with NuPAGE® LDS Loading Buffer 
(4×, Invitrogen) and denatured by heating at 70ºC for 10 minutes prior to loading. 
Prepared samples, along with a mixture of SeeBlue® Plus 2 pre-stained standard 
(Invitrogen) and Precision Plus ProteinTM unstained standards (Bio-Rad), were 
loaded into wells of NuPAGE® Novet 4-12% Bis-Tris Mini Gels (Invitrogen) in 
XCell SureLockTM Mini-Cell (Invitrogen) containing 1× NuPAGE® MOPS SDS 
running buffer (50 mM MOPS, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA, pH 7.7, 
Invitrogen). Electrophoresis was performed at 150V for 90 minutes before being 
transferred to a solid support for further analysis. 
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2.4.1.4 Transfer of proteins to solid support 
 
 
Trans-Blot® Turbo™ Mini PVDF (polyvinylidene fluoride) Transfer Packs (Bio-
Rad) containing precut PVDF membrane, filter paper and transfer buffer was 
used for transfer of proteins. An assembled sandwich with the gel placed 
between top and bottom stacks was placed on the cassette base, after ensuring 
air bubbles were excluded by rolling out between the layers. Transfer was carried 
out by Trans-Blot® Turbo™ Transfer System (Bio-Rad) for 30 minutes. The 
success of transfer was evaluated by Ponceau S staining. 
 
 2.4.1.5 Immunodetection 
 
The successfully transferred membrane was blocked in 1× TBS-T (Tris buffered 
saline-Tween, 2 mM Tris, 15 mM NaCl and 0.05% Tween (v/v), pH 7.6) with 1% 
non-fat dried milk (w/v, Marvel) for 1 hour at room temperature to block non-
specific binding of antibody, and incubated in primary antibody (listed in Table 2-
11) that was appropriately diluted in block solution overnight at 4°C.  
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Table 2-11: Name, description, supplier and dilution of primary antibodies 
 
Protein 
Primary 
antibody 
Supplier Dilution Size (kDa) 
PHD2, EGLN1 
Rabbit 
polyclonal 
Abcam 1/1000 46 
PHD1, EGLN2 
Rabbit 
polyclonal 
Abcam 1/1000 44 
PHD3, EGLN3 
Rabbit 
polyclonal 
NOVUS 1/1000 27 
HIF-1α 
Rabbit 
polyclonal 
GeneTex 1/500 115 
Actin 
Mouse 
monoclonal 
Santa Cruz 1/2000 43 
Ku80 
Mouse 
monoclonal 
Abcam 1/2000 86 
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On the following day, the membrane was washed three times for 10 minutes in 
TBS-T solution and incubated with block solution containing species specific 
horseradish peroxidase (HRP) - conjugated secondary antibody (Table 2-12) for 
1 hour at room temperature. Precision Protein™ StrepTactin-HRP Conjugate 
was also added for detection of Precision Plus Protein unstained standards. 
Three times of 10 minutes washes by TBS-T buffer were subsequently required. 
Equal volume of Luminol and Peroxide solution (Immobilon Western 
Chemiluminescent HRP Substrate kit, Millipore) were applied to the membrane 
before visualization by VersaDoc imaging system.  
 
Table 2-12: Name, description, supplier and dilution of secondary antibodies 
 
Conjugated Target Secondary antibody Supplier Dilution 
HRP Mouse IgG Goat polyclonal Dako 1:10, 000 
HRP Rabbit IgG Swine polyclonal Dako 1:10, 000 
 
2.4.1.6 Normalization with loading control 
 
To evaluate the loading equivalence, levels of loading controls (Ku80 and Actin) 
were measured either by separating the blot with target protein and control 
protein, or re-probing the loading controls after stripping (7% Trichloroacetic acid 
(w/v), Sigma) the membrane. Following a serials of washes, stripped membranes 
were blocked, re-probed with loading control and visualised as described in 
2.4.1.4.  
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2.4.2 Immunofluorescence 
 
 
Cells were grown as monolayer in Nunc® Lab-Tek® Chamber Slide™ (0.8 m2/well, 
 Sigma-Aldrich) to reach 50% of confluence (approximate 0.1 million cells/well). 
By the time of harvest, cells were washed by PBS before fixed with 300 µl 4% 
(w/v) paraformaldehyde for 20 minutes. To stop the fixation, paraformaldehyde 
was washed off by PBS three times, followed by permeabilization of cells with 
300 µl of 0.1% Triton for 5 minutes and subsequent three times of PBS washes. 
Cells were sequentially incubated in blocking buffer (0.3% BSA in PBS) for 1 
hour, primary antibody (1:100 dilution) for 1hour, and fluorescent conjugated 
secondary antibody (1:800 dilution) in dark for 1 hour, with each step followed by 
3 times of washes by PBS. After the chamber was removed, the slides containing 
the cells were mounted with ProLong® Gold antifade reaper with DAPI (4’, 6-
diamidino-2-phenylindole) (Invitrogen), sealed with coverslip on top and nail 
polish along the edges to prevent drying and contamination, and movement 
under microscope. All steps were carried out at room temperature. Results were 
examined by Zeis Axioskop2 microscope with fluorescence. 
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2.5 Cell biology assays 
 
2.5.1 Transient transfection of short interfering RNA (siRNA)  
 
2.5.1.1 Resuspension of siRNA 
 
Pelleted siRNA was briefly centrifuged and dissolved in a mixture of 1 volume 5× 
siRNA buffer (Dharmacon) and 4 volumes of RNase-free water to make a stock 
at final concentration of 20µM. Once dissolved by gently pipetting and mixing on 
an orbital shaker for 30 minutes at room temperature, siRNA solution was 
aliquoted and stored at -20°C. siRNAs used in this project were listed in Table 2-
13. 
 
2.5.1.2 Optimisation of transfection reagents 
 
The transfection efficiency of OligofectamineTM reagent (Invitrogen), 
LipofectamineTM 2000 (Invitrogen), HiPerFect transfection reagent (Qiagen) and 
LipofectamineTM RNAiMAX (Invitrogen) was compared in the melanoma cell line 
COLO829 treated by SMAD4 ON-TARGET plus SMARTpool siRNA (detailed in 
Table 2-13) at a final concentration of 100nM. Control cells were treated with 
100nM of AllStars negative control siRNA. LipofectamineTM RNAiMAX showed 
the best efficiency of silencing SMAD4 protein expression (Figure 2-5). It is 
difficult to judge the efficiency of LipofectamineTM 2000 due to its severe toxicity. 
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Comparatively, COLO829 cells were more tolerant to the other three transfection 
reagents. Therefore, LipofectamineTM RNAiMAX was selected to transfect the 
siRNAs in this study. 
 
 
Table 2-13: Name, company and target sequence of siRNAs 
 
Gene target Company Target sequence 
SMAD4 Thermo Scientific 
GUACAGAGUUACUACUUAG 
GAAUCCAUAUCACUACGAA 
CCACAACCUUUAGACUGA 
GCAAUUGAAAGUUUGGUAA 
EGLN3 Thermo Scientific 
GGAGCCGGCUGGGCAAAUA 
CAAGCUACAUGGUGGGAUC 
GAUAUGCUAUGACUGUCUG 
UCUACUAUCUGAACAAGAA 
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2.5.1.3 siRNA transfection procedure 
 
Cells were seeded the day before transfection in medium without antibiotics. 
Appropriate volumes of RNAi and LipofectamineTM RNAiMAX were mixed with 
Opti-MEM® I Reduced Serum Medium by gently mixing, respectively. Two 
mixtures were combined, mixed gently and incubated for 20 minutes at room 
temperature before drop-wise adding to the cells. The final concentration of RNAi 
and the duration of the treatment were optimized for each individual siRNA. 
 
LipofectamineTM 2000  
 
 
HiPerFect  
 
 
OligofectamineTM  
 
 
LipofectamineTM RNAiMAX 
AllStars siRNA SMAD4 siRNA 
A 
B 
D 
C 
Figure 2-5: Comparison of the efficiency of four transfection reagents in COLO829 
melanoma cell line:  OligofectamineTM reagent, LipofectamineTM 2000, HiPerFect 
transfection reagent and LipofectamineTM RNAiMAX.  
Both SMAD4 and AllStars siRNA were used at a final concentration of 100Nm. A: No 
SMAD4 expression was detected in SMAD4 siRNA or negative control probably due to 
the severe toxicity of LipofectamineTM 2000. B, C: Degrees of SMAD4 protein silencing 
compared to the negative controls when transfected by HiperFect or OligofectamineTM. D: 
Total silencing of SMAD4 protein expression when transfected with LipofectamineTM 
RNAiMAX. 
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2.5.2 Methylation reversal assay 
 
Cells were grown to confluence and split into 10cm dishes before 5 days of 
methylation reversal treatment with or without the demethylating reagent 5’-
azacytidine (5’ AZA, dissolved in DMSO to a final concentration of 5µM, Sigma).  
DMSO, the dissolving solution of 5’ AZA, was added to the control cells. 
Replacement of fresh medium supplemented with either 5’ AZA or DMSO was 
carried out every 2 days.  During the last 24 hours, additional trichostatin A (TSA, 
dissolved in DMSO to a final concentration of 500nM, Sigma) was added to cells 
treated with 5’ AZA. Each treatment was performed in triplicate. RNA was 
extracted from both treated and control cell lines as described in 2.3.1.2. 
 
 
2.5.3 Hypoxia treatment 
 
Cells were seeded at 50% confluence in T25 flasks. On the following day, flasks 
containing cells for each time point were placed into the In Vivo 500 hypoxia 
workstation (Ruskinn Technologies, Bridgend, UK) (37°C, 1% O2). At the time 
point of harvest, cells for RNA or protein was lysed by the corresponding lysis 
buffer and scraped into eppendorfs as described in 2.3.1.2 and 2.4.1.1, 
respectively. 
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2.5.4 Cell counting 
 
Cells were seeded at a density of 0.1×106 cells/well in 12-well plates before the 
day the appropriate treatment was added to the cells. At each time point, cells 
were disassociated with 400µl of trypsin, neutralised with 600 µl of culture 
medium and counted by CASY® cell counter (Innovatis). 
 
 
2.6 Microarray analysis 
 
2.6.1 Methylation reversal assay with expression microarray 
 
Methylation reversal assay was performed on cell lines MEL224, MEL501, 
MEL505, C8161 and C81-61 as described in 2.5.2. RNA samples were 
harvested and sent to the Institute of Cancer Research (London) for in house 
cDNA arrays, which included two colour hybridizations. The data was generated 
by GenePix software, and analysed by Dr Alan MacKay (The Breakthrough 
Breast Cancer Research Centre, Institute of Cancer Research) using 
Significance Analysis of Microarrays (SAM) statistical software. 
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2.6.2 Expression microarray  
 
RNA samples prepared as described in 2.1.2 were analysed on HumanHT12 v4 
expression microarrays by Cambridge Genomic services (University of 
Cambridge). RNA samples were amplified using Ambion® TotalPrep™ RNA 
Amplification Kit and hybridized on the HumanHT12 v4 BeadChip following Direct 
Hybridisation Assay (Illumina). The data was scanned by the Bead Array Reader. 
Quality control and analysis were performed by Dr Runxuan Zhang (The James 
Hutton Institute, Dundee). Briefly, the raw data was loaded to R (version 2.13.0) 
for density plot before and after normalization. Normalized data were tested by 
Hierarchical Clustering, Principle Component Analysis (PCA). Analysis of 
Variances (ANOVA) was used to detect differentially expressed genes according 
to the experimental design. The p values were corrected for multiple testing using 
Benjamini & Hochberg method and a FDR (adjusted p value, also known as false 
discovery rate) of 0.01 was used as threshold to select the significantly 
differentially expressed genes. 
 
 
2.6.3 Methylation microarray 
 
DNA samples prepared as described in 2.1.2 were analysed on Infinium® 
HumanMethylation450 microarrays by Cambridge Genomic services (University 
of Cambridge). The methylation profiling consists of a bisulfite modification (EZ 
DNA MethylationTM Kit, Zymo), Illumina’s Infinium methylation procedure, and 
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loading samples on the Infinium® HumanMethylation450 BeadChip. Slides were 
scanned on the iScan for analysis. Normalisation and analysis were undertaken 
by Dr Helena Carén (Sahlgrenska Cancer Center,  
Gothenburg, Sweden). Raw data was normalised with Illumina’s Subset-quantile 
Within Array Normalization (SWAN) and analysed by Limma (Linear Models for 
Microarray) package for the pairwise comparisons and p value correction. The 
output files from the Limma analysis contain methylation variable positions 
(MVPs) with an adjusted p-value of <0.01 and a change in the beta-value 
(methylation frequency) of more than 20%.  
 
2.7 Statistics 
 
Statistical analysis, including t-test, Mann-Whitney U test, Receiver operator 
characteristic (ROC) and one way ANOVA were all performed by GraphPad 
Prism® software. Statistical analysis of the significance of P4HA3 methylation as 
a melanoma serum biomarker was kindly performed by Dr Mathieu Boniol 
(International Prevention Research Institute, Lyon, France) using SAS version 
9.2 software. In his analysis, Kernel density analysis was used to examine the 
distribution of all tested CpG sites within a target gene. Multivariate regression 
analysis was used to compute the various odd ratios. 
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3.1 Introduction 
 
DNA methylation is a biologically crucial mechanism that transcriptionally 
silences gene expression. One research and therapeutic opportunity presented 
by DNA methylation is that the modification to DNA induced by methylation is 
potentially reversible with demethylating agents, such as 5’ azacytidine (5’ AZA), 
which inhibits DNA methylation by binding to DNA methyltransferase (DNMT) I 
(Kaminskas et al. 2005). 5’ AZA has been frequently used to investigate genes 
that are dysregulated by DNA methylation in human cancers and, importantly, a 
low dose of 5’ AZA will not interfere with DNA replication. The histone 
deacetylase (HDAC) inhibitor, trichostatin A (TSA), is often used in conjunction 
with 5’ AZA in methylation reversal experiments. TSA removes acetyl residue 
groups to make chromatin less condensed and more transcriptionally active 
allowing better interaction between 5’ AZA and DNMT. Combining methylation 
reversal treatment with gene expression profiling has proven to be a powerful tool 
for de novo identification of genes silenced by DNA methylation and this 
approach has been widely explored in epigenetic biomarker discovery studies 
(Arai et al. 2006; Mikata et al. 2006; Wong et al. 2007; Nojima et al. 2009; He et 
al. 2011).  
 
DNA methylation analytical methodology has undergone rapid evolution 
development lately (section 1.2.3.3). The recent introduction of Infinium 
Methylation 450K microarray provided a powerful method for genome-wide 
methylation profiling. It is a robust technique comprehensively and proportionally 
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investigates methylated DNA at single-base resolution (Kilaru et al. 2012). 
Approximately 480,000 CpG sites are assayed by this microarray, with a 
coverage of 96% of CpG islands as well as regions outside CpG islands, such as 
island shores and the regions flanking them (Dedeurwaerder et al. 2011). 
Infinium Methylation 450K microarray has shown promising results for the 
investigation of aberrant methylated genes in several human cancers (Devaney 
et al. 2013; Heyn et al. 2013; Shen et al. 2013), and this technique also exhibits 
good consistency with other methodologies such as reduced representation 
bisulfite sequencing (RRBS) (Pan et al. 2012). 
 
In this section of work my aim was to investigate epigenetically dysregulated 
genes by several systematic approaches including methylation reversal 
screening, gene expression profiling and methylation profiling. I proposed to 
investigate the methylation status of candidate genes identified using systematic 
approaches in melanoma cell lines and patient materials, and to determine 
whether they have potential clinical utility as diagnostic and/or prognostic 
biomarkers that predict tumour progression and patient outcome. Importantly, the 
candidacy of these genes as serum epigenetic biomarkers will also be assessed, 
in particular evaluating the significance of detection of methylated DNA in patient 
sera as a predictor of metastatic disease. 
 
By performing a methylation reversal screen, Dr Tim Crook has identified a 
number of candidate genes (shown in Table 3-2). I have selected 5 (TFPI2, 
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DKK1, EGR2, SMAD3 and TSC22D1) for further validation and investigation. The 
background for these candidate biomarkers is now introduced:  
 
3.1.1 Tissue factor pathway inhibitor 2 (TFPI2) 
 
TFPI2, also known as placental protein 5 (PP5), was named and characterised 
based on its TFPI-like features (Kisiel et al. 1994). As a member of the matrix-
associated Kunitz-type serine proteinase inhibitor family and being capable of 
inhibiting serine proteinases such as factor VIIa-tissue factor, trypsin and plasmin 
(Petersen et al. 1996), TFPI2 functions in the regulation of a number of biological 
processes, including extracellular matrix (ECM) digestion, tissue remodeling and 
blood coagulation. Its role in ECM remodeling makes it a good candidate as a 
‘metastasis’ gene. 
 
DNA methylation of TFPI2 has been reported in a variety of human cancers in 
the last few years (summarised in Table 3-1). Detection of methylated genomic 
DNA in circulating blood has been described in both gastric cancer (Hibi et al. 
2011) and hepatocellular carcinoma (Sun et al. 2013). Interestingly, methylated 
genomic DNA in serum from gastric cancer patients becomes undetectable after 
curative surgery (Hibi et al. 2012). Investigation of TFPI2 methylation in 
melanoma has revealed a low frequency in one study ((Liu et al. 2008) and 
methylation exclusively in metastases (Nobeyama et al. 2007). Investigation of 
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TFPI2 methylation in human cancers has suggested an important potential role 
for TFPI2 as an epigenetic biomarker for human cancers.  
 
 
 
 
Table 3-1: Investigation of TFPI2 CpG island methylation in human cancers 
Cancer Methylation frequency in human cancers Reference 
Gastric 
carcinoma 
80.9% (123/152) primary gastric cancers  (Jee et al. 2009) 
Gastric cancer 83% (15/18) primary gastric cancers (Takada et al.) 
Pancreatic ductal 
adenocarcinoma 
73%(102/140) pancreatic cancer xenografts and 
primary pancreatic adenocarcinomas  
(Sato et al. 2005) 
Colorectal 
cancer 
97%(55/56) adenomas (pre-malignant lesions) 
and 99%(114/115) colorectal cancers 
(Glockner et al. 
2009) 
Hepatocellular 
carcinoma 
47% (16/34) primary hepatocellular carcinomas 
(Wong et al. 
2007) 
Cervical 
carcinoma 
82% (18/22) invasive cervical cancer 
(Sova et al. 
2006) 
Non-small-cell 
lung cancer 
30% (12/40) cases of non-small-cell lung cancer, 
with more frequent methylation in late stage and 
metastases 
(Rollin et al. 
2005) 
Melanoma 
29% (5/17) metastatic melanomas, 0% (0/20) 
primary melanomas  
(Nobeyama et al. 
2007) 
 12.5%(5/40) freshly procured melanoma samples  (Liu et al. 2008) 
 21.7%(overall 122) melanomas 
(Tanemura et al. 
2009) 
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Together with its characterisation as a promising epigenetic biomarker for 
cancers, the molecular function of TFPI2 in tumourigenesis and progression has 
also been extensively studied. In vitro and in vivo studies have provided evidence 
of its negative regulatory function in tumour proliferation, invasion, metastasis 
and angiogenesis, which is probably associated with its broad spectrum inhibitory 
action on serine proteinases and matrix metalloproteases (MMPs) (Rao et al. 
1999; Izumi et al. 2000; Konduri et al. 2001; Chand et al. 2004; Yanamandra et al. 
2005; Gessler et al. 2011). There is also likely to be cross-talk between TFPI2 
and cancer-related pathways, such as the apoptotic pathway (George et al. 
2007), TGF-β pathway (Fuchshofer et al. 2009), and MKK7/JNK pathway (Chand 
et al. 2005). 
 
3.1.2 Early growth response gene 2 (EGR2) 
 
EGR2 protein, encoded by the EGR2 gene, is a transcription factor with zinc-
finger DNA binding motifs (Joseph et al. 1988). The zinc-finger DNA binding 
structure of EGR2 allows its interaction with multiple signaling pathways. EGR2 
has also been reported to cause human disease such as Charcot-Marie-Tooth 
syndrome (Warner et al. 1998).  The mechanism of EGR2 action in terms of its 
molecular function in regulating tumour behaviour is not well understood. EGR2 
has been previously reported to be a tumour suppressor acting to induce 
apoptosis (Unoki and Nakamura 2003; Yokota et al. 2010) and positively 
mediating PTEN growth-suppressive signaling in human cancers (Unoki and 
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Nakamura 2001). Conversely, EGR2 is also reported to act in an oncogenic 
manner by inhibiting T cell activation to cause anergy wherein it acts in concert 
with its family member EGR3 (Safford et al. 2005), and increasing expression 
of ErbB2, a poor prognostic factor for breast cancer (Dillon et al. 2007). 
 
3.1.3 Dickkopf homolog 1 (DKK1) 
 
DKK1 encodes a member of the dickkopf family that inhibits the canonical Wnt/β-
catenin pathway. The Wnt pathway modulates cellular activities including cell 
proliferation, migration, senescence and apoptosis. The function of DKK1 in 
human cancers remains controversial (Menezes et al. 2012). Evidence has 
shown both increased and decreased DKK1 expression in cancers in a context-
dependent pattern. DKK1 is more likely to be a tumour suppressor in melanoma. 
Expression of DKK1 is inducible by UVB in melanocytes (Yang et al. 2006), but, 
conversely, is reduced in melanoma (Kuphal et al. 2006). Promoter methylation 
appears to be a mechanism that silences DKK1 expression in some cancers 
(Kocemba et al. 2012; Na et al. 2012; Wang et al. 2013), but no direct evidence 
for methylation has been previously reported in melanoma. Another possible 
explanation for the reduction of DKK1 expression in melanoma is the cross-talk 
between MAPK signaling and Wnt/β-catenin signaling (Parisi et al. 2012). 
Melanoma cells with a BRAFV600E mutation are able to inhibit the activity of 
DKK1 and prevent induction of senescence. 
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3.1.4 SMAD family member 3 (SMAD3) 
 
SMAD3 is an intracellular mediator of the TGF-β pathway that transduces signals 
and activates transcription after activation of the TGF-β receptor by TGF-β ligand. 
The most well-established signalling effector pathway activated after TGF-β 
signalling is through a cell-surface complex of the TGF-β receptors known as the 
SMAD signalling pathway (Feng and Derynck 2005). TGFβ receptor 
phosphorylates and drives Smad2 and Smad3 to form a complex with Smad4. 
This complex then translocates to the nucleus and activates the transcription of 
TGF-β target genes (Derynck et al. 2001; Millet and Zhang 2007). TGF-β is a 
pleiotropic cytokine acting as a potent tumour suppressor in many early stage 
cancers, but switching to become a potent tumour promoter in advanced 
malignancy (Ikushima and Miyazono 2010). The switch to a pro-proliferative 
TGF-β response may be controlled epigenetically and may be a crucial 
biomarker for high risk head and neck squamous cell carcinoma (Hannigan et al. 
2011). TGF-β pathway impairment has not previously been reported in 
melanoma, but identification of SMAD3 by our methylation reversal screen 
suggests the possibility that SMAD3 may be silenced by DNA methylation in 
some melanomas which may indirectly impact on TGF-β signalling. 
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3.1.5 TSC22 domain family, member 1 (TSC22D1) 
 
TSC22D1 is a TGF-β responsive transcription factor, composed of a long isoform 
TSC22D1.1 and a short isoform TSC22D1.2 (Shibanuma et al. 1992; Fiol et al. 
2007). Reduced TSC22D1 expression in human cancers implicates it as a 
tumour suppressor (Shostak et al. 2003; Shostak et al. 2005; Rentsch et al. 
2006). For the short isoform, functions such as inhibiting cell proliferation, 
inducing apoptosis and senescence and inhibition of degradation of p53 have 
been identified in human cancers (Nakashiro et al. 1998; Hino et al. 2000; 
Homig-Holzel et al. 2011; Yoon et al. 2012). Reduced gene expression due to 
DNA methylation of TSC22D1.2 has been reported in leukaemic transformation 
(Yu et al. 2009). 
 
3.2 Results 
 
 
3.2.1 Identification of candidate genes by methylation reversal assay 
combined with gene expression profiling 
 
Dr Tim Crook provided preliminary data from a methylation reversal screen on 5 
melanoma cell lines MEL224, MEL501, MEL505, C81-61 and C8161. Briefly, 
these melanoma cell lines were treated with the methylation reversal agents 5’ 
AZA, with or without additional TSA. DMSO which is the diluent reagent for 5’ 
AZA and TSA was used as the negative control. This data has been analysed by 
Dr Alan MacKay (The Breakthrough Breast Cancer Research Centre, Institute of 
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Cancer Research). To confirm the reproducibility of the analysis, we sent data 
from one cell line, C81-61, to Dr Runxuan Zhang (The James Hutton Institute, 
Dundee) for repeat analysis. Principle component analysis performed by Dr 
Runxuan Zhang revealed all 4 treatments as different clusters with tight 
clustering of replicates, suggesting good reproducibility of the replicates in each 
group (Figure 3-A). Notably, 5’ AZA and 5’ AZA+TSA treatment groups are 
clustering closely and are widely separated from the DMSO control, illustrating 
more similar gene expression profiling between the 5’ AZA and 5’ AZA+TSA 
treatments than the negative control. ANOVA carried out using treatment as a 
single factor showed genes significantly differentially expressed (Fold 
change>1.5 or <-1.5, FDR<0.05) due to different treatments (Figure 3-B). In cell 
line C81-61, a total of 54 genes were similarly influenced by treatments of 5’ AZA 
and 5’ AZA+TSA. 
 
A large number of candidate genes potentially subject to methylation-dependent 
transcriptional silencing have been identified. 78 genes were significantly 
upregulated following methylation reversal in at least 2 of 5 melanoma cell lines 
(Fold change > 1.5, Listed in Table 3-2), including 2 genes TIMP1 and DKK1 that 
were up-regulated in all 5 cell lines, and 7 genes PPM2C, SERPINI1, GLRX, 
EGR2, KDELR3, FN1 and TMEM158 that were up-regulated in 3 cell lines. We 
selected two genes DKK1 and EGR2 for further investigation due to their large 
CpG islands. TFPI2 was also chosen for additional study because it showed the 
highest fold change in two cell lines. 
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To gain insight into the biological function of these candidate genes, pathway 
analysis was carried out using the DAVID (the database for Annotation, 
Visualization and Integrated discovery) bioinformatics tool. Candidate genes 
involved in pathways such as TGF-β signalling, antigen presentation and 
processing signalling and cancer related pathways (Figure 3-2) were visualized 
on Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database. 
TGF-β signalling plays a critical role in the regulation of multiple cancer 
associated biological events in a context dependent manner (Hannigan et al.). It 
Figure 3-1: Analysis of methylation reversal screen in cell line C81-61. 
(A): Principle component analysis investigating the effects of distinct treatments 
during methylation reversal assay. The figure shows that the effects of AZA are 
mainly captured on the second principle component while on the third principle 
component clearly shows the effects of TSA. There is clear clustering of gene 
expression according to treatment with AZA or with AZA plus TSA compared with 
DMSO control. (B): Venn Diagram showing the gene profiles in 5’ AZA treated 
group and 5’ AZA+TSA treated group. 
Second principle component 
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has both pro-oncogenic and tumour suppressive functions in human cancers. 
Hence, I selected two TGF-β signalling components SMAD3 and TSC22D1 
identified in our screen, and have investigated their impact on TGF-β signalling in 
the context of transcriptional silencing by DNA methylation.  
 
 
 
 
 
 
 
 
 
Table 3-2: Candidate genes identified by Methylation reversal screen 
PPM2C DUSP1 ODC1 ARNTL TncRNA DUSP6 LOC151534 SERPINE2 
SERPINI1 HIST1H2BK CCL20 BIRC3 ZNF135 ENC1 KLF4 LEP 
GLRX RBM15 GCH1 C21orf2 CYR61 APLP2 ERRFI1 SMAD3 
EGR2 FUCA1 ACVRL1 FLNB DDR1 CDKN2B CXADR HIST2H2BE 
KDELR3 PBEF1 CD36 GADD45A IL8 TFPI2 FAT LPL 
FN1 TCEB3 DCBLD2 GJB1 LYRM7 LGMN MGST3 PDE6G 
TMEM158 HIST1H1C VIM GJB2 SLC7A8 LOC729408 KDM1A SULT1C1 
TSC22D1 NFE2L3 C4orf18 SOD2 HLA-A MYO15B ADFP MYO5A 
ID1 HSPA2 MMP1 IER3 HLA-B TMSB4X ARFGAP3  
ANXA1 CTGF HPRT1 GLIPR1 THBS2 DKK1 TIMP1  
Figure 3-2: Pathway analysis by David bioinformatics (National Institute of Allergy 
and Infectious Diseases (NIAID)). 
http://david.abcc.ncifcrf.gov/ 
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3.2.1.1 Investigation of TFPI2 methylation in melanoma 
 
3.2.1.1.1 Genomic structure of TFPI2 
 
TFPI2 is located on the reverse strand of chromosome 7q22, and consists of five 
exons and four introns, with its CpG island overlapping the promoter region, Exon 
1 and Exon 2 (Figure 3-3 A). In this study, I have explored two analytic 
techniques, MSP and pyrosequencing to examine the methylation status of 
TFPI2 in melanomas. Pyrosequencing analysis was performed in collaboration 
with Dr Cristiana Lo Nigro (Cuneo, Italy). Figure 3-3 B shows the positions of the 
primers for two protocols that were designed with proximity to the transcription 
start site (TSS). 
 
 
 
 
 
 
 
 
A 
B 
CpG island 
3’ 
I V II III IV 5’  
CpG island 
Figure 3-3: Genomic structure of human TFPI2 gene.  
(A): Schematic diagram of TFPI2 gene including 5’ and 3’ UTRs, exon-intron 
boundaries and the location of the CpG island; (B): CpG dinucleotides of CpG island 
and the location of MSP and pyrosequencing primers. Red bars represent the individual 
CpG dinucleotides. 
 
Product size: 170 
Product size: 154 bps 
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3.2.1.1.2 Identification of TFPI2 methylation in melanoma cell lines 
 
I initially tested the reproducibility of the two methylation-investigative techniques 
in a subset of cell lines. MSP analysis showed that TFPI2 was methylated in 3 of 
6 melanoma cell lines, and unmethylated in 2 independent preparations of 
normal human epidermal melanocytes, HEMA-LP and HEMN-LP (Figure 3-4 A). 
Consistent methylation status of the same cell lines was shown by 
pyrosequencing (Table 3-3), indicating good reproducibility for the two assays. In 
total, I have observed TFPI2 DNA methylation in 11/17 of the melanoma cell lines 
in our panel and complete absence of methylation in the melanocytes (and 
normal keratinocyte) controls.  
 
The mean methylation level and methylation status of TFPI2 is shown in Table 3-
2. Representative pyrograms of TFPI2 unmethylated cell line WM266.4 and 
methylated cell line SKMEL-23 are shown in Figure 3-4 B.  
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Figure 3-4: Identification of TFPI2 methylation in melanoma cell lines by MSP 
(A) and pyrosequencing (B).  
(A): MSP analysis of TFPI2 methylation. The presence of visible bands in the 
methylated or unmethylated lanes indicates the methylation status of TPFI2. 
Methylated and unmethylated control DNA samples, processed in parallel with test 
samples, were included in the MSP reactions. (B): Pyrograms of TFPI2 methylation 
in WM266.4 and SKMEL23 cell lines. The digital numbers (%) represent the 
methylation percentage of individual CG dinucleotides.   
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Pyro 2 5 90 90 2 1 20 20 32 81 38 50 93 67 2 2 2 2 42 2 
MSP U U M M U U M M M M M M M M U U U U M U 
Table 3-3: Mean methylation (%) and methylation status of TFPI2 in melanoma cell lines, melanocytes and 
keratinocytes by pyrosequencing and MSP, respectively. 
*The digital numbers represent the methylation percentage (%) of candidate genes in melanoma cell lines. (M and U represent the 
methylation status of candidate genes).  
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3.2.1.1.3 TFPI2 mRNA expression is transcriptionally regulated by promoter methylation 
 
I subsequently analysed expression of TFPI2 by qPCR in the same cell line panel and observed a significant inverse 
correlation between methylation and gene expression (p < 0.05, Figure 3-5 A). For example (Figure 3-5 B, C), TFPI2 was 
almost fully methylated in Mel501 and Mel505 cell lines with no associated gene expression. In contrast, methylation was 
undetectable in cell line C8161 which showed abundant TFPI2 expression. Mean methylation of 20% in A375M and 
WM239A cell lines correlated with low TFPI2 expression, suggesting that modest levels of DNA methylation may be 
sufficient to reduce expression.  
Figure 3-5: Inverse correlation of TFPI2 methylation and gene expression. 
(A): Mann Whitney test (one-tailed, p<0.05) showing that expression of TFPI2 in cases positive for CpG island methylation 
was significantly lower than in cases negative. (B, C): Gene expression and methylation of TFPI2 in five representative 
melanoma cell lines, showing inverse correlation between expression (B) and CpG island methylation (C). 
C A B 
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To seek further evidence that TFPI2 CPG island methylation transcriptionally 
silences gene expression, I treated melanoma cell lines with the demethylating 
agent 5’ AZA, with or without additional TSA. Cell lines COLO829 (50% TFPI2 
methylation) and MEL501 (90% TFPI2 methylation) do not normally express 
TFPI2 mRNA, however, treatment with 5’ AZA and TSA dramatically restored 
expression (Figure 3-6). Interestingly, methylation reversal treatment also 
produced a small increase in TFPI2 expression in cell line SKMEL2, a cell line 
with no detectable methylation. In comparison, COLO819 and MEL501 showed 
a >1700 fold change increase in mRNA but only a five-fold increase was seen in 
SKMEL2. Moreover, restored TFPI2 expression in SKMEL2 remained lower than 
in the other two cell lines. Modest upregulation of TFPI2 gene expression in 
SKMEL2 may be due to an indirect effect of upstream targets, as methylation 
reversal treatment causes a global hypomethylation, and is no restricted to 
specific targets. Another explanation for this observation is that expression 
associated DNA methylation at alternative CpG sites has not been sampled by 
our methodology.  
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3.2.1.1.3 TFPI2 CpG island methylation and expression in paired melanoma 
cell lines  
 
Next I extended my cell line investigations to examine TFPI2 in poorly metastatic 
parental cell lines and matched highly metastatic daughter cell lines. A significant 
decrease in TFPI2 expression was detected in the highly metastatic derivatives 
WM266.4 and WM293A, LM9 and LM29 in comparison to their parental lines 
WM115 and LM2, respectively (Figure 3-7 A). An inverse pattern of TFPI2 
methylation was also shown (Figure 3-7 B). However, I noticed that the level of 
methylation in the paired metastatic derivatives was quantitatively different 
(Figure 3-7 B) with rather less methylation and less suppression of mRNA in LM9 
Figure 3-6: Reactivation of TFPI2 expression by pharmacological 
demethylation.  
The indicated cell lines were grown in the presence of 5’ AZA, TSA, both agents 
(A + T) or drug vehicle only (DMSO).  Expression of TFPI2 was determined by 
qPCR. Data shown are mean +/- 1SD from 3 independent experiments. 
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than LM29.  Thus, absolute silencing of TFPI2 is not a prerequisite for metastasis. 
Notably, increased TFPI2 methylation was not exactly proportional to the 
decrease in gene expression, suggesting other genetic or epigenetic 
mechanisms may regulate TFPI2 mRNA expression co-ordinately with DNA 
methylation. Alternatively, methylation of other CpG dinucleotides within the CpG 
island may contribute to transcriptional downregulation of gene expression. 
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Figure 3-7: TFPI2 CpG island methylation and expression in paired melanoma cell 
lines. 
(A): qPCR analysis of TFPI2 in paired (non-metastatic / weakly metastatic) parental cell 
lines and highly metastatic daughter cell lines. Data shown are mean +/- 1SD from 3 
independent experiments. B: Pyrograms of TFPI2 CpG island in the same cell lines. 
Methylation was quantified by the intensity of shading in the circles, each of which 
represents an individual CG dinucleotide. 5 levels of shading are used as indicated in the 
figure. In all cases, methylation increased in the highly metastatic cell lines relative to the 
respective parental cell line. 
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3.2.1.1.4 TFPI2 CpG island methylation may correlate with melanoma 
progression 
 
Identification of TFPI2 methylation in melanoma cell lines and the likely 
association with metastasis, prompted me to investigate the methylation status of 
TFPI2 in clinical melanoma samples. Accordingly, pyrosequencing was 
performed on 122 clinical samples from melanoma patients at different stages of 
disease. The study population included 53 primary melanomas, 59 metastases 
and 9 benign pigmented naevi which served as negative controls. Less than 5 % 
mean methylation is usually considered as background noise. Pyrosequencing 
analysis showed that TFPI2 was methylated at higher than 5% in 0/9 of benign 
neavi, 35/44 (80%) of primary melanomas and 56/64 (88%) of metastatic 
melanomas. The complete absence of TFPI2 methylation in all 9 benign naevi 
and the high frequency of TFPI2 methylation in both primary and metastatic 
melanomas (Figure 3-8 and 3-9) suggests that TFPI2 methylation is an 
appropriate cancer biomarker being specifically detectable in cancer but not in 
the benign control. 
 
The level of methylation in the TFPI2 CpG island increased as a function of 
melanoma progression with the highest methylation level found in the metastatic 
cases (Figure 3-9). By performing the Mann-Whitney U test, I observed a 
significantly higher level of TFPI2 CpG island methylation in metastases 
compared to primary tumours (p < 0.05), and both groups showed a much higher 
methylation level than benign controls (p < 0.01 and p < 0.001, Figure 3-9). It 
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appears that TFPI2 methylation does correlate with melanoma progression. This 
now requires validation in a larger data set. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0-5% 6-10% 11-20% 21-50% 51-100% 
Figure 3-8: Pyrosequencing profiles of TFPI2 CpG island methylation in 
benign naevi, primary and metastatic melanomas.  
Methylation is quantified by the intensity of shading in the circles, each of which 
represents an individual CpG dinucleotide. 5 levels of shading are used as 
indicated in the figure.  
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Having observed a correlation between TFPI2 methylation and melanoma 
progression, I proceeded to investigate TFPI2 methylation in paired primary 
melanoma and metastases collected from the same patients. I performed crude 
micro-dissection on these specimens after histopathological examination to 
obtain high tumour cell representation without contamination from normal tissue 
and/or inflammatory cells. This will allow us to make a relatively more accurate 
assessment of the difference between primary melanomas and metastatic 
disease. However, only limited numbers of melanoma tissues are suitable for 
crude micro-dissection, because of technical difficulties posed by high pigment 
levels inside tumours or high levels of tumour-associated inflammatory cells, or 
extensive infiltration of tumour cells into the stroma.  
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Figure 3-9: Mann Whitney U analysis of TFPI2 CpG island methylation in 
benign naevi, primary and metastatic melanomas.  
Mean % methylation was determined by pyrosequencing. Methylation is strongly 
associated with melanoma and specifically with metastatic melanoma. 
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Table 3-4: TFPI2 methylation at individual CpG site of promoter region in 6 paired 
primary and metastatic melanomas from the same patients 
 
Patient CpG 1 CpG 2 CpG 3 CpG 4 CpG 5 CpG 6 CpG 7 CpG 8 CpG 9 Sum 
1  P 8 15 31 20 25 36 21 23 21 200 
M 19 29 34 36 36 48 49 31 34 316 
2  P 4 39 59 32 43 22 1 4 1 205 
M 14 17 65 44 44 52 65 16 15 332 
3  P 0 0 10 0 3 7 0 0 0 20 
M 0 0 14 2 5 8 0 2 2 31 
4  P 0 0 13 0 2 7 0 1 2 23 
M 0 0 23 0 11 15 0 2 1 51 
5  P 0 0 10 0 8 13 0 0 0 31 
M 0 0 21 6 11 16 0 4 7 58 
6  P 0 0 21 1 9 12 0 3 4 50 
M 0 0 19 1 7 11 0 4 4 46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary Melanoma 
 
Lymph Node Metastasis 
4 
2 3 
5 
1 
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Figure 3-10: TFPI2 CpG island methylation increases in metastatic melanoma relative 
to matched primary melanoma. 
Eight paired primary and metastatic melanomas from the same patients were analysed by 
pyrosequencing for TFPI2 methylation. The figure shows % methylation at each of 9 
individual CpG dinucleotides. Primary melanomas are shown in blue and metastatic 
melanomas in red. The metastases were lymph node in all cases. Tissues were subject to 
microdissection to enrich for malignant cells prior to DNA isolation. 
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Of 8 paired melanomas that I examined, 5 pairs (patients 1, 2, 3, 4, and 5) 
showed increased TFPI2 methylation in the metastasis compared to the matched 
primary melanomas at each CG dinucleotide, one pair (patient 6) showed similar 
methylation levels, and 2 pairs did not show clear differences with higher 
methylation in some CpGs in metastases but lower methylation in the others 
(Table 3-4 and Figure 3-10. These results clearly support a potential role for 
TFPI2 CpG island methylation in predicting tumour progression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-11: Quantitative TFPI2 CpG island methylation profiles from serum 
of healthy volunteers (Normals), patients with no metastases and patients 
with metastases.  
(A): Representative profiles. (B): Summarised analysis of all sera. Mean % 
methylation was determined by pyrosequencing as described in Methods. 
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3.2.1.1.5 TFPI2 CpG island methylation in melanoma patient sera 
 
 
The presence in serum of circulating DNA released from tumour cells has 
provided us with a novel approach to detect DNA methylation in cancer patients’ 
peripheral blood. Theoretically, therefore, increased methylated DNA will be 
detected in patients who develop metastatic disease, particularly those patients 
with visceral metastases. To address this hypothesis, we used pyrosequencing 
to determine TFPI2 CpG island methylation levels in a series of 41 serum 
samples from 6 healthy volunteers and 35 melanoma patients. An advantage of 
pyrosequencing over many other methylation detection techniques is the high 
sensitivity and resolution (at the level of individual CG dinucleotides). DNA in 
circulating blood released from tumour cells is typically present at low levels and 
is difficult to quantify by conventional methods. However, a number of studies 
have illustrated the utility of pyrosequencing in detecting circulating DNA 
methylation in cancer patients’ peripheral blood (Korshunova et al. 2008; 
Sturgeon et al. 2012; van Bemmel et al. 2012; Yoon et al. 2012; Tahara et al. 
2013; Zmetakova et al. 2013). 
 
 
In my study, I successfully detected TFPI2 methylation in circulating blood from 
melanoma patients, and TFPI2 methylation increased according to the degree of 
tumour progression as shown in Figure 3-9. Unsurprisingly, TFPI2 methylation 
was detectable but at lower levels in serum from 6 healthy volunteers and from 
melanoma patients with no metastases. 
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I next compared TFPI2 methylation in 20 cases where both tissue and serum 
samples were available, and observed an overall correlation between the two 
groups. Importantly, patients with TFPI2 methylation in serum also showed 
detectable methylated DNA in their tissues (Figure 3-12 A), although the 
methylation level of TFPI2 in serum samples did not correlate with Breslow 
thickness (Figure 3-12 B). However, I discovered that the level of TFPI2 
methylation was statistically significantly higher (p < 0.01, Figure 3-12 C) in cases 
where metastatic involvement was known compared to cases in which 
metastasis was not suspected, regardless of the Breslow thickness of the 
primary tumour. To assess the significance of TFPI2 methylation in specifically 
detecting metastatic disease, a receiver operator characteristic (ROC) curve was 
generated by GraphPad Prism Software to compare TFPI2 methylation levels 
between individuals with and without metastases. This analysis demonstrated a 
diagnostic sensitivity of 74% and specificity of 91% for metastatic disease when a 
mean methylation cut-off value of TFPI2 methylation of 4.5% in serum is applied. 
The area (0.9015) under the curve (AUC) measurement illustrated that 86% of 
melanoma patients with metastases have significantly higher TFPI2 methylation 
level than individuals without metastases (p < 0.0001, Figure 3-12 D). 
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ROC Curve 
Figure 3-12: Detection of methylated TFPI2 CpG island genomic DNA in serum is 
associated with metastatic melanoma.  
(A): Concordance of tissue and serum pyrosequencing of TFPI2 CpG island in melanoma 
patients. Pyrosequencing of genomic DNA from tissue and serum was done as described in 
Methods. The figure shows the 20 paired cases for which tissue and serum was available. In 
each case, mean % TFPI2 CpG island methylation in melanoma tissue is shown in the black 
box and mean % TFPI2 CpG island methylation in corresponding serum is shown in the 
white box. (B): Scatter plot of serum TFPI2 CpG island methylation vs Breslow thickness. 
CpG island methylation is independent of Breslow thickness. (C): Mann-Whitney analysis of 
mean % CG methylation in patients without metastatic disease (No metastasis) and known 
metastatic disease (Metastasis). Detection of TFPI2 CpG island methylated DNA in serum is 
strongly associated with the presence of metastatic disease (p < 0.01). (D): Receiver 
Operator Characteristic curve showing predictive utility of detection of TFPI2 CpG island 
methylated DNA in serum of patients with melanoma in the diagnosis of metastatic disease. 
The ROC curve was constructed as described in Materials and Methods. 
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3.2.1.2 DNA methylation of DKK1 and EGR2 
 
 
I initially validated methylation reversal data in cell lines MEL501, MEL505 and 
MEL224 that showed up-regulated expression of DKK1 and EGR2 upon 
methylation reversal treatment. Consistent with the microarray data, these three 
cell lines all showed significant restored DKK1 and EGR2 gene expression 
(Figure 3-13).   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  MEL501       MEL505        MEL224       MEL501        MEL505       MEL224     
                      DKK1                                                      EGR2     
Figure 3-13: Expression of DKK1 and EGR2 in melanoma cell lines with 
methylation reversal treatment.  
All cell lines were either treated with DMSO as the negative control or treated with 
demethylating agents 5’ AZA and TSA. Each treatment condition was performed in 
biological triplicates. Gene expression was measured by qPCR. T test was used to 
compare the significant difference between DMSO control and 5’AZA+TSA 
treatment. ***  is p value < 0.001. 
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MSP was then performed to identify the methylation status of these two 
candidates in our melanoma cell line panel and in normal melanocytes and both 
genes have shown a high frequency of methylation.  
 
EGR2 was methylated in 12/17 (71%, Figure 3-14 B) of the melanoma cell lines, 
but not in normal melanocytes, (HEMA). Disappointingly, I did not observe a 
correlation between DNA methylation and mRNA expression (Figure 3-14 C). For 
example, in MEL501 and SKMEL2 cell lines, ie those with the highest expression, 
EGR2 was found to be methylated, and in contrast cell lines that were 
unmethylated showed generally a low level of mRNA expression. EGR2 
methylation has been reported to act like an enhancer that induces gene 
expression (Unoki and Nakamura 2003), but I did not detect this correlation in 
our methylation positive cell lines. Lack of correlation between EGR2 methylation 
and gene expression suggested EGR2 methylation is not a gene expression 
regulatory mechanism in melanoma cell lines.  
 
EGR2 was not methylated in cell line MEL505, a line in which gene expression 
was induced by methylation reversal treatment (Figure 3-13). Upregulation of 
EGR2 expression in MEL505 cells after methylation reversal treatment may 
represent an indirect effect of demethylating an upstream gene. Another 
possibility is that failure to detect methylation of EGR2 by MSP may be a false 
negative result.  
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Figure 3-14: Methylation and expression of EGR2, as well as methylation of DKK1.  
(A), (B):  Methylation of DKK1 and EGR2 in 17 melanoma cell lines and melanocyte HEMA by 
MSP, respectively. (C): Relative expression of EGR2 mRNA (qPCR) in 12 methylated and 5 
unmethylated cell lines and unmethylated melanocytes (HMEMA). 
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Despite the high frequency of methylation seen in melanoma cell lines (14/17, 
77%, Figure 3-14 A), DKK1 was also methylated in normal human melanocytes 
(HEMA), indicating that DKK1 is not exclusively differentially dysregulated in 
melanomas. As such, DKK1 does not meet the criteria for a melanoma biomarker. 
 
Taken together, these results imply that despite being frequently methylated in 
melanoma cell lines, EGR2 and DKK1 are not suitable melanoma biomarkers for 
further development. 
 
 
3.2.1.3 CpG island methylation of TGF-β signalling components SMAD3 and 
TSC22D1 
                                                                                                                                                           
3.2.1.3.1 SMAD3  
 
 
I have identified SMAD3 methylation in melanoma by pyrosequencing. To our 
knowledge, SMAD3 methylation has not been reported previously in human 
cancers. In my study, SMAD3 showed a high frequency of methylation in the 
melanoma cell line panel (14/17, 82%), but a low frequency in melanoma tissues 
(24/94, 22%). SMAD3 methylation was also detected at only a low level in normal 
human keratinocytes (NHK, 7%) and melanocytes (HEMA, 10%). However, 
promoter methylation of SMAD3 is unlikely to be a mechanism to regulate gene 
expression, because I was unable to show any correlation between SMAD3 
mRNA expression (Figure 3-15 A) and methylation (Figure 3-15 B).  
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Figure 3-15: Expression (A) and methylation (B) of SMAD3 in melanoma cell lines and 
melanocyte HEMA and keratinocyte NHK.  
(A): Relative expression of SMAD3 mRNA (qPCR) in 17 melanoma cell lines, a 
melanocyte line (HEMA) and normal human keratinocytes (NHK). (B): Average 
methylation (%) of CpG dinucleotides within SMAD3 gene promoter determined by 
pyrosequencing in 17 melanoma cell lines, HEMA and NHK.” 
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3.2.1.3.2 TSC22D1 
 
 
There are two isoforms of TSC22D1, a short isoform TSC22D1.1 and a long 
isoform TSC22D1.2 (Figure 3-16 C). Homig-Holzel et al. have reported their 
antagonistic roles in regulating senescence in human keratinocytes and 
melanocytes (Homig-Holzel et al. 2011). Our methylation reversal screen 
suggested that TSC22D1 was potentially methylated in melanoma, so I 
hypothesized that methylation-related TSC22D1 gene silencing may be a 
mechanism that attenuates the senescence pathway in melanoma.  
 
To test this hypothesis, I first needed to determine the methylation status of 
TSC22D1 gene in melanoma cell lines. The antagonistic function of the two 
isoforms in senescence prompted me to study the two isoforms separately. I 
performed qPCR on methylation reversal agent-treated cell lines including 
MEL501, MEL505, as well as cell line MEL224 which showed upregulated 
TSC22D1 expression in microarray data. Demethylating agents 5’ AZA and TSA 
failed to restore gene expression of TSC22D1.1 in all three cell lines (Figure 3-16 
A), suggesting that expression of TSC22D1.1 is not controlled by methylation. 
Conversely 5’ AZA and TSA treatment upregulated TSC22D1.2 expression in 
MEL501 and MEL224 (Figure 3-16 B), although not significantly, suggesting 
TSC22D1 isoform 2 may be methylated in melanoma.  
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I next used pyrosequencing to verify TSC22D1.2 methylation in 10 melanoma 
cell lines. TSC22D1.2 has a short CpG island of 244 base pairs, and I designed 4 
sets of pyrosequencing primers whose products cover the whole CpG island. The 
PCR product of the fourth set of primers was near the TSS. As shown in Figure 
3-17 A and B, cell line PMWK is heavily methylated through the whole CpG 
island, and this is associated with absent gene expression. Methylation was also 
detected in cell lines C8161 and SKMEL23, albeit at different locations. Low 
mRNA expression in SKMEL23 cell line and high mRNA expression in C8161 
cell line implies that methylation near TSS has more influence on regulation of 
gene expression. In the remaining 7 melanoma cell lines I did not detect 
methylation of TSC22D1.2 by pyrosequencing. In a subset of 30 melanoma 
tissue samples, TSC22D1.2 was only methylated in 2 cases. The low frequency 
of methylation in TSC22D1.2 in melanoma cell lines and tissues suggested that 
TSC22D1.2 methylation is only detectable in a small subset of melanoma and is 
not, therefore, likely to have utility as a melanoma biomarker. 
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TSC22D1 isoform 1 
A 
 
TSC22D1 isoform 2 
B 
C 
Figure 3-16: Reactivation of TSC22D1.1 and TSC22D1.2 expression by 
pharmacological demethylation (A, B) and the genomic structure of the human 
TSC22D1 gene (C).  
(A, B): The indicated cell lines were grown in the presence of 5’ AZA, TSA, both agents (A + 
T) or drug vehicle only (DMSO). Expression of TSC22D1.1 and TSC22D1.2 was determined 
by qPCR. Date shown is mean +/- 1SD from 3 independent experiments. (C): Schematic 
diagram of TSC22D1 gene including 5’ and 3’ UTRs, exon-intron boundaries, CpG island, 
and the location of pyrosequencing primers. 
TSC22D1 isoform 1 
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Figure 3-17: Methylation and expression of TSC22D1.2 in melanoma cell lines.  
(A): Detection of TSC22D1.2 CpG island methylation by 4 sets of pyrosequencing 
primers. (B): mRNA expression of TSC22D1.2 by qPCR. 
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3.2.2 Identification of candidate genes by systematic methylation 
profiling and gene expression profiling in paired melanoma cell lines 
 
Gene expression profiling and methylation profiling for identification of genes that 
are differentially epigenetically regulated between primary and metastatic 
melanoma cell lines were performed on the following 3 sets of melanoma cell 
lines which were derived from 3 patients:  
 
Table 3-5: Paired melanoma cell lines used for microarray analysis 
 
 Primary 
Metastasis 
Lymph node 
Metastasis 
Skin 
Set 1 WM115 WM239A WM266.4 
Set 2 LM2 LM9 LM29 
Set 3 WM983A WM983B  
 
For initial data analysis (work flow shown in Figure 3-19), gene expression from a 
microarray experiment was analysed by Dr Runxuan Zhang (The James Hutton 
Institute, Dundee) (analysis protocol shown in section 2.6.2). This generated a 
list of 60 genes that were either downregulated in three lymph node metastatic 
cell lines (WM239A, LM9, and WM983B) or in any 4 out of the 5 metastatic cell 
lines. A ﬁlter criteria of at least a 1.5-fold change with adjusted p<0.01 (Figure 3-
18) was applied to this analysis. To investigate whether downregulation of these 
60 candidates was dependent upon DNA methylation, Dr Helena Carén 
(Sahlgrenska Cancer Centre, Gothenburg, Sweden) compared methylation levels 
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between primary and metastases within each set of cell lines This study identified 
30 genes (A2M, ACOX2, BCAT1, CA9, CBFA2T3, CYP1B1, GOLGA8B, HRH2, 
KIF26B,MAOA,MAP1B,MAP1LC3A,PCSK1,PDK4,PRDM16,RAB31,SEZ6L2,TC
EA2,TUBB2B,ZNF788,EFNB2,FAM-134B, HLA-DPA1, IFITM1, LIMCH1, MT1E, 
MX1, RASAL1, TCEA3, TFPI2) which showed methylation changes at more than 
5 methylation variable positions (MVPs); selected through a filter criteria of an 
adjusted p-value of <0.01 and with a change in the beta-value (methylation 
frequency) of more than 20%.  
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Figure 3-18: Heat map visualization of 60 genes that are signiﬁcantly downregulated in all 
three lymph node metastatic or 4/5 metastatic melanoma cell lines.  
Columns: samples; rows: genes; colour key indicates gene expression (mRNA) where red is 
significantly downregulated compared with green. Primary melanoma cell lines WM115, LM2 and 
WM983A were clustered at left of figure whereas metastatic cell lines WM239, LM9, WM266, LM9 
and WM983B were clustered to the right. 
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A further data mining process investigated whether these 31 genes are 
differentially regulated in other gene expression studies by searching a cancer 
microarray database platform, Oncomine (Rhodes et al. 2004). Three separate 
studies, the Riker study, the Haqq study, and the Talantov study, detailed in 
Oncomine website, have systematically compared gene expression between 
melanoma tissues and normal tissues. From this process only 7 of 30 from the 
original gene panel remained (Table 3-6). These 7 genes were also significantly 
downregulated in the metastasis compared to primary melanomas in three 
studies Riker, Xu, and Haqq. Of these 7 genes all had a well-defined CpG island 
and so all 7 genes passed the selection criteria for suitable candidate methylated 
genes for melanoma. Summary of the data mining results for these 7 genes: 
A: significantly downregulated in metastasis of all 3 paired primary and 
metastatic melanoma cell lines. 
B: methylated at significantly higher levels in metastasis in all 3 sets. 
C: significantly downregulated in melanoma tissue samples compared to 
benign neavus 
D: have a well-defined CpG island 
 
Therefore, further investigation of gene expression and methylation of these 7 
genes (LIMCH1, HLA-DPA1, EFNB2, RASAL1, TCEA3, MT1E, FAM134B) will 
be undertaken in our collection of melanoma cell lines, melanoma tissues and 
serum samples. This will be a future continuation of my work and is beyond the 
scope of this thesis. 
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7 genes for further validation (expression and methylation): 
LIMCH1, HLA-DPA1, EFNB2, RASAL1,  
TCEA3, MT1E, FAM134B 
Expression profiling analysis: 60 genes downregulated in all three 
lymph node metastasis or 4/5 metastasis. 
Methylation profiling analysis: 30 genes have 5 or more MVPs AND 
associated with downregulated gene expression 
Oncomine database: Significantly downregulated in melanoma vs 
skin or in metastasis versus primary melanoma in other gene 
expression profiling 
Figure 3-19: Data mining work flow for the identification of differentially 
epigenetically regulated candidate genes in 3 paired melanoma cell 
lines. 
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Table 3- 6: Differential expression results of candidate genes in RIKER, HAQQ 
TALANTOV, XU tissue studies and their CpG island status 
 
Melanoma versus skin (√: Significantly downregulated in melanoma 
versus benign naevus other skin) 
  RIKER  HAQQ  TALANTOV  CpG island 
LIMCH1 √ √ √ √ 
HLA-DPA1 NO NO √ √ 
EFNB2 √ √ √ √ 
RASAL1 NO N.D. √ √ 
TCEA3 √ √ N.D. √ 
MT1E √ NO NO √ 
FAM134B  √ NO NO √ 
Metastasis versus primary melanomas (√: Significantly downregulated in 
metastatic melanoma versus primary melanomas. ) 
  RIKER  XU Haqq CpG island 
LIMCH1 √ √ NO √ 
HLA-DPA1 NO √ NO √ 
EFNB2 NO √ √ √ 
RASAL1 √ √ N.D. √ 
TCEA3 √ NO UP √ 
MT1E NO √ NO √ 
FAM134B  NO √ √ √ 
 
NO: No statistical significance. N.D.: Not done. UP: upregulated 
RIKER, HAQQ, TALANTOV analysis results were obtained from Oncomine website 
(https://www.oncomine.com). 
CpG island status was obtained from UCSC genome browser (genome.ucsc.edu/ ).  
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3.3 Discussion 
 
The use of pharmacological demethylation to identify epigenetically silenced 
genes is a recent technique building upon the basis that DNA methylation is a 
reversible phenomenon. It has been successfully used to study methylation 
events in tumours, particularly when accompanied by gene expression profiling 
to identify candidate genes that are transcriptionally silenced by DNA methylation 
whose expression is reactivated by demethylation. This approach has 
established useful protocols for DNA methylation studies, and these are 
especially applicable for methylation biomarker investigation. 
 
However, the results of methylation reversal experiments must be interpreted 
with some caution. Methylation reversal only informs as to whether a particular 
gene is potentially methylated, but it does not provide information about the exact 
gene sequence where methylation occurs. Many genes have extensive CpG 
islands containing hundreds of CpG sites, within which only a small part of the 
CpG island, such as the part near the TSS is likely to be critical for transcriptional 
regulation. Techniques such as MSP or sequencing based techniques such as 
pyrosequencing or bisulfite sequencing can be used to narrow down the 
methylation status to a specific region in the gene sequence. In the case of 
pyrosequencing, multiple sets of primers may be required to cover as much of 
the entire CpG island as possible, as the optimal size of pyrosequencing product 
is only approximately 100 base pairs, and can be even smaller when testing 
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patient materials. This potentially limits the utility of this technique in gene 
discovery given the cost of pyrosequencing. 
 
Global demethylation can also result in inappropriate upregulation of some genes. 
Many genes can be spuriously or indirectly upregulated by global demethylation. 
For example, expression of a particular gene can be altered due to methylation of 
an upstream regulator of this particular gene. Therefore, upregulation of a 
particular gene may be a consequence of restored gene expression of its 
methylated upstream regulator by the demethylating treatment. We have seen 
this in our methylation reversal screen, where a large number of genes were 
upregulated, yet, many of these candidates don’t have CpG islands. I saw this 
with TIMP1, HLA-A and IL8. However, we must bear in mind that methylation of 
areas other than the CpG island may also regulate gene expression (Jones 
2012). Inconsistent results between methylation reversal screens and 
downstream investigations have been reported for some genes. In my study for 
example, EGR2 was upregulated in cell line MEL505 in our methylation reversal 
screen, but its methylation was undetectable by MSP. 
 
Another technique often used in place of methylation reversal is a methylation 
microarray. This methodology has the advantage of being applicable to a wider 
range of starting materials, including cell line material, frozen tissue and paraffin-
embedded tissue whereas methylation reversal analysis clearly requires living 
cell line starting material. Methylation microarray is also more powerful than 
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methylation reversal analysis because it can inform the methylation level of a 
particular gene and of the exact sequence that is methylated. It should be noted, 
however, that methylation of candidate genes identified by methylation 
microarrays may not correlate with gene expression. Many genes that undergo 
methylation are very likely to be related to non-tumourigenic events, such as 
maintained cell type specific lineage commitment which was already established 
in embryogenesis (Sproul et al. 2011), or de novo (new) methylation which 
occurs in normal tissues later than embryogenesis, such as de novo methylation 
on inactive X-chromosome (Keshet et al. 2006). This disadvantage can be 
overcome by integrating methylation data with gene expression data to validate 
methylation reversal assay results. Indeed I have attempted to do this here in my 
work. Integration of gene expression profiling and methylation profiling has 
rigorously selected the candidate genes whose regulation is dependent upon 
methylation. Data mining has ultimately provided us with 8 candidate genes for 
further investigation. Of particular note is TFPI2 which was also identified by both 
methylation reversal analysis and integrative analysis, suggesting consistency 
between methylation reversal screen results and methylation profiling candidate 
approaches. 
  
Identification of TFPI2 by our methylation reversal screen has provided us with 
an encouraging and promising methylation biomarker for melanoma. An eligible 
epigenetic biomarker for melanoma must meet certain criteria: (i) exclusively and 
frequently dysregulated by DNA methylation in melanoma, but not in the benign 
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tissue equivalent; (ii) clinically useful for predicting tumour progression and 
patient outcome; (iii) correlation of methylation with gene expression, with 
functional significance for the initiation and progression of melanoma. An 
additional necessary requirement for a serum epigenetic biomarker is that 
methylation should be detectable in serum from melanoma patients with 
metastasis, and that this level of methylation should be significantly higher than 
that detected in serum from patients with non-metastatic melanomas. This would 
lead to the possibility of early detection of metastasis by a simple and minimally 
invasive blood test.  
 
The data presented in this chapter shows that TFPI2 has met these requirements. 
First, I have observed a high frequency and high level of TFPI2 methylation in 
melanoma cell lines and patient specimens. In patient samples, including a 
clinical series of approximately equal numbers of non-metastatic and metastatic 
melanomas, and paired primary and metastatic melanomas from the same 
patients, a significantly increased level of TFPI2 CpG island methylation has 
been detected in aggressive metastatic disease. Importantly, methylation in the 
control benign naevi was uniformly low. These results support a role for TFPI2 as 
an epigenetic biomarker that can potentially predict the advanced stages of 
melanoma. The association between TFPI2 methylation and reduced gene 
expression in melanoma cell lines further supports the importance of TFPI2 
silencing in driving the tumour progression. 
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TFPI2 methylation frequencies of 10-20% have been reported in three previous 
melanoma studies (Nobeyama et al. 2007; Liu et al. 2008; Tanemura et al. 2009). 
Comparatively, TFPI2 showed a much higher methylation frequency in our 
melanoma clinical cases. This could be because less sensitive methods for 
detecting methylation were used by these groups. All three studies (Nobeyama et 
al. 2007; Liu et al. 2008; Tanemura et al. 2009) used MSP to assess TFPI2 
methylation in their melanoma patients which is somewhat less sensitive a 
method than the pyrosequencing technique employed in my study. 
Pyrosequencing quantitatively measures the level of cytosine methylation at each 
individual CG site whereas MSP provides a more global assessment of 
methylation. Detection of methylation in patients’ sera requires a very sensitive 
method that can detect the extremely low concentration of free DNA circulating in 
patients’ blood. Additionally, these other studies (Nobeyama et al. 2007; Liu et al. 
2008; Tanemura et al. 2009) have used patient cohorts from Japan and USA. 
Our patients are UK-based, and there may be distinct population variations in 
melanomagenesis associated with different geographical locations. In this study, 
I successfully detected methylated DNA in the serum samples, and most 
importantly, the presence of TFPI2 methylation is associated with metastatic 
disease, regardless of the Breslow thickness of the primary melanoma. A high 
sensitivity of 74% and specificity of 91% of TFPI2 methylation in metastasis 
implies utility as a serum biomarker to detect metastatic disease. I would now like 
to take this forward to determine if TFPI2 is a robust serum biomarker in a multi 
centre prospective study. 
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The other candidate genes highlighted in my investigation have not fully met the 
requirements for an appropriate biomarker. I detected a high frequency of DKK1 
and SMAD3 methylation in our melanoma cell lines, however, both genes were 
also methylated in benign melanocytes, suggesting that the DNA methylation of 
these candidates was not a specific event in melanomagenesis. EGR2 was also 
an unsuitable biomarker because of the lack of association between DNA 
methylation and dysregulated gene expression. The low frequency of TSC22D1 
methylation in melanoma cell lines and melanoma tissue samples illustrated its 
lack of utility as a melanoma biomarker. 
 
In future work confirmation of TFPI2 as a melanoma progression biomarker and 
a melanoma serum biomarker will be undertaken in a larger scale study of 
melanoma tissues and a prospective study, respectively. The molecular function 
of TFPI2 in driving the initiation and progression of melanoma should also be 
investigated. In addition, other candidate genes identified by the integrative 
genome-wide methylation profiling and expression profiling will evaluated for their 
potential as epigenetic biomarkers in melanoma. 
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Chapter 4 Methylation 
investigation of candidate genes 
NT5E, DUSP2, and Dab2. 
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4.1 Introduction 
 
Hundreds of genes have been found to be hypermethylated in human cancers 
(Baylin and Jones 2011). These include those that are ubiquitously methylated in 
a broad range of cancers and those whose methylation is more cancer type 
specific. For example, a mediator of alkylating chemotherapeutic agents’ 
sensitivity (Christmann et al. 2011), O6-methylguanine-DNA methyltransferase 
(MGMT) is methylated in colon cancer, lung cancer, prostate cancer and 
lymphoma etc (Heyn and Esteller 2012), and TFPI2 is methylated in more than 
ten human cancers, as introduced in Chapter 3.1.1. Loss of expression of these 
genes by promoter methylation is therefore likely to be important for the initiation 
and progression of multiple cancer types. It is also very likely that methylation of 
some tumour-related genes is a cancer type specific event (Esteller et al. 2001). I 
therefore wished to determine the methylation status of specific genes in 
melanoma to expand our knowledge of the methylome of this disease. The 
methylation study of NT5E, DUSP2 and Dab2 will be described in this chapter, 
including the background of these three candidates. 
 
4.1.1 NT5E (ecto-5’-nucleotidase, CD73) 
 
NT5E encodes an enzyme located at the plasma membrane that hydrolyses 
extracellular nucleotides into membrane permeable nucleosides (Klemens et al. 
1990). The most recognised signalling pathway involving the catalytic function of 
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NT5E is the phosphohydrolytic conversion from extracellular adenosine 
triphosphate (ATP) to adenosine. The last step of this conversion, generation of 
adenosine from adenosine 5’ monophosphate (AMP) requires NT5E to stimulate 
an adenosine cascade (Zimmermann 1992). Along with its catalytic function, 
NT5E also acts as an adhesive protein that mediates endothelium-binding (Airas 
et al. 1995; Arvilommi et al. 1997) and activation and proliferation of lymphocytes 
(Airas et al. 1997). NT5E activity or expression is elevated in breast carcinoma 
(Canbolat et al. 1996), cutaneous T cell lymphoma (Fukunaga et al. 1989), 
gastric cancer (Durak et al. 1994), and melanoma (Sadej et al. 2006). The well-
established immunosuppressive role of NT5E involving adenosine combined with 
the lymphocyte mediating function of NT5E implies that NT5E will have important 
regulatory functions in the host immune response to human cancers. Improved 
efficacy of T cell immunotherapy and increased in vivo survival rate in an ovarian 
mouse model with NT5E knock down has been observed (Jin et al. 2010). 
Further, Stagg et al. have shown that melanoma mice with deficient NT5E 
escaped from immunosuppression and development of metastasis (Stagg et al. 
2011). More recently Forte et al. introduced the concept of a tumour immunity 
inhibitory role of NT5E by revealing improved anti-tumour immunity when 
inducing B cells in mouse melanoma treated with an NT5E inhibitor (Forte et al. 
2012). These recent studies have provided evidence that NT5E alters tumour 
immunity and tumour progression. 
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It appears that adenosine drives tumour progression via promotion of cell 
proliferation, angiogenesis and drug resistance (Spychala 2000), implying a 
possible involvement of NT5E in these cancer promoting processes. A positive 
correlation between NT5E expression and breast cancer cell growth, invasion, 
migration and adhesion has been described using in vitro knockdown (Zhi et al. 
2007) and over-expression experiments (Zhou et al. 2007; Wang et al. 2008) and 
in in vivo studies (Zhou et al. 2007). However, different studies have reported 
that NT5E may be associated with good or poor prognosis in two breast cancer 
cohorts (Leth-Larsen et al. 2009; Supernat et al. 2012). A reverse impact on cell 
migration of NT5E has been demonstrated in hepatic cells, suggesting its 
potential as a tumour suppressor (Andrade et al. 2011). NT5E has been shown 
to be induced by TGF-β (Regateiro et al. 2013) and in hypoxia (Synnestvedt et al. 
2002; Li et al. 2006). The controversial roles of NT5E shown in different studies 
and regulation of NT5E by microenvironmental elements suggest that NT5E may 
be expressed in a context-dependent and cell specific manner and suggest 
further study of NT5E may yield valuable data. 
 
4.1.2 DUSP2 (Dual-specificity phosphatase 2) 
 
DUSP2 encodes a protein belonging to a subfamily of dual-specificity 
phosphatases which negatively regulate members of the mitogen-activated 
protein (MAP) kinase pathway, i.e. ERK, JNK and p38 by dephosphorylation (Yi 
et al. 1995). The high frequency of aberrant regulation of the MAPK pathway in 
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melanoma suggested the potential involvement of DUSP family members in this 
tumour. Being first cloned in human T cells (Rohan et al. 1993), DUSP2 has 
been identified as involved with immune regulation since it is highly induced by 
activated immune cells and it positively mediates immune cell function and the 
immune response through JNK and ERK kinase (Jeffrey et al. 2006). DUSP2 has 
higher binding affinity to ERK than to p38 and JNK (Zhang et al. 2005) and 
decreased DUSP2 expression has been identified in a variety of human cancer 
cells. By using knockdown and re-expression techniques a role for DUSP2 in 
negatively regulating hypoxia-induced chemoresistance, apoptosis, angiogenesis 
and cell survival has been illustrated (Lin et al. 2011). Yin et al. found that 
DUSP2 is a transcriptional target for p53 that mediates p53-induced apoptosis 
and growth suppression (Yin et al. 2003). Wu et al. further proved the 
engagement of DUSP2 in apoptosis by showing that ectopic DUSP2 expression 
induces apoptosis and suppresses ERK in an E2F-1 dependent manner (Wu et 
al. 2007). Taken together, these studies are consistent with a tumour 
suppressive role for DUSP2. The molecular mechanism facilitating 
downregulation of DUSP2 have not been established, but identification of DUSP2 
methylation in breast cancer cells (Demircan et al. 2009), implies that promoter 
methylation of DUSP2 may make a contribution. However, two other studies 
raise the possibility of an oncogenic role for DUSP2 in malignant neoplasia by 
showing a positive correlation of DUSP2 and association of DUSP2 expression 
with poor outcome of ovarian carcinoma (Le et al. 2002; Givant-Horwitz et al. 
2004). 
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4.1.3 Dab2 (Disabled-2) 
 
Dab2 is an adaptor molecule involved in signalling cascades such as the TGF-β 
pathway and the Wnt pathway (Hocevar et al. 2001; Hocevar et al. 2003). Loss 
of Dab2 protein expression was first identified in ovarian cancer cells and 
cancerous ovary tissues (Mok et al. 1998). Dab2 was subsequently shown to be 
down-regulated in a variety of human tumours, including breast cancer, bladder 
cancer, head and neck squamous cell carcinoma (HNSCC), oesophageal cancer, 
and colorectal cancer (Fazili et al. 1999; Kleeff et al. 2002; Anupam et al. 2006; 
Bagadi et al. 2007; Karam et al. 2007; Hannigan et al. 2011). Identification of 
absent or reduced expression of Dab2 in human cancers suggests Dab2 is a 
tumour suppressor. Several reports show that DNA methylation of Dab2 may 
contribute to this tumour suppression (Bagadi et al. 2007; Tong et al. 2010; 
Hannigan et al. 2011). Dab2 exerts its tumour suppressor role by regulating 
cancerous behaviours of cell death, growth arrest, and cell adhesion in a MAPK 
pathway-dependent manner (Sheng et al. 2000; He et al. 2001; Tseng et al. 
2003). The Wnt pathway is also negatively regulated by Dab2 and this pathway 
may contribute to the tumour suppressive effect of Dab2 (Jiang et al. 2009). The 
prognosis of lung and prostate cancer is poor when Dab2 expression is absent, 
suggesting Dab2 as a candidate biomarker for tumour progression (Zhoul et al. 
2005; Xu et al. 2011). Another interesting function of Dab2, found in HNSCC, is 
that when Dab2 is silenced due to DNA methylation this acts as a ‘switch’ for 
TGF-β to change from a tumour suppressing to an oncogenic cytokine (Hannigan 
et al. 2011). 
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4.2 Results 
 
4.2.1 NT5E methylation in melanoma 
 
4.2.1.1 NT5E methylation in less aggressive metastatic melanoma line C81-
61 and more aggressive melanoma line C8161  
 
Dr Tim Crook has provided the NT5E methylation investigation data as shown in 
Figure 4-1. Five melanoma cell lines were used in this investigation. In this panel 
one melanoma line, C81-61, with low metastatic potential is compared to its more 
aggressive derivative line C8161 (derived from the same patient). Normal human 
melanocytes, NHEM, were also included in the initial detection of NT5E 
methylation and mRNA expression (Figure 4-1 A). NT5E methylation was 
detected in cell line C81-61 by MSP, and was associated with absent NT5E 
mRNA expression by qPCR. No NT5E methylation was detected in the other 
melanoma cell lines or in melanocytes. Bisulfite sequencing was also performed 
on cell lines C8161 and C81-61 (Figure 4-1 B) to quantitatively determine the 
methylation level of NT5E at individual CpG sites through the whole CpG Island. 
NT5E was heavily methylated at all CpG sites in cell line C81-61, including the 
sites in which NT5E methylation was indicated by MSP. In contrast, the NT5E 
CpG island was entirely unmethylated in C8161 cells. The presence of NT5E 
methylation and absence of gene expression suggests that DNA methylation of 
NT5E transcriptionally silences gene expression. Methylation reversal treatment 
was then performed on cell lines C8161 and C81-61 to further confirm the effect 
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of aberrant NT5E methylation on gene expression.  As shown in Figure 4-1 C, 
NT5E gene expression was strongly induced by the methylation reversal agent 
5’AZA in C81-61 cells (NT5E methylated), but was much less affected in C8161 
cells (NT5E unmethylated). 
 
4.2.1.2 NT5E CpG island methylation in melanoma cell line panel  
 
Based on the observation of NT5E CpG island methylation in melanoma cell line 
C81-61 by Dr Tim Crook, I analysed NT5E methylation in an expanded collection 
of melanoma cell lines by pyrosequencing. NT5E methylation was detected in 5 
of 15 (33%) melanoma cell lines (Figure 4-2 A), which are SKMEL2, SKMEL23, 
MEL501, MEL505 and WM35. In this panel of 15 melanoma cell lines I also 
showed that NT5E mRNA expression is low or absent in those 5 lines where the 
CpG island is methylated (Figure 4-2 B). Of particular interest is cell line MEL501 
which has the highest methylation level (mean methylation 89%) and 
undetectable NT5E expression.  
 
 
 
 
 
 
 131 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
DMSO
O 
5’AZA  DMSO 5’AZA  
A C 
qPCR 
MSP 
Figure 4-1: NT5E was methylated in the less aggressive melanoma cell line C81-61 
but not in the more aggressive derivative, C8161.  
(A): Expression of NT5E correlated inversely with CpG methylation in C81-61 and its 
highly metastatic isogenic C8161. NT5E expression and methylation was measured by 
qPCR and MSP, respectively. GAPDH was used as a control for qPCR. (B): Bisulfilte 
sequencing showing the methylation status of NT5E at each CpG dinucleotide in the CpG 
island in C81-61 and C8161 cell lines. CpG sites are shown as vertical lines. Methylated 
CpG sites are shown as black blocks, unmethylated CpGs as open blocks. (C): 
Expression of NT5E mRNA was reactivated by demethylation in C81-61 but not in C8161. 
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Figure 4-2: Analysis of NT5E expression and methylation in melanoma cell line panel.  
(A): NT5E was frequently methylated in melanoma cell lines. Methylation was quantified by the 
intensity of shading in the circles, each of which represents an individual CpG dinucleotide. 5 
levels of shading were used as indicated in the figure. (B): Expression of NT5E correlated 
inversely with CpG methylation in majority of melanoma cell lines. NT5E mRNA expression was 
measured by qPCR against reference gene B2M. 
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4.2.1.3 NT5E methylation in melanoma clinical samples  
 
4.2.1.3.1 NT5E CpG island methylation in primary melanomas and 
derivative metastases 
 
Identification of methylation-dependent transcriptional silencing of NT5E in the 
less aggressive metastatic melanoma cell line C81-61 revealed a possible 
association between NT5E methylation and less aggressive phenotype of 
melanomas. I therefore decided to analyse methylation of NT5E in two sets of 
paired melanomas with both primary melanoma and lymph node metastasis 
available. As shown in figure 4-3, NT5E was methylated at higher level at each 
CpG site in the primary tumour (red) than the metastasis (blue) in one patient, 
and methylated only in the primary melanoma in the other patient. The decrease 
in NT5E methylation in each metastasis compared to that in the primary 
melanoma supports a potential role of NT5E methylation in predicting good 
prognosis. 
 
 
 
 
 
Figure 4-3: NT5E methylation in two sets of paired melanoma with both 
primary melanoma and lymph node metastasis were both available.  
Pyrosequencing analysis showing methylation percentage of 6 CpG sites in two 
paired primary melanomas and metastasis.            Primaries            Metastasis      
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4.2.1.3.2 NT5E methylation in primary melanomas 
 
Identification of NT5E CpG island methylation in melanoma cell lines encouraged 
me to extend the study to melanoma clinical cases and I determined NT5E 
methylation status in 27 well-characterised primary melanomas, these 
comprising 17 non-relapsing primary melanomas and 10 cases which 
subsequently relapsed with recurrent disease. 12 out of 27 (44%) cases showed 
NT5E methylation using a mean methylation level of 5% as cut-off. These cases 
were 10 examples of primary melanomas which did not relapse and 2 primary 
melanomas from patients who subsequently developed lymph node metastasis, 
suggesting that NT5E methylation may be a feature of non-relapsing cases. It is 
important to emphasise that NT5E methylation in the 10 relapsed primary 
melanomas was detected only in cases which relapsed as lymph node 
metastases (2/5 lymph node) and not in visceral metastases (0/4) or cutaneous 
metastases (0/1), indicating a lymph node site methylation specificity of NT5E 
methylation. Melanomas with visceral metastasis invariably have a worse 
prognosis than lymph node metastasis. The higher frequency of NT5E 
methylation in non-relapsing primary melanomas and the presence of NT5E 
methylation in primary tumours with lymph node only metastasis suggests that 
NT5E methylation may be a good prognostic biomarker for melanoma patient 
outcome. 
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Figure 4-4: NT5E methylation in 27 well characterised primary melanomas.  
Clinical information including primary site, Breslow thickness (BT), tumour subtype 
(superficial spreading malignant melanoma (SSMM), nodular malignant melanoma (NMM), 
malignant melanoma with unknown subtype (MM)), growth phase (vertical growth phase, 
VGP), site of metastasis (lymph node (LN), parotid gland (PA), liver (Li), cutaneous (Cu), 
lung (Lu), spleen (Sp), and brain (Br)) are all shown in the figure. NT5E methylation level at 
8 CpG sites was shown by the intensity of shading in the circles. 5 levels of shading were 
used to represent differing extents of methylation. The average methylation level of NT5E 
(%) was also listed next to the quintile circles. Metastasis status of primary melanomas with 
greater than 5% of NT5E methylation was highlighted in either blue circle (no relapse) or red 
square (lymph node metastasis). 
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4.2.1.3.3 NT5E methylation in metastasis  
 
Finally, I analysed NT5E CpG island methylation in a subset of 23 melanoma 
metastasis specimens, comprising 15 lymph node (LN) metastases, 3 cutaneous 
(Cu) metastases, 4 soft tissue (ST) metastases and 1 bladder (Bl) metastasis. By 
using the previously designated mean methylation level of 5% as cut off, I 
detected NT5E methylation at similar frequency (9/23, 39%) in these metastasis 
cases as in primary melanomas (44%). Interestingly, 7 of 9 cases with NT5E 
methylation were in lymph node metastasis from patients who did not develop 
other metastasis. Moreover, NT5E methylation was not detected in 8 of 9 cases 
from melanoma patients who developed visceral metastasis (liver, lung, bone, 
brain and bladder). The high frequency of NT5E methylation in lymph node 
metastasis from patients free of distant metastasis and the absence of NT5E 
methylation in patients with visceral metastasis further imply that NT5E 
methylation is a potential biomarker of good prognosis melanoma.  
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Figure 4-5: Detection of NT5E methylation in 23 melanoma metastasis.  
The level of methylation is indicated by the intensity of shading in the circles as shown in 
the key, each of which represented an individual CpG site. Information including the site of 
biopsies for examination, the mean % methylation, and the sites of all metastasis that 
melanoma patients ultimately developed: Bl, Bo (bone), Br, Cu, Li, LN, Lu, and ST are also 
shown. Sites of metastatic disease which showed higher than 5% of NT5E methylation are 
highlighted in blue circles. 
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4.2.2 DUSP2 methylation in melanoma 
 
4.2.2.1 DUSP2 methylation in melanoma cell lines 
 
DUSP2 methylation was quantitatively measured by pyrosequencing in 15 
melanoma cell lines. 10 melanoma cell lines showed over 10% mean methylation, 
including 5 cell lines SKMEL147, MEL224, SBCL2, MEL501 and PMWK with a 
particularly high level of DUSP2 methylation (mean methylation > 60%) (Figure 
4-6 A). qPCR analysis performed on the same batch of melanoma cell lines 
revealed a generally low level of DUSP2 expression in cell lines with DUSP2 
methylation (Figure 4-6 B). DUSP2 expression was particularly low or absent in 
cell lines (SKMEL147, MEL224, SBCL2, MEL501 and PMWK) which have a high 
level of DUSP2 methylation. Cell lines positive for DUSP2 methylation showed 
significantly reduced DUSP2 mRNA expression compared to cell lines with no 
DUSP2 methylation (unpaired t test, p<0.01, figure 4-6 C), suggesting that 
promoter methylation silences DUSP2 gene expression at the transcriptional 
level. I next performed methylation reversal assay on the SKMEL2 cell line which 
had a mean methylation level of 32% and low gene expression, to assess if 
increased DUSP2 expression in this cell line is induced by demethylation. Figure 
4-6 D shows that 5’AZA alone significantly increased DUSP2 gene expression 
(p<0.001), and the combination of 5’AZA and TSA also significantly increased 
DUSP2 expression (p<0.01). Methylation reversal analysis indicated that DUSP2 
gene expression was inducible by demethylation and further confirms that DNA 
methylation of DUSP2 negatively regulates gene expression. 
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Figure 4-6: Identification of DUSP2 methylation and mRNA expression in melanoma 
cell lines.  
(A): DUSP2 methylation in melanoma cell lines and normal melanocytes. The level of 
methylation is indicated by the intensity of shading in the circles as indicated in the key, 
each of which represents an individual CpG site. (B): Bar chart showing DUSP2 relative 
expression in melanoma cell lines divided to methylation positive and methylation negative 
groups. (C): Unpaired t test showing significant inverse correlation between DUSP2 
expression and DNA methylation (p<0.01). (D): Relative expression of DUSP2 in 
melanoma cell line SKMEL2 with methylation reversal treatments under different 
conditions: DMSO, 5’ AZA, TSA, and 5’ AZA+TSA. 
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4.2.2.2 Overexpression of DUSP2 in the metastasis of paired melanoma cell 
lines 
 
Three sets of paired melanomas comprising a primary line and metastatic 
daughter derivative lines were then analysed for DUSP2 gene expression and 
DNA methylation. Figure 4-7 A shows significant over-expression of DUSP2 in 
metastatic lines WM239A, LM9 and WM983B when compared with their parental 
lines WM115, LM2 and WM983A, respectively. It is notable that the three 
metastases with significantly increased DUSP2 expression were all derived from 
lymph nodes, whereas the other metastatic cell lines WM266.4 and LM29, which 
expressed much lower levels of DUSP2 were both skin metastases. These 
results indicate that DUSP2 may be specifically over-expressed in lymph node 
metastases. Cell line WM266.4 showed low level DUSP2 expression in the whole 
cell line panel (Figure 4-6 C). From looking at DNA methylation and the mRNA 
expression level of DUSP2 in the three sets of paired primary and metastatic 
daughter lines which includes WM266.4, I noticed DNA methylation levels are 
between 41% and 72%, and cell line WM983B which had the highest amount of 
DUSP2 expression is only approximately 3 fold higher than WM266.4, 
suggesting an overall low level of mRNA expression across all the 8 lines. 
Consequently, the correlation between DUSP2 methylation and reduced 
expression is not as clear as the correlation we saw in the 15 melanoma cell line 
panel. However, there is clearly more DUSP2 mRNA expression in the 
metastasis compared to the primary tumour lines. This suggests that other 
mechanisms may be influencing DUSP2 expression in metastasis but that DNA 
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methylation is the predominant regulatory mechanism in primary melanomas. 
Another possibility would be methylation of other CpG dinucleotides that have not 
been identified in this study may also have impact on regulating gene expression. 
Also, we should be bear in mind that DNA methylation does not necessarily 
reduce gene expression in a proportional manner.  
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Figure 4-7: Expression and methylation of DUSP2 in paired melanoma cell 
lines. 
 (A): DUSP2 expression analysis by qPCR. One way ANOVA was used to compare 
the difference between metastatic lines and their parental primary melanomas 
(WM115 vs WM266.4, wm115 vs WM239A; LM2 vs LM9, LM2 vs LM29; WM983A 
vs WM983B) (B): Mean methylation % of DUSP2 in paired melanoma cell lines by 
pyrosequencing. 
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4.2.2.3 DUSP2 is methylated in melanoma clinical samples 
 
The DUSP2 methylation results from our melanoma cell line panel and paired 
cell lines prompted me to investigate DUSP2 methylation status in melanoma 
clinical tissues using benign naevi as negative controls. A total of 61 clinical 
samples comprising 10 benign naevi, 12 primary melanomas and 39 metastases 
were selected for this validation investigation. Using pyrosequencing I 
determined that DUSP2 methylation was at a generally low level (mean 
methylation less than 10%) in benign controls, with one outlier showing a higher 
methylation level of 15%. Comparatively, as shown in figure 4-8 A, DUSP2 was 
frequently methylated at a level higher than 10% in both primary melanomas 
(9/12) and metastases (22/39). When comparing the differences in DUSP2 
methylation between the three groups of tissues (Figure 4-8 B), I observed that 
DUSP2 was methylated at a significantly higher level in primary melanomas 
(p<0.001) and metastases (p<0.01) compared to benign naevi. Furthermore, 
DUSP2 methylation in primary melanomas was also significantly higher than in 
metastases (p<0.05). Together, these results show that DUSP2 is frequently 
methylated in melanomas. The significantly higher level and frequency of DUSP2 
methylation in primary melanomas than in metastases and benign naevi supports 
a role for DUSP2 methylation in initiation of melanoma, but also implies that 
reactivation of expression, associated with loss of methylation, may occur in 
disease progression.  
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Figure 4-8: DUSP2 methylation in melanoma tissues.  
(A): Bar chart representing mean methylation of DUSP2 in 10 benign naevi, 12 primary 
melanomas and 29 metastases. (B): Mann-Whitney U test showing the significant 
differences in comparisons: benign naevi vs primary melanomas (p<0.001), benign naevi vs 
metastasis (p<0.01) and primary melanomas vs metastasis (p<0.05). 
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4.2.2.4 DUSP2 methylation in paired melanoma tissues 
 
Having observed that DUSP2 methylation is elevated in clinical primary 
melanoma samples and shown decreased DUSP2 expression in primary 
melanoma lines of paired cell lines, I examined 8 pairs of primary and metastatic 
melanoma tissue samples. These samples have also been studied for TFPI2 
methylation. As shown in figure 4-9 A and B, DUSP2 methylation was detected at 
a higher average level in the primary melanomas than in the corresponding 
metastatic samples in 6 out of 8 pairs. The methylation level of DUSP2 at each 
individual CpG site in primary melanomas was significantly higher than that in the 
corresponding metastasis by paired t test (p<0.05). Two representative cases 
displayed higher DUSP2 methylation at most of the CpGs in the primary tumour 
compared to the lymph node metastasis as shown in figure 4-9 C. However, the 
level of DUSP2 methylation is only slightly higher in most primary tumours than 
metastasis, as these secondary tumours were all lymph node metastasis, which 
presumably still maintain similar biological properties to the primary melanomas 
from which they derive. I have not measured DUSP2 mRNA expression in this 
set of paired primary and lymph node metastatic tissues. However, from the 
paired cell line data (section 4.2.2.2) I would predict that the inverse relationship 
between DNA methylation and mRNA expression would be stricter in primary 
tumour tissues than in metastatic tumour tissues, since other mechanisms may 
contribute to the regulation of DUSP2 expression in the more disordered genetic 
and epigenetic environment of metastatic cancer.  
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Figure 4-9: DUSP2 methylation in paired melanoma tissues.  
(A): Methylation level of DUSP2 in paired melanoma tissues. DUSP2 methylation level at each 
CpG site and mean methylation value are indicated numerically and listed in a table. (B): Paired t 
test comparing the difference of methylation level of each CpG site of paired primaries and 
metastasis (p<0.05). (C): Two representative cases of patients from whom we have collected 
both primary melanoma and lymph node metastasis showing overall decreased DUSP2 
methylation at most CpG sites. 
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4.2.3 Dab2 methylation in melanoma 
 
4.2.3.1 Dab2 CpG island methylation is undetectable in melanoma cell lines 
 
Using qPCR, I analysed Dab2 mRNA expression in a panel of 17 melanoma cell 
lines, one normal human keratinocyte (NHK) line and two lightly pigmented 
human melanocyte lines, HEMA and HEMN. Cell lines under investigation 
showed variable levels of Dab2 expression, suggesting that Dab2 may be 
transcriptionally regulated by genetic or epigenetic mechanisms. Dysregulation of 
Dab2 by aberrant DNA methylation has previously been reported in squamous 
carcinoma (Hannigan et al. 2011), so I asked if CpG island methylation of Dab2 
occurs in melanoma, and if methylation of Dab2 transcriptionally regulates gene 
expression in our cell line panel. Unexpectedly, I did not detect Dab2 methylation 
in any lines. There are a total of 53 CpG sites in the CpG island of Dab2. It is 
possible, therefore, that Dab2 is methylated in an area of the CpG island other 
than the 8 CpG dinucleotides I have examined. If Dab2 is methylated in the area 
outside the analysed one, methylation reversal assay may induce the gene 
expression in cell lines with Dab2 methylation. However, demethylation analysis 
performed on three cell lines with low (MEL224), high (HEMN) and intermediate 
(SKMEL2) Dab2 expression, did not show any inducible effect on Dab2 gene 
expression. Therefore, I conclude that Dab2 CpG island is not methylated in our 
melanoma cell lines.  
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Figure 4-10: Dab2 was not methylated in melanoma cell lines.  
(A): Relative expression of Dab2 in 17 melanoma cell lines, one keratinocyte 
and two melanocytes. (B): Dab2 methylation % detection by pyrosequencing. 
(C): Dab2 expression in cell lines MEL224, HEMN and SKMEL2 with 
demethylating treatment. 
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4.2.3.2 Dab2 is frequently methylated in melanoma tissues 
 
Despite the absence of detectable Dab2 methylation in melanoma cell lines, I 
consequently identified a remarkably high level and frequency of Dab2 
methylation in a collection of 112 melanoma clinical samples including 52 primary 
melanomas and 60 secondary metastases by pyrosequencing. As shown in 
figure 4-11 A, most primary melanomas and nearly all metastases showed a 
greater than 10% mean methylation level of Dab2. A low level of Dab2 
methylation was also observed in 8 benign naevi which were used as negative 
controls. The Dab2 methylation level significantly increased in primary 
melanomas compared with benign naevi, and was even higher in metastasis, 
suggesting that the methylation level of Dab2 is elevated corresponding to the 
malignant transformation progress from benign naevi to primary melanoma, and 
ultimately to metastasis. Increased Dab2 methylation may also be required for 
the adaption to the changes in microenvironments. 
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Figure 4-11: Dab2 methylation in melanoma tissues and benign naevi.  
(A): Mean methylation % of 8 benign naevi, 52 primary melanomas and 60 metastases. (B): 
Mann-Whitney U test showing methylation level of Dab2 correlated with melanoma 
progression (p<0.001 for each pair-wise comparison). 
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4.3 Discussion 
 
In this section I have analysed the methylation status of candidate genes that are 
known to be methylated in other human cancers and genes that may relate to 
tumour progression or tumour suppression. This is another candidate approach, 
in addition to the systematic approach employed in other sections of the project. 
Using this approach, I have assessed the methylation status of three candidates 
NT5E, DUSP2 and Dab2 in melanoma cell lines and clinical tissues.   
 
Increased NT5E expression has been reported in highly aggressive phenotype 
melanoma cell lines (Sadej et al. 2006). Dr Tim Crook has observed a similar 
pattern of NT5E expression in paired metastatic melanoma cell lines such as 
C81-61 and C8161 which have less aggressive and highly aggressive 
phenotypes, respectively. NT5E expression was up-regulated in the highly 
invasive cell line C8161 but absent in its less aggressive partner C81-61, 
suggesting that over-expression or restoration of NT5E enhanced the metastatic 
potential of C8161. The transcriptional silencing of NT5E seen in less aggressive 
C81-61 can be attributed to promoter methylation, shown by MSP and bisulfilte 
sequencing, and also proved by methylation reversal with 5’AZA. The dynamic 
alteration of NT5E expression from normal detectable level of expression in 
human melanocytes, to absent expression due to DNA methylation in the less 
aggressive phenotype C81-61, and ultimately to restored expression after 
demethylation in C8161 with greater metastatic potential suggests that epigenetic 
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change in NT5E potentially contributes to malignant progression. It also provides 
insight into the dynamic changes in the epigenome of the melanoma cell during 
evolution of individual disease. Based on these results provided by Dr Tim Crook, 
I have detected an intermediate frequency of NT5E methylation in an expanded 
panel of 15 melanoma cell lines (33%) and 50 melanoma clinical cases (42%) by 
pyrosequencing. Of the 50 clinical cases, NT5E was methylated at a similar 
frequency in 27 primary melanomas (44%) and 23 tumour metastases (39%). 
NT5E methylation in melanoma tissues appears to be a good prognosis 
biomarker. In 27 primary melanomas, NT5E methylation was only observed in 
primary melanomas that did not relapse with metastatic disease or relapsed with 
lymph node only metastasis, but was not present in cases which ultimately 
developed distant and/or visceral metastasis. Accordingly, cases of lymph node 
metastases where there was also visceral disease, were NT5E unmethylated. 
Based on these results, I conclude that NT5E methylation is probably important 
for early malignant transformation or development of lymph node metastasis and 
restored NT5E expression is required for the formation of a highly aggressive 
phenotype. Again, this is consistent with dynamic changes and ongoing adaptive 
evolution of the epigenome during the natural history of an individual melanoma. 
 
Dynamic changes in promoter methylation of E-cadherin have been tracked in a 
breast cancer cell line (Graff et al. 2000). In this study, E-cadherin was 
hypermethylated in the cells grown in monolayer culture, but became 
hypomethylated when cells were grown in a three-dimensional model. Such 
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dynamic switching was regarded as important for cells to adapt to the different 
microenvironments. NT5E is a multifunctional protein engaged in both metabolic 
and molecular signalings, and tightly regulated by microenvironment, as 
introduced in 4.1.1. Identification of the selective pressure(s) driving the 
reversible NT5E methylation identified in this study would clearly be of interest. 
However, in contrast to irreversible genetic change, the reversiblity of NT5E 
methylation could be exploited as a novel biomarker monitoring melanoma 
patients’ response to chemotherapy. NT5E may also be a therapeutic target for a 
subset of melanoma patients, particularly in those with visceral metastasis.  
 
DUSP2 methylation was initially assessed in 15 melanoma cell lines including 10 
lines showing an average methylation level over 10%. Transcriptional silencing of 
DUSP2 by promoter methylation was then confirmed by qPCR. In fact, of all the 
candidate genes I have studied, DUSP2 showed the strongest correlation 
between DNA methylation and statistically significantly reduced gene expression. 
Interestingly, in the three sets of paired melanoma cell lines, a significant 
increase in DUSP2 expression was seen in the lymph node metastasis 
compared to the parental primary melanoma cell lines, suggesting that a 
transcriptional increase in DUSP2 expression may contribute to the formation of 
lymph node metastasis. However, this significant change in DUSP2 expression 
was not reflected by a corresponding change in DNA methylation. A technical 
fault in our analysis has been ruled out by repeat analysis. This result suggests 
that promoter methylation of DUSP2 in primary melanoma cell lines may be the 
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predominant mechanism regulating gene expression, whereas DUSP2 mRNA 
expression is regulated by both DNA methylation and other mechanisms in 
metastatic disease. It is difficult to measure mRNA expression from paraffin 
embedded tissues due to the lack of reliable techniques for obtaining good 
quality RNA. Therefore, I could only assess the methylation level of DUSP2 in 
melanoma tissues and not the expression level. An overall significant increase in 
DUSP2 methylation was observed in primary melanomas compared to both 
benign naevi and metastases. In 8 primary melanoma tissues paired with 8 
lymph node metastases, DUSP2 was also methylated at a significantly higher 
level in the primary melanomas. These results suggest that DUSP2 methylation 
may be an indicator of good prognosis in melanoma.   
 
It is interesting to see similar changes in NT5E and DUSP2 methylation in 
primary melanomas and metastasis, implying that the two genes may function in 
similar or related pathways in the early stages of melanoma progression. Both 
NT5E and DUSP2 have been implicated in modulating the immune system 
(Jeffrey et al. 2006; Stagg et al. 2011). Here I hypothesize a potential underlying 
mechanism: NT5E and DUSP2 could initially act as tumour suppressors during 
the early stage of melanomagenesis, where their transcriptional silencing is 
required for tumour cells to escape from host immunity. After the tumour cells 
have adapted to the host immune system, re-expression occurs by demethylation 
and their oncogenic function(s) contribute to the formation of a highly invasive 
phenotype and adaption to new tumour microenvironments.  
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Unlike NT5E and DUSP2, Dab2 showed a classic methylation pattern in a 
collection of benign naevi, primary melanomas and metastases. The average 
level of Dab2 methylation constantly increased according to tumour progression, 
from lowest in benign controls, to dramatically higher levels in primary 
melanomas and even higher levels in metastasis, revealing a potential role of 
Dab2 methylation in predicting tumour progression. Despite being at a high level 
and high frequency in melanoma tissues, Dab2 methylation was undetectable in 
any melanoma cell lines. The reason we see this paradoxical result in melanoma 
tissue and cell lines is unclear, but has been seen in other genes for examples 
14-3-3 in breast cancer (Ferguson et al., PNAS, 2000). Therefore, Dab2 may be 
a reflector, but not a functional regulator of tumour progression. 
 
In conclusion, I have identified NT5E and DUSP2 as potential epigenetic 
biomarkers predictive of good prognosis in melanoma, and Dab2 in which 
methylation potentially correlated with tumour progression. Validation of these 
candidates as clinically useful biomarkers is now required in large, prospective 
studies. 
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Chapter 5  CpG island 
methylation dependent 
transcriptional silencing of prolyl 
hydroxylases in melanoma 
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5.1 Introduction 
 
The prolyl hydroxylases belong to a family of iron- and 2-oxoglutamate-dependent 
dioxygenase enzymes (Myllyharju 2003). At least two distinct groups of prolyl 
hydroxylases have been characterised: collagen prolyl hydroxylases and hypoxia-
inducible factor (HIF) prolyl hydroxylases. These hydroxylases catalyse the post-
translational formation of hydroxyproline residues in essential proteins such as 
collagens and HIFs. 
 
5.1.1 Collagen prolyl hydroxylases (C-PHs) 
 
Collagen prolyl 4 hydroxylases (C-P4Hs) and collagen prolyl 3 hydroxylases (C-
P3Hs) catalyse the formation of hydroxyproline in collagens by binding to a proline 
residue in the Y position of the (X-Y-Gly) and X position of (X-Hyp-Gly) amino acid 
sequence, respectively (Hutton et al. 1967; Vranka et al. 2004). This biological 
process is critical for the biosynthesis, folding, assembly, and stabilization of 
collagens (Helaakoski et al. 1990; Myllyharju 2003; Shoulders and Raines 2009). 
Both C-P3H and C-P4H can hydroxylate a broad spectrum of collagens including 
collagen I, the most abundant collagen in the human body (Di Lullo et al. 2002),  and 
collagen IV, the major constituent of the basement membrane. Human C-P4Hs are 
α2β2 tetramers containing 3 variants of the catalytic α subunit, encoded by P4HA1 
P4HA2 and P4HA3 and a constant  subunit encoded by P4HB. Isoform 1 (P4HA1) 
and isoform 2 (P4HA2) are expressed more abundantly in human tissues than 
isoform 3 (P4HA3) (Kukkola et al. 2003). The human genome encodes other C-P3Hs. 
 157 | P a g e  
 
These are leucine proline-enriched proteoglycan 1 (leprecan, LEPRE1), leprecan-
like 1 (LEPREL1), leprecan-like 2 (LEPREL2), cartilage-related protein (CRTAP) and 
leprecan-like 4 (LEPREL4) (Hatzimichael et al. 2012). 
 
Collagen is a fundamental structural protein and constituent of basement membrane 
and extracellular matrix, both of which are critical components of the tumour 
microenvironment (TME) and thus involved in tumour invasion, metastasis and 
angiogenesis. Alterations of collagens in the TME by aberrant post-translational 
modification could impact upon tumour invasion and tumour aggressiveness 
(Egeblad et al. 2010). Collagen IV in the basement membranes has been well 
studied in human cancers. The basement membrane is a thin structural layer that 
provides support for epithelium, creating structural anchorage between epidermis 
and dermis in skin and surrounding the lumen of blood vessels (Timpl and Aumailley 
1989; Paulsson 1992). In melanoma, the basement membrane at the dermo-
epidermal junction (DEJ) functions as a barrier limiting the invasion of melanoma 
cells from epidermis to dermis. (Figure 5-1) Penetration of melanoma cells through 
the DEJ is the initial step in the metastatic cascade and aggressive melanoma cells 
are more able to break through this barrier than low grade melanomas (Meier et al. 
2000).  
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Subsequent tumour metastasis involves the formation of local and/or distant tumour 
growth. To establish distant metastases, melanoma cells must undertake 
‘intravasation’, a phenomenon which entails transit of tumour cells through the blood 
vessel wall into the blood circulation and subsequent dissemination to distant organs 
to form metastases (Figure 5-1). Although unproven, it is likely that destabilization or 
alterations of the basement membranes consequent to dehydroxylation may allow 
more efficient penetration of melanoma cells. There is evidence indicating that 
absence of P4HA1 protein results in less assembled collagen IV and a defect in the 
basement membrane in mice (Holster et al. 2007). Such association between 
inactivated C-PHs and disrupted basement membrane is a plausible mechanism for 
promoting invasion and metastasis in human cancers. Collagen IV in the basement 
membrane contains a tumour suppressor-like domain, noncollagenous 1 (NC1), 
which has anti-proliferation, anti-invasion and anti-angiogenesis properties in 
Basement membrane 
Intravasation 
Figure 5-1:  Invasion and intravasation of melanoma cells. 
Accumulation of invasive melanoma cells forms a sphere which breaks through the skin 
basement membrane. Wandering melanoma cells in the dermis intravasate into the blood 
circulation through the blood vessel which contains basement membrane (Miller and Mihm 
2006). 
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melanoma (Han et al. 1997; Maeshima et al. 2000; Pasco et al. 2005). Elastin is rich 
in proline residues and is another substrate for C-P4H. It provides elastic support for 
connective tissues, which are particularly important in tissues such as blood vessels 
and lung (Gorres and Raines 2010). Correlation between the absence of elastic 
tissues at invasive tumour edge and poor prognosis has been reported in melanoma, 
suggesting its potential as a prognostic biomarker of melanoma (Feinmesser et al. 
2002). C-P3H members, Leprel1 and Leprel2 have previously been reported to be 
transcriptionally silenced by DNA methylation in breast cancer and Leprel1 and 
Leprel2 together with P4HA2 and P4HA3 in non-Hodgkin’s lymphoma (Shah et al. 
2009; Hatzimichael et al. 2012). Silenced C-P3Hs and C-P4Hs may destabilize 
collagen IV and elastin to disrupt their tumour suppressor functions. Identification of 
C-PH methylation in other cancers and their probable tumour suppressor function 
prompted analysis of their expression and methylation status in melanoma. 
 
5.1.2 HIF prolyl hydroxylases (HIF-PHs) 
 
HIF-PH is another important family of prolyl 4 hydroxylase enzymes comprising 
prolyl hydroxylase domain-containing protein 1 (PHD1, EGLN2), PHD2 (EGLN1) and 
PHD3 (EGLN 3). HIF1-α expression is induced by low oxygen, by production of 
reactive oxygen species (ROS) and by certain growth factors. When HIF1-α binds to 
HIF1-β (ARNT), the resulting HIF1-α transcription factor upregulates expression of 
many proteins that assist the cell, organ and organism to adapt to low oxygen (Greer 
et al. 2012). Whilst expression of ARNT is constitutive and levels are generally stable, 
those of HIF1-α can rapidly fluctuate (Huang et al. 1998). This tells us that HIF1-α is 
tightly regulated. The expression of HIF1-α in keratinocytes and melanocytes is a 
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reflection of the mildly hypoxic microenvironment in the skin (Evans et al. 2006; 
Rosenberger et al. 2007). Regulation of HIF1-α levels occurs by multiple post 
translational mechanisms (Dimova and Kietzmann 2010) and by differential 
regulation of specific isoforms of HIF1-α by oxygen (Weir et al. 2011). In an oxygen 
rich environment, EGLNs catalyse the addition of hydroxyl groups to HIF1-α in 
positions 402 and 564. As a result, HIF1-α is recognised by proteosomal enzymes as 
a target for degradation (Semenza 2001; Semenza 2004). Collagen P4Hs on the 
other hand do not hydroxylate HIF1-α (Jaakkola et al. 2001). However PHD/EGLN 
activity is tissue specific and the patterns of PHD/EGLN expression in melanocytes 
have not been studied to date. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-2: Scheme representing the classical hypoxia pathway.  
In the normoxic condition, HIF1-α is tightly regulated by an EGLN-dependent 
proteasomal degradation pathway. Siah-2 negatively regulates EGLN1 and 
EGLN3. In the hypoxic condition, prolyl hydroxylase activity is limited and this 
leads to stabilisation of HIF1-α and subsequent activation of a number of 
downstream targets. This figure was generated by Dr Lynda Weir. 
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There is increasing interest in the role of HIF1 and hypoxia in the field of melanoma. 
In 2008, Zbytek et al. reported that HIF1-α expression was higher in melanoma 
samples compared to HIF1-α expression in benign naevi (Zbytek et al. 2008). Soon 
afterwards Valencak et al. detected HIF1-α by immunohistochemical staining of 
melanoma tissue sections in 87.6% of melanoma samples (Valencak et al. 2009). 
Also, in 2009, Mills et al. used melanoma cell lines to show that increasing 
expression of HIF1-α mRNA and protein correlated with increasing tumour severity 
and demonstrated that expression of HIF1-α was barely detectable in normal human 
melanocytes (Mills et al. 2009). Of note, HIF1- α was higher in a radial growth phase 
melanoma cell line, increased further in a vertical growth phase melanoma cell line 
and was highest of all in a metastatic melanoma cell line (Mills et al. 2009). More 
recently, Trevino-Villareal et al. have suggested that increased HIF1-α is not only a 
feature of melanoma cells but also is associated with co-localised tumour-associated 
stromal cells in a model where B16 melanoma cells were injected into mice (Trevino-
Villarreal et al. 2011). These observations have been repeated and, by using tissue 
sections and HIF1-α immunostaining, the area of increased HIF1-α expression has 
been seen to extend into regions of keratinocytes where melanoma cells have 
infiltrated (Zbytek 2013). 
 
Not only is melanoma associated with increased expression of HIF1-α protein, but 
hypoxia has also been shown to affect the tumourigenic behaviour of melanoma 
cells. Preconditioning melanoma cells with an 18hr treatment of 1% oxygen 
increased the invasiveness and tumourigenicity of these cells when injected into 
mice as judged by the number and size of lung metastases (Cheli et al. 2012). 
Furthermore, when B16 melanoma cells were injected into mice, those mice treated 
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with hypoxia for 6hrs out of every 24hrs (intermittent hypoxia treatment) developed 
significantly more lung metastasis than those kept throughout in a normoxic 
environment (Almendros et al. 2013). These experiments suggest that a hypoxic 
tumour environment may have detrimental effects upon tumour outcome for 
melanoma patients and that additional studies are warranted (Nakayama et al. 2009). 
 
Another avenue worthy of study is the effect of methylation of EGLN genes on 
melanomas. Aberrant methylation of ELGN genes could result in gene silencing and 
reduction or cessation of EGLN activity. This would be predicted to impact upon 
HIF1-α activity and upon hypoxia signalling. Methylation of ELNG3 has previously 
been reported in some human cancers (Shah et al. 2009; Hatzimichael et al. 2010; 
Huang et al. 2010), however this methylation is not universally applicable to all 
cancers (Place et al. 2011). Taken together, these observations prompted me to 
explore the role of EGLN3 methylation in melanoma. 
5.2 Results    
 
5.2.1 Analysis of the biomarker utility for C-P3H and C-P4H CpG island 
methylation in melanoma  
 
5.2.1.1 Identification of CpG island methylation of C-P3H and C-P4H in 
melanoma cell lines  
 
Using pyrosequencing I initially investigated CpG island methylation in the C-P3H 
and C-P4H gene families in our melanoma cell line panel. LEPRE1 was not included 
in this methylation screen, because unlike the other two C-P3H members, no 
 163 | P a g e  
 
LEPRE1 methylation was detected in breast cancer or lymphoma (Shah et al. 2009). 
None of the C-P3H or C-P4H genes were found to be methylated in normal 
melanocytes. Similarly, no P4HA1 methylation was detected in any melanoma cell 
line (Figure 5-3 A), but all other genes were methylated at varying frequencies. The 
most common methylated gene was P4HA3, with 8/13 cell lines, including cell lines 
derived from both primary and metastatic melanomas, being positive for methylation. 
In five of the primary melanoma cell lines, only LEPREL2 and P4HA3 were 
methylated, suggesting that de novo methylation of these two genes may occur in 
the early stages of melanoma.  
 
Gene expression of LEPREL1, LEPREL2, P4HA2 and P4HA3 was evaluated in the 
same panel of cell lines by qPCR (Figure 5-3 B). Expression of LEPREL1 and 
LEPREL2 was variable, but there was a generally good correlation between CpG 
island methylation and down-regulated gene expression. For example, SKMEL23 
and MEL501 were LEPREL1 methylation positive and did not express LEPREL1, 
whereas LEPREL2 expression was low or undetectable in SBCL2, PMWK and 
MEL501 all of which showed LEPREL2 methylation. There was also a good inverse 
correlation between P4HA3 methylation and gene expression: 7/8 cell lines with high 
levels of methylation had absent gene expression. Similarly, there was abundant 
gene expression and no P4HA3 methylation in PMWK and COLO829. No correlation 
between P4HA2 methylation and gene expression was evident. 
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Figure 5.2  
 
 
 
 
Figure 5-3: CpG island methylation and expression of C-P3H and C-P4H in melanoma 
cell line panel.  
(A): Pyrosequencing profiles of C-P3H and C-P4H CpG island methylation in our melanocytes 
(normal), primary and metastatic melanoma cell lines. Methylation is quantified by the intensity 
of shading in the circles, each of which represents an individual CpG dinucleotide. 5 levels of 
shading are used as indicated in the figure. (B): qPCR analysis of LEPREL1, LEPREL2, 
P4HA2 and P4HA3 mRNA expression in melanoma cell lines. 
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5.2.1.2 Methylation status of C-P3H and C-P4H in paired melanoma cell lines  
 
C-P3H and C-P4H processing of collagen IV in the basement membrane implies a 
potential for their involvement in tumour invasion and metastasis and this prompted 
me to explore correlations between C–PH methylation and metastatic melanoma. 
Again using pyrosequencing, the methylation status of C-P3H and C-P4H families 
was analysed in 3 sets of paired parental primary melanoma and their derivative 
daughter metastasis cell lines (Figure 5-4 and Table 5-1). Consistent with the high 
frequency of methylation already observed in the initial cell line panel analysis, 
P4HA3 was also frequently and heavily methylated in these 8 cell lines. In the first 
set of paired cell lines (WM115/WM266.4/WM239A), P4HA3 was moderately 
methylated in the primary cell line WM115 (% mean methylation 16%), and its 
methylation level increased in both skin metastasis WM266.4 (% mean methylation 
33%) and lymph node metastasis WM239A (% mean methylation 28%). In the 
second set (LM2/ LM9/ LM29), there was again increased P4HA3 methylation in the 
lymph node metastasis LM9 (% mean methylation 19%), compared to lower level of 
methylation in the primary line LM2 (% mean methylation 10%). However, in the third 
set (WM983A/WM983B), a lower level of P4HA3 methylation (% mean methylation 
2%) was demonstrated in the lymph node metastasis WM983B, compared to its 
parental line WM983A (% mean methylation P4HA3 19%). In these same cell lines 
P4HA1, P4HA2 and LEPREL2 were barely methylated, with only a small increase of 
P4HA1 and P4HA2 methylation in the skin metastasis LM29. LEPREL1 was heavily 
methylated in the LM set, with increased methylation in LM29. Like P4HA3, 
LEPREL1 was also methylated at a lower level in the metastatic WM983B cell line, 
suggesting this set of paired cell lines are in some way distinct from the other two 
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sets. Taken together however, increased methylation in the P4HA3 CpG island was 
observed in the metastases of 2 out of 3 paired melanoma cell lines implying an 
association between its methylation and progression to advanced disease.  
 
 
 
 
 
 
 
  
 
 
 
Table 5-1: Mean % methylation level of C-PHs in paired melanoma cell lines 
 
 
 
 
 
 
 LEPREL1 LEPREL2 P4HA1 P4HA2 P4HA3 
WM115 2 1 1 2 16 
WM266.4 3 3 3 2 33 
WM239A 4 2 2 3 28 
LM2 37 2 2 1 10 
LM9 30 1 4 2 23 
LM29 51 3 7 8 2 
WM983A 6 1 1 3 19 
WM983B 3 2 6 15 3 
WM115 
 WM266.4 
 WM239A 
 LM2 
 LM9 
 LM29 
 WM983A 
 WM983B 
 
P4HA1 
 
LEPREL1 
 
P4HA3 
 
P4HA2 
 
0-5% 
 
6-10% 
 
11-20% 
 
21-50% 
 
51-100% 
 
Figure 5-4: Pyrosequencing analysis of LEPREL1, P4HA1, P4HA2 and P4HA3 in 3 sets 
of paired primary melanoma and metastatic cell lines.  
Methylation is quantified by the intensity of shading in the circles, each of which represents 
an individual CpG dinucleotide. 5 levels of shading are used as indicated in the figure. In all 
cases, methylation increases in the highly metastatic cell lines relative to the respective 
parental cell line. 
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5.2.1.3 Methylation status of C-P3H and C-P4H CpG islands in melanoma 
tissues  
 
5.2.1.3.1 P4HA3 is frequently methylated in melanoma tissues  
 
These studies reveal high level and frequent methylation in the P4HA3 CpG island in 
melanoma cell lines. I next analysed, again using pyrosequencing, the methylation 
status of P4HA3 in a series of clinical cases, these comprising 50 melanomas and 
10 benign pigmented naevi controls, to evaluate the potential utility of P4HA3 
methylation as a melanoma biomarker (Figure 5-5). There was a significantly higher 
level of methylation in melanomas compared to the benign naevi controls (Mann-
Whitney u test, p<0.01). The mean methylation level of P4HA3 in all 10 benign naevi 
was 5%, suggesting the application of 5% as an appropriate cut-off for P4HA3 
methylation. Using this cut off, P4HA3 was hypermethylated in 37/50 (74%) of 
melanoma clinical samples. Only a limited number of cases in this melanoma series 
were primary melanomas, so it was not possible to examine any difference in P4HA3 
methylation between primary and metastatic melanomas in this cohort. We will need 
to expand our sample size and include a broad range of melanomas to further 
validate the potential of P4HA3 for metastatic disease. 
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Figure 5-5: Methylation of P4HA3 in melanoma clinical samples and benign naevi. 
(A): Methylation percentage of 10 cases of benign naevi and 50 cases of melanoma. (B): 
Mann-Whitney U test of methylation level between benign naevi and melanomas. 
(p<0.01) 
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5.2.1.3.2 Methylation status of P4HA3 CpG island in paired melanoma tissues  
 
Previous analyses identified a correlation between P4HA3 CpG island methylation 
and metastatic disease in paired melanoma cell lines as discussed in 5.2.1.2, 
consistent with a role for P4HA3 CpG island methylation in progression of primary 
melanoma to metastatic disease. To further substantiate this hypothesis, I next 
examined the methylation status of the P4HA3 CpG island in 8 paired melanoma 
tissues, each comprising a primary melanoma and nodal metastasis from the same 
patient. Each tissue section was subjected to micro-dissection prior to isolation of 
genomic DNA to maximise melanoma representation. In 5 pairs of cases there was 
an increased mean level of P4HA3 CpG island methylation in the lymph node 
metastasis compared to the matched primary melanoma. Figure 5-6 A shows two 
representative cases with increased level of P4HA3 methylation in the metastasis at 
the individual CpG sites within the examined sequence. I used a one-tailed paired t 
test (Figure 5-6 B) to compare the methylation level between all metastatic and 
primary melanomas at each CpG sites. This revealed a statistically significantly 
higher level of P4HA3 methylation in the metastases, thus supporting a role for 
methylation in the P4HA3 CpG island in melanoma progression. It will be noted, 
however, from the panel of results in Figure 5-6 B that two of the cases (numbers 2 
and 7) showed reduced methylation level in the metastasis compared with the 
primary melanoma. 
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Figure 5-6: P4HA3 CpG island methylation in 8 pairs of clinical samples 
comprising primary melanomas and their matched lymph node metastasis 
derived from the same patient.  
(A): Comparison of P4HA3 CpG island methylation between primary melanoma and 
lymph node metastasis at the individual CpG sites in two representative cases. (B): 
Paired t test (one tailed) showed significantly higher average methylation level of 
P4HA3 in lymph node metastasis compared to primary melanomas (p<0.01).  
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5.2.1.3.3 Methylation status of LEPREL1 CpG island in melanoma tissue and 
serum samples 
 
My results showed a moderate methylation frequency of LEPREL1 in melanoma cell 
line panels, so I next assessed the methylation status of the CpG island in the same 
series of melanoma tissues and control benign naevi previously tested for P4HA3. In 
the 10 benign naevi, LEPREL1 methylation was invariably low. Significantly 
increased LEPREL1 CpG island methylation was demonstrated in the majority of the 
melanoma cases (p<0.001). However, compared to the high methylation level of 
P4HA3 in the same cases, LEPREL1 was methylated at a much lower level (up to 
10%) in most melanoma samples.  When analysing C-P3H methylation in the paired 
cell lines, I observed increased LEPREL1 methylation in the metastasis of one set 
(LM2/29). I therefore attempted to determine whether LEPREL1 methylation 
increased in the metastasis of the paired tissues compared to their matched primary 
melanomas. However, inconsistent changes in LEPREL1 methylation were identified 
in the 8 pairs of matched melanoma tissue samples. Four of eight pairs (patients 1, 2, 
6 and 7) showed similar (low levels) of LEPREL1 CpG island methylation, whereas 
patients 4 and 5 exhibited increased LEPREL1 methylation in the metastasis, and 
patients 3 and 8 showed the inverse. Therefore, no robust correlation between 
LEPREL1 and metastatic disease was present in these 8 pairs, implying that 
LEPREL1 is unlikely to be a useful biomarker of melanoma progression. This 
hypothesis was further strengthened by analysis of sera in which a generally low 
level of LEPREL1 methylation was detected (Figure 5-7 B).  
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Figure 5-7: Quantitative LEPREL1 CpG island methylation profiles in 
melanoma clinical samples (tissue and serum) and benign naevi.  
(A): Methylation level of LEPREL1 in10 cases of benign naevi and 50 cases of 
melanoma (B): Methylation level of LEPREL1 in 40 melanoma serum samples. (C): 
Mann-Whitney U test of methylation level between benign naevi and melanomas. 
(p<0.001) 
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Table 5-2: LEPREL1 methylation level in paired melanomas 
 
The table shows % methylation at each CG dinucleotide in the amplified fragment of 
LEPREL1 in eight matched pairs of clinical cases of primary (P): metastatic melanoma (M). 
 
 
5.2.1.4 P4HA3 is a serum biomarker for metastatic melanoma 
 
Based on these results in paired melanoma cell lines and tissue samples, my data 
suggested that P4HA3 might be potentially predictive of melanoma metastasis. 
Examination of the biomarker potential of methylated P4HA3 was subsequently 
undertaken in a collection of serum samples from 44 patients with lymph node or 
visceral metastases and from 23 patients who were clinically metastasis-free at the 
time of blood harvesting. ROC analysis using GraphPad Prism software showed a 
sensitivity of 56% and a specificity of 71% for P4HA3 methylation in detecting 
metastatic disease using a methylation cut-off of 5% (Figure 5-8 B). This cut-off level 
generated by GraphPad Prism was consistent with the level we have used to 
determine P4HA3 methylation frequency in melanoma tissue samples. The area 
under the curve (AUC) indicated a diagnostic accuracy of 71% (95% CI, 0.59-0.83, 
p<0.01). Risk analysis performed by Dr Mathieu Boniol (International Prevention 
Research Institute, Lyon, France) also showed a statistically significant association 
 CpG1 CpG2 CpG3 CpG4 CpG5 CpG6 CpG7 CpG8 Average 
P1 2 4 3 11 8 0 8 0 5 
M1 6 7 10 12 9 3 11 0 7 
P2 0 0 3 3 7 0 2 0 2 
M2 0 0 0 4 0 0 1 0 1 
P3 4 0 2 32 28 21 27 24 17 
M3 4 5 6 19 13 5 16 8 10 
P4 0 0 0 4 4 0 4 0 2 
M4 6 11 9 11 12 0 9 0 7 
P5 0 0 5 10 3 0 5 0 3 
M5 29 22 1 11 23 0 9 26 15 
P6 0 0 1 2 0 0 3 0 1 
M6 0 0 0 5 5 0 3 0 2 
P7 7 8 9 11 9 0 9 3 7 
M7 7 7 9 9 9 0 9 0 6 
P8 53 72 60 71 62 14 60 69 58 
M8 10 13 5 10 11 8 10 12 10 
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between P4HA3 methylation and metastatic disease when using 5% as the 
methylation cut-off (adjusted odds ratio (OR) 6.2, 95% CI 1.7-21.8, Table 5-3). 
Table 5-3: Risk analysis of association between P4HA3 methylation and 
melanoma metastasis 
P4HA3 
Control (No 
metastasis) 
Case (with 
metastasis) 
OR adjusted  
(95% CI) 
Less than 5% 19 21 1.00 Ref 
5% or more 4 23 6.2 (1.7-21.8) 
 Adjusted on Breslow thickness 
OR: odds ratio indicating the association between P4HA3 methylation and melanoma 
metastasis. CI: confidence interval. 
 
Mann-Whitney analysis showed the level (mean %) of P4HA3 methylation in patients 
with metastasis was significantly higher than in patients without metastatic disease 
(p<0.01) (Figure 5-8 A), suggesting a correlation between P4HA3 methylation and 
increased risk of metastasis. Dr Mathieu Boniol also confirmed such a correlation 
with his statistical analysis (OR=1.18, 95%CI 1.00-1.38). These data have 
demonstrated that methylated P4HA3 genomic DNA may have utility as a serum 
biomarker in the detection of metastatic melanoma.  In the 23 serum samples from 
patients free of metastatic disease, P4HA3 was methylated in 22% (5/23). Of the 5 
non-metastatic cases with methylation, only 1 was from 15 low risk melanoma 
patients (Breslow thickness < 2 mm). The other 4 non-metastatic cases with 
methylated P4HA3 were from high risk melanoma patients (Breslow thickness > 
3mm). This observation raises the interesting possibility that P4HA3 methylation 
could be a serum prognostic biomarker predictive of poor patient outcome even in 
patients with, as yet, no clinical evidence of metastatic disease. To confirm and 
extend these findings, an independent prospective study involving a larger sample 
set needs to be similarly investigated. 
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Figure 5-8: P4HA3 CpG island methylation in melanoma serum samples.  
(A): Mann Whitney test of average methylation level of P4HA3 in serum samples from 
melanoma patients with no metastasis and with metastasis. (B): Receiver Operator 
Characteristic curve showing predictive utility of detection of P4HA3 CpG island 
methylated DNA in serum of patients with melanoma in the diagnosis of metastatic 
disease. The ROC curve was constructed as described in Materials and Methods 
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5.2.2 Identification of EGLN3 methylation and mechanistic study of 
EGLN3 in melanoma  
 
5.2.2.1 EGLN3 CpG island methylation in melanoma cell lines 
 
Our paired cell line panel was used in this investigation. Using MSP, I detected 
partial EGLN3 methylation in the melanoma cell line WM266.4 (Figure 5-9 A). In the 
same cell line, I have observed reduced EGLN3 mRNA expression by qPCR (Figure 
5-9 B), suggesting EGLN3 methylation transcriptionally silences EGLN3 gene 
expression at the RNA level. For the cell line panel as a whole there was a general 
correlation between EGLN3 mRNA and protein expression (Figure 5-8 B and C). For 
example, cell lines LM9 and LM29 which had the highest EGLN3 RNA expression 
also showed the highest level of protein expression. In the other cell lines, EGLN3 
protein expression was generally low, this correlating with low mRNA expression 
including cell line WM266.4 in which the EGLN3 CpG island was partially methylated. 
Thus, low protein expression of EGLN3 in this cell line may be the consequence of 
methylation-dependent transcriptional silencing of EGLN3.  
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Figure 5-9: EGLN3 methylation in melanoma cell lines.  
(A): Identification of EGLN3 methylation in 8 melanoma cell lines by MSP. (B): qPCR 
analysis of EGLN3 mRNA expression in the same panel of cell lines. *** is p<0.001; 
ns: no significance. (C): Western blots of EGLN3 protein expression. EGLN3 is the 
bottom band of the indicated double bands. Actin was used as the loading control. 
The EGLN3 antibody gave 2 to 3 bands in the region of 27kDa, however later studies 
identified that the lower band was likely to be that of EGLN3. 
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5.2.2.2 EGLN3 protein does not inversely correlate with HIF1-α protein 
expression 
 
EGLNs predominantly and negatively regulate HIF1-α activity in normoxia where 
oxygen is abundant. I performed western blots in 8 melanoma cell lines cultured in 
normoxia to test the correlation between EGLN3 and HIF1-α protein under these 
conditions (Figure 5-10). However, there was not a reciprocal expression pattern 
between EGLN3 and HIF1-α as had been expected. For examples, cell lines LM9 
and LM29 which had the highest expression level for EGLN3 also showed the 
highest levels of HIF1-α. Moderate co-expression of EGLN3 and HIF1-α protein was 
also observed in the other lines. Although across these 8 lines I did not see any 
correlation between EGLN3 and HIF1-α level, this does not automatically imply that 
within a particular line alteration of EGLN3 protein level will not impact upon HIF1-α 
level. 
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Figure 5-10: Western blots of EGLN3 and HIF1-α protein in 8 
melanoma cell lines.  
30 µg protein from each cell line was loaded for detection of EGLN3 and 
HIF1-α proteins. HRP-labelled secondary antibodies were used before the 
result was visualised by VersaDoc system. Actin was used as the protein 
loading control. 
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5.2.2.3 Localization of EGLN3 and HIF1-α  
 
Sub-cellular localisation by immunoflourescent staining of fixed cells was performed 
on the WM266.4 cell line cultured in normoxic conditions (21% oxygen) (Figure 5-11). 
Any HIF1-α located in the nucleus suggests that dimerization with ARNT has 
occurred and that HIF1 transcriptional machinery has been triggered in these cells. 
From the results presented here I show that some HIF1-α protein was located in the 
cytoplasm of WM266.4 cells (the cytoplasm is where HIF1-α is synthesised in cells), 
but most of the HIF1-α is concentrated in the nucleus. EGLN3 protein is 
predominantly cytoplasmic, surrounding the nucleus in a peri-nuclear location, 
suggesting that perhaps EGLN3 may control the amount of HIF1-α protein that 
enters the nucleus. 
 
I showed that EGLN2 protein has a predominantly nuclear location in normoxia-
cultured WM266.4 cells. This tells us that EGLN2 may perhaps be controlling the 
amount of HIF1-α in the nucleus that is available to bind to ARNT. EGLN1 staining is 
not as specific as that of the other EGLNs in WM266.4 cells. The reason for this is 
not clear but is unlikely to be due to poor antibody performance as this antibody has 
proven very specific when staining keratinocytes and other epithelial cell types 
cultured in this laboratory. In WM266.4 cells EGLN1 staining is located throughout 
the entire cell so I cannot surmise a specific subcellular location for the action of 
EGLN1 in these cells. My results highlight how EGLN expression is tissue and cell 
type specific. 
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Figure 5-11: Subcellular localisation of HIF1-α, EGLN1, EGLN2 and 
EGLN3. 
Immunofluorescence staining showing the subcellular localisation of HIF1-α 
(A), EGLN3 (B), EGLN1 (C), and EGLN2 (D) in melanoma cell line 
WM266.4. DAPI staining showed the localisation of the nuclei of the cell 
populations. Negative control, in which the cell line was incubated with Alexa 
Fluor 594 dye antibody diluent without the primary antibody, was used  to 
rule out the non-specific staining. 
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5.2.2.4 Exploring the hypoxic pathway in WM266.4 cells  
 
To determine the extent, if any, of the impact of partially methylated EGLN3 in the 
hypoxic response of WM266.4 cells, they were cultured in hypoxia and various 
parameters of the hypoxia pathway were assessed. According to the literature, 
EGLN1 and EGLN3 are hypoxia responsive at the mRNA level (Pescador et al. 
2005). I observed a 2.7 fold increase in EGLN1 mRNA expression after 18 hours 
treatment with 1% oxygen and a corresponding and impressive 25.5 fold increase in 
EGLN3 mRNA expression by qPCR (Figure 5-12 A and C). EGLN2 mRNA levels do 
not alter in most systems in hypoxia and the 0.4 fold decrease we see in EGLN2 
mRNA expression is consistent with these previous studies (Figure 5-12 B). EGLN 
mRNA patterns are not entirely reflected by changes at the protein level suggesting 
that post translational events are a feature of EGLN protein expression (Figure 5-12 
E). At the protein level there was a sustained increase in EGLN1 and a transient 
increase, peaking after 8 hours of 1% oxygen treatment, for both EGLN2 and EGLN3 
protein. An increase in EGLN protein expression in hypoxia may appear somewhat 
counter intuitive since oxygen is required for EGLN hydroxylation activity. However it 
has been suggested that EGLN protein levels and activity may increase in chronic 
hypoxic conditions as intracellular oxygen is released due to inhibition of 
mitochondria activity to decrease levels of HIF1-α to ensure cell survival (Ginouves 
et al. 2008). 
 
I also measured levels of VEGF protein by ELISA. VEGF is a classical downstream 
target of HIF1-α transcription, and I showed a steady increase in VEGF protein 
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throughout the hypoxic period suggesting that the HIF pathway is intact and 
functioning appropriately in this cell type (Figure 5-12 D). 
 
The overall increase in levels of EGLN mRNA and protein detected when WM266.4 
cells are cultured in hypoxic conditions suggests that partial methylation of EGLN3 in 
these cells does not block up-regulation in hypoxia. As such, partial methylation may 
affect a HIF1-α independent function of EGLN3, if it has any effect at all.  
 
 
5.2.2.5 EGLN3 knock down by siRNA 
 
We cannot rule out the possibility that EGLN3 may be involved in a HIF1-α 
independent pathway in melanoma cell lines. To address this function of EGLN3, I 
used siRNA to knock down EGLN3 expression in WM266.4 and LM2 lines (Figure 5-
13). EGLN3 was successfully silenced at both mRNA (100%) and protein levels at 
72 hour and 96 hour time points in cell line WM266.4. In cell line LM2, despite a 
dramatic reduction in reduced EGLN3 RNA (80%), EGLN3 protein levels did not 
change at these time points, suggesting non transcriptional mechanisms may 
stabilise EGLN3 protein levels in this cell line. 
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Figure 5-12: Measurement of hypoxic response of WM266.4 cells. 
 (A, B, C): mRNA expression of EGLN1, EGLN2 and EGLN3 in WM266.4 cell 
line under hypoxic time course. (D): Production of VEGF in WM266.4 cell line in 
hypoxia time course. (E): Protein expression of EGLN1, EGLN2, and EGLN3 by 
western blots, actin was also loaded as internal control.  
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Figure 5-13: EGLN3 knock down in WM266.4 and LM2 by siRNA.  
(A, B): qPCR analysis detecting EGLN3 gene expression after EGLN3 siRNA 
treatment. Untreated cells were used as negative control. Transfection reagent 
treated cells were also used as mock control to rule out the false effect caused by 
the transfection reagents. Expression of EGLN3 was relative to endogenous control 
B2M. (C): Protein expression of EGLN3 in negative control, mock control and 
EGLN3 siRNA treated cells.   
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5.2.2.6 EGLN3 knock down does not affect the HIF1-α pathway 
 
EGLN1 and EGLN2 protein expresion was measured in WM266.4 cells in normoxia 
after EGLN3 knock down, in order to determine if silencing EGLN3 leads to a 
compensatory increase in other proteins (Figure 5-14). However, there were no 
compensatory increase of EGLN1 or EGLN2 after knock down of EGLN3. I futher 
confirmed the lack of impact of silencing EGLN3 on HIF signaling by showing 
sustained production of VEGF, which is a classical HIF1-α responsive target. 
Together, these data suggest that silencing of EGLN3 protein does not impact upon 
the activity of the whole pathway, and that EGLN3 may have functions other than 
determination of response to hypoxia in WM266.4. 
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Figure 5 -14: EGLN3 knock down does not interfere the HIF1-α pathway.  
(A): Western blots detecting EGLN1 and EGLN2 expression with or without 
EGLN3 siRNA transfection after 72 hours and 96 hours of culture. (B): 
Measurement of production of VEGF by VEGF ELISA in WM266.4 with or without 
EGLN3 siRNA transfection after 96 hours of culture. 
 186 | P a g e  
 
5.2.2.7 EGLN3 knock down causes reduction in WM266.4 cell number  
 
To further investigate the possibility of a HIF1-α independent function of EGLN3, I 
assessed the effect of knock down on proliferation. siRNA transfected cell lines 
WM266.4 (Figure 5-15 A) and LM2 (Figure 5-15 B) were seeded at the same density 
and the cell number counted 96 hours post transfection. In cell line WM266.4, with 
silenced EGLN3, there was a 0.4 fold decrease in cell number, compared to the 
negative control and mock control. DMOG, an inhibitor of hydroxylase activity of 
EGLNs failed to alter the cell number, thus suggesting a hydroxylase-independent 
response of EGLN3 in this cell line. There was no alteration of cell number in LM2 
with stabilised EGLN3 protein after siRNA knock down. Identical results were 
observed in multiple repeats of these experiments.  These data indicate that EGLN3 
in WM266.4 cell line may promote proliferation in a HIF1-α independent way. 
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Figure 5-15: Cell counting in WM266.4 and LM2 cell lines.  
(A, B): WM266.4 and LM2 cell lines were grown in different groups at the same 
starting density, including negative control (without treatment), mock control 
(transfection reagent treatment), DMOG treatment (inhibitor of hydroxylase activity of 
EGLNs), and EGLN3 siRNA treatment. Cell number of each group under different 
conditions was counted after 48 hours. 
LM2 
 
C
e
ll 
n
u
m
b
er
/ 
w
el
l 
B 
 
WM266.4 
 
C
el
l n
u
m
b
er
/ 
w
el
l 
A 
 
 188 | P a g e  
 
5.3 Discussion 
 
5.3.1 Specific C-PHs are transcriptionally silenced by methylation in 
melanoma 
 
Prolyl hydroxylases are fundamental components of molecular and metabolic 
signalling that regulate the biological activity of many essential proteins. Collagen 
and HIF are well known substrates of the collagen prolyl hydroxylases and HIF prolyl 
hydroxylases, respectively. Here I demonstrate methylation-dependent 
transcriptional silencing of both collagen and HIF prolyl hydroxylase members in 
melanoma, implying that these enzymes may be important melanoma suppressors.  
 
In this chapter I present data showing that P4HA3 is a potential novel epigenetic 
biomarker of melanoma progression and metastasis. P4HA3 satisfies all the 
eligibility criteria for biomarkers that I have already discussed in Chapter 3. To briefly 
summarise:  
(i) I have shown a good correlation between P4HA3 methylation and melanoma by 
demonstrating that P4HA3 CpG island methylation occurs at a high frequency and 
density in melanoma cell lines and melanoma clinical samples, compared to a 
generally low level of P4HA3 methylation in melanocytes and benign naevi.  
(ii) A correlation of methylation with disease progression was strongly implied by the 
demonstration that P4HA3 methylation quantitatively increased in the metastases of 
paired melanoma cell lines and paired melanoma tissues. Specifically, I have shown 
increased P4HA3 methylation in 2/3 metastatic lines in the paired melanoma cell 
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lines, and a significantly higher level of P4HA3 CpG island methylation in clinical 
metastases relative to paired primary melanomas from which they derived.  
 (iii) Finally, I demonstrated a significant inverse correlation between P4HA3 
methylation and gene expression, suggesting that P4HA3 expression is subject to 
transcriptional regulation by DNA methylation and may be mechanistically relevant to 
tumour progression and development of metastasis. These data support the 
candidacy of P4HA3 methylation as a predictor of melanoma progression, implying 
that P4HA3 has significant potential as a prognostic melanoma biomarker.  
 
I went on to examine P4HA3 methylation in melanoma patients’ serum and observed 
significantly higher levels of detectable P4HA3 methylated DNA in sera from 
melanoma patients with metastasis (n=44) than from those with no evidence of 
metastatic disease (n=23) (Figure 5-7 A). Importantly, with a methylation cut-off of 
5%, P4HA3 methylation showed a relatively high sensitivity (56%) and specificity 
(71%) for detection of metastatic disease. Risk analysis also confirmed a statistically 
significant association between P4HA3 methylation and melanoma metastasis. It is 
also noteworthy that detection of P4HA3 methylated DNA in serum may correlate 
with the classic diagnostic parameter of Breslow thickness from non-metastatic 
melanomas, as methylation was detected in only 1/15 samples from low risk 
melanoma (with a Breslow thickness less than 2 mm) and the other 3 methylated 
positive cases were from patients with higher risk melanomas (Breslow thickness > 
3mm). Taken together, these data support methylated P4HA3 DNA as a novel 
epigenetic serum biomarker for melanoma. To test whether detection of P4HA3 
methylation in non-metastatic melanoma patients’ serum is predictive for poor 
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outcome, it will be necessary to undertake prospective studies in large patient 
cohorts involving the full clinical range of melanomas and these studies are now 
commencing. 
 
The methylation status of other C-PHs in melanoma cell lines and patient materials 
was also analysed. LEPREL1, LEPREL2 and P4HA2 were all methylated in a 
smaller number of melanoma cell lines compared to P4HA3 and methylation of 
LEPREL1 and LEPREL2 correlated well with reduced gene expression. P4HA1 
methylation was undetectable in any melanoma cell line tested. P4HA1 and P4HA2 
have been recently proposed as oncogenes in breast cancer by Gilkes et al. and 
both genes were shown to have prognostic utility in breast cancer (Gilkes et al. 
2013). In our melanoma study, interestingly, P4HA2 was still expressed at a 
reasonable level in cell lines SKMEL23 and SKMEL30 in which CpG island 
methylation is detectable suggesting that CpG island methylation was not a 
transcriptional regulatory mechanism for P4HA2. Likewise, undetectable methylation 
of P4HA1 raises the question of the utility of P4HA1 and P4HA2 as epigenetic 
biomarker in melanoma.  
 
In the subsequent investigation of LEPREL1 CpG island methylation in a panel of 
melanoma tissues, I observed only moderate levels of methylation in the LEPREL1 
CpG island but with significantly increased LEPREL1 methylation in melanomas 
relative to control benign pigmented naevi. However despite detection in melanoma 
tissue, methylated LEPREL1 genomic DNA was only rarely detectable in serum from 
melanoma patients. One possible reason that contributes to the lack of detectable 
methylated LEPREL1 DNA but readily detectable methylated P4HA3 DNA in 
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melanoma patients’ serum is the different levels of LEPREL1 and P4HA3 CpG island 
methylation in melanoma tissues. DNA from melanoma released into the circulating 
blood is diluted by normal tissue DNA. DNA with LEPREL1 methylation at a general 
low level in melanomas (mean methylation < 10%) may become undetectable after 
being released into the blood. In contrast, the higher level of P4HA3 methylation 
seen in melanoma tissue may remain detectable in serum by pyrosequencing. 
Another potential explanation is the distinct functions of the two genes. The 
metastasis cascade is a complicated and dynamic progress. Methylated P4HA3 but 
not methylated LEPREL1 may be more functionally relevant for metastasis.  
 
In conclusion, I have identified methylation-dependent transcriptional silencing of C-
PHs in melanoma cell lines and melanoma tissues, including a particular highlighted 
epigenetic biomarker P4HA3 whose methylation correlates with melanoma 
progression and metastasis. Importantly, P4HA3 is a robust serum biomarker for 
detection of metastatic melanoma. In future work, the candidacy of P4HA3 
methylated DNA will be rigorously tested in large, prospectively collected serum 
samples from melanoma patients in multiple independent centres. 
 
5.3.2 EGLN3 methylation and involvement of EGLN3 in HIF1-α 
independent pathway in melanoma 
 
Cancer cells are frequently starved of oxygen during tumour development and 
progression (Harris 2002). This is because tumour cell demand for oxygen often 
outstrips the amount of oxygen that can be supplied from normal tissue vasculature, 
due to the rapid growth and cell division rates of many tumour cells. This problem is 
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frequently exacerbated in larger tumours that are supported by their own vasculature. 
Tumour vasculature is often unable to deliver appropriate amounts of oxygen owing 
to the faulty and abnormal nature of the vascular structures that develop during 
tumorigenesis (Nagy et al. 2009; Fukumura et al. 2010). The result of tumour growth 
in low oxygen conditions is stabilisation of HIF1-α protein and subsequent activation 
of many HIF1 target genes including those involved in regulation of tumour 
behaviour, for example senescence, apoptosis or angiogenesis. In melanoma, a role 
for increased HIF1-α expression has been established in both transformation of 
melanocytes and in the progression or metastasis of melanoma (Bedogni et al. 2005; 
Mills et al. 2009), as has a role for various downstream effectors of HIF1-α such as 
VEGF (Rofstad and Danielsen 1999). It is, however, important to appreciate that a 
hypoxic microenvironment will result in heterogeneous changes within the population 
of melanoma cells (Widmer et al. 2013) and we clearly see this from looking at HIF1-
α expression in our paired primary and metastatic melanoma lines (Figure 5-9). 
Increased HIF1-α may drive tumour progression in some melanomas, but changes in 
other genes may be responsible for metastatic progression in others. It must also be 
borne in mind that some genetic and epigenetic changes in our melanoma cell lines 
may result from the techniques used to isolate and culture these cells. 
 
EGLN proteins catalyse the addition of hydroxyl groups to specific proline residues in 
the HIF1-α protein. This reaction ensures recognition of the hydroxylated HIF1-α by 
proteosomal enzymes such that HIF1-α is degraded and is non-functional. The level 
of HIF1-α is tightly regulated and, as mentioned previously HIF1-α levels are 
regulated through multiple mechanisms. In addition to regulation of the hypoxia 
pathway at the level of HIF1-α, we also see control at the level of the EGLN proteins. 
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Several pathways are known to control the level of EGLN proteins. EGLNs 1 and 3 
are regulated by a closely related protein, Siah2 (Qi et al. 2008; Nakayama et al. 
2009). Siah2 proteins target both EGLN1 and EGLN3 proteins for ubiquitination and 
degradation by the proteosomal route. In melanoma, regulation of EGLN3 by Siah-2 
was reported previously and shown to occur through both HIF1-α dependent and 
HIF1-α independent pathways (Qi et al. 2008). Additionally, EGLN proteins can be 
regulated by metabolic processes. Cancer cells frequently alter metabolism to favour 
anaerobic metabolic pathways. Increased glycolysis via the Krebs cycle produces 
succinate and fumarate, both of which inhibit EGLN activity (Selak et al. 2005).  It is 
also appreciated that EGLN gene expression can be silenced by methylation. In this 
study, I have detected partial EGLN3 methylation in one of eight melanoma cell lines 
and this methylation correlates with a low level of mRNA and protein expression. 
 
In this investigation, I have obtained some preliminary evidence for a HIF1-α 
independent role of EGLN3, as evidenced from cell counts obtained after knockdown 
of EGLN3. Several HIF1-α independent roles for EGLN3 have been described. 
These include a description of EGLN3 as a tumour suppressor by the inhibition of 
tumour progression and induction of angiogenesis in glioma and pancreatic cancer 
(Su et al. 2010; Sciorra et al. 2012), and reports of EGLN3 functioning as an anti-
apoptotic protein in non-small cell lung cancer (Chen et al. 2011). Additionally, 
EGLN3 has also been shown to be responsible for promoting cell cycle transition in 
head and neck squamous cell carcinoma (Hogel et al. 2011).  However, we can only 
speculate as to the function of the HIF1-α- independent EGLN3 signalling in our 
melanoma cells as further investigation was beyond the scope of this thesis. 
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The use of siRNA enabled silencing of EGLN3 mRNA and protein in the WM266.4 
cell line. In the LM2 cell line, knock down of EGLN3 mRNA levels did not cause 
commensurate reduction in EGLN3 protein expression. The reason for this 
difference is unclear since the level of EGLN3 protein expression was similarly low in 
both of these lines. Perhaps HIF1-α signalling is impaired in one of these lines, 
however we showed that WM266.4 underwent a normal hypoxic response by 
displaying a classical induction of EGLNs and VEGF in response to hypoxia. 
Alternatively it may be that EGLN3 protein is differentially regulated between the two 
cell lines resulting in a protein with a longer half-life in LM2 cells.  
 
There was more efficient knockdown of EGLN3 mRNA in WM266.4 than LM2, and 
this could have been significant for protein expression. In WM266.4 with EGLN3 
silenced at both mRNA and protein level by siRNA, I showed that the response to 
hypoxia was not impaired, as there was no compensatory increase in either EGLN1 
or EGLN2 proteins and no alteration in the amount of VEGF produced as a result of 
hypoxic challenge. However, the selective pressure(s) favouring EGLN3 methylation 
in WM266.4 is still not clear. I had hypothesized that EGLN3 may be important for  
inducing apoptosis and had assumed that in reducing EGLN3 expression I would 
see a reduction in apoptotic activity accompanied perhaps by an increase in cell 
viability and that this may be the consequence of methylation of EGLN3 in WM266.4 
cells. However, unexpectedly the opposite was observed when EGLN3 was knocked 
out in WM266.4 cells. A link between EGLN3 and the Krebs cycle is established 
(Selak et al. 2005); it is known that EGLN3 catalyses the conversion of α-
ketoglutarate to succinate. When EGLN3 is totally silenced this reaction may not 
occur and α-ketoglutarate levels may build up in the cells. Accumulation of α-
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ketoglutarate has been shown to inhibit G1 to S phase transition in the cell cycle 
(Hogel et al. 2011) and is a possible explanation as to why we see a decreased cell 
number after silencing EGLN3 in WM266.4 cells. This hypothesis assumes that the 
low level of EGLN3 protein in our partially methylated WM266.4 cells was sufficient 
to allow some conversion of α-ketoglutarate to succinate to ensure faster 
progression through the cell cycle. 
 
In future studies I would wish to examine the effects of EGLN3 overexpression and 
to investigate the effects of EGLN3 expression on cell viability in melanoma cells. It 
may be that levels of EGLN3 are critical within a specific range above which we see 
induction of apoptosis and below which we see slower progression through the cell 
cycle. 
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Chapter 6 Conclusions and 
Future Perspectives 
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6.1 Conclusions 
 
Melanoma is a highly aggressive and lethal skin cancer with an increasing 
incidence in Caucasian populations. Genetic and epigenetic alterations 
collaboratively facilitate the malignant transformation from benign naevus to 
melanoma, and subsequently to development of local or distal metastasis. As a 
hallmark of cancer, metastasis is a major determinant of cancer patient outcome 
(Hanahan and Weinberg 2011). Although the majority of patients with low risk 
melanomas are cured by surgical excision of the primary lesions, the outcome for 
melanoma patients with metastatic disease (particularly at visceral and/or central 
nervous system sites) remains very poor (Balch et al. 2009). New agents 
including vemurafenib and ipilimumab have significantly benefited patients with 
advanced melanoma (Flaherty et al. 2010; Hodi et al. 2010; Chapman et al. 2011; 
Robert et al. 2011). However, the two treatments are least effective when they 
are used at late stage, large volume disease when tumour load is high and 
patient performance status typically poor. Indeed, there is clear evidence that 
ipilimumab is far more effective in stage M1a and M1b disease than in M1c 
(disseminated melanoma) (Hodi et al. 2010). New strategies for the early 
detection of sub-clinical relapsed and/or metastatic disease, such as sensitive 
and specific serum biomarkers would allow the introduction of these treatments 
when tumour load is low thereby creating a therapeutic window in which there is 
sufficient time for the patient to mount an effective anti-melanoma response. 
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Recently, methylation-dependent silencing of tumour-related genes has emerged 
as a frequent molecular genetic feature of cancer with specific signatures 
associating with defined clinico-pathological disease states (Sandoval and 
Esteller 2012). This highlights the potential clinical utility of assessing DNA 
methylation to measure tumour progression or to predict treatment response and 
patient outcome. Increased amounts of methylated DNA present in the circulating 
blood of cancer patients has made it a very attractive target for the detection of 
metastatic disease by a simple blood test. In this work, I have used different gene 
finding strategies with the goal of assembling a panel of serum epigenetic 
biomarkers with clinical potential for detecting metastatic melanoma. These gene 
finding strategies included both a systematic approach and a candidate gene 
approach and they have allowed me to identify a number of novel epigenetically 
dysregulated genes in melanoma. The systematic approach used unbiased, 
microarray-based methodology to screen selected melanoma cell lines, including: 
(i) A pharmacological methylation reversal screen of 5 random melanoma cell 
lines (preliminary data provided by Dr Tim Crook) to identify a number of genes 
that are potentially methylated in melanomas, including some candidates that are 
involved in cancer-related signalling such as the TGF-β pathway and the WNT 
pathway (section 3.2.1). In the validation of selected candidates, a role for TFPI2 
as an epigenetic biomarker was identified and TFPI2 was shown to have 
potential clinical utility in predicting melanoma progression and detection of 
metastasis.  
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(ii) An integrative analysis of genome-wide methylation profiling and expression 
profiling to identify additional candidate genes that are differentially regulated by 
DNA methylation between primary melanoma cell lines and their metastatic 
derivatives. Rigorous data mining analysis ultimately selected 7 candidate genes 
for further validation, including immunity-related gene HLA-DP1 (Pryds et al. 
1987),  RAS inhibitor RASAL1 (Bernards and Settleman 2009) and MT1E that are 
known to methylated in human cancers (Faller et al. 2010; Noetzel et al. 2010),  
tumour related gene EFNB2 (Vogt et al. 1998; Liu et al. 2004; Tachibana et al. 
2007), and LIMCH1, TCEA3 and FAM134B which are entirely novel. The 
potential of these genes as melanoma biomarkers is needed to be further 
investigated. 
 
The candidate gene approach identified additional genes of interest. Specifically, 
I have shown that NT5E and DUSP2 are biomarkers prognostic of good outcome 
when they are methylated in melanoma. Conversely, P4HA3 has been shown to 
be a biomarker of poor prognosis and advanced melanoma when methylated in 
melanoma tissues or serum. 
 
Taken together, my work has identified several promising epigenetic biomarkers 
whose methylation positively (TFPI2 and P4HA3) or negatively (NT5E and 
DUSP2) correlates with melanoma progression. A high frequency and high level 
of TFPI2 and P4HA3 methylation in melanoma cell lines and clinical tissues 
 200 | P a g e  
 
compared to an absent or low level in normal melanocytes or benign naevi 
suggests that methylation of these two genes forms a specific signature of 
malignant melanoma. My data suggests also that these two genes may be 
mechanistically relevant not only to melanomagenesis but also to progression 
from primary to metastatic disease. The significantly increased level of TFPI2 
and P4HA3 CpG island methylation in aggressive metastatic disease suggests a 
role for TFPI2 and P4HA3 as epigenetic biomarkers that can potentially predict 
poor prognosis of melanoma. Furthermore, in my work a highly sensitive and 
specific correlation between methylation of TFPI2/P4HA3 in melanoma patients’ 
sera and metastatic disease has been established, implying potential clinical 
utility for TFPI2 and P4HA3 as serum biomarkers for the detection of metastatic 
melanoma. Validation of these two biomarkers in a larger collection of melanoma 
patient blood samples would establish the clinical significance of TFPI2, or 
P4HA3, or the combination of TFPI2 and P4HA3 as serum biomarkers for 
metastatic melanoma. Such validation in large, multi centre studies would 
strongly encourage the routine use of these two genes, together with additional 
markers identified in parallel studies, as part of the routine clinical follow up of 
melanoma patients. The use of protein tumour markers in oncology follow up 
clinics is well-established, for example CEA in colorectal cancer (Banaszkiewicz 
et al. 2011) and CA125 in epithelial ovarian cancer (Song et al. 2013), but no 
methylation marker has yet entered routine clinical use as a diagnostic or 
predictive tumour marker. 
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Methylation investigations in this study have also detected aberrant methylation 
of NT5E and DUSP2 in melanoma cell lines and melanoma tissue materials. 
Despite being methylated in both primary and metastatic melanomas, 
methylation of NT5E appears to be a good prognostic biomarker of melanoma 
because NT5E methylation was associated with early stage of melanoma and 
became undetectable when melanoma metastasis progressed to visceral sites. 
Similarly, the significantly higher methylation level of DUSP2 in primary 
melanomas than in metastasis implies that DUSP2 methylation may also be a 
biomarker for good prognostic in melanoma. However, the sample number used 
in the DUSP2 investigation is small and would need to be confirmed in a larger 
study. The stage specificity in distribution of methylation in NT5E and DUSP2 
suggests that these two genes may be involved in initiation of melanomagenesis. 
These genes may then exploit the dynamic reversibility of DNA methylation to 
switch on gene expression to promote the metastatic progression of melanoma. 
Such bimodal methylation may be common in the natural history of an individual 
cancer and illustrates how epigenetics allows changes in expression of genes as 
cancers evolve phenotypically.   
 
In summary, my study proposes that epigenetic dysregulation by CpG island 
methylation of tumour-related genes TFPI2, P4HA3, NT5E and DUSP2 is 
important in melanoma development and progression and that detection of 
methylated DNA from these genes may provide novel biomarkers for assessing 
tumour progression and patient outcome. Molecular functions of these 
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biomarkers in melanoma should be investigated in future work for the purpose of 
better understanding the biology of this highly aggressive tumour. Such studies 
may also lead to new therapeutic strategies for advanced melanoma. Moreover, 
detection of circulating methylated TFPI2 and P4HA3 from patient’s sera may be 
useful for predicting prognosis and in the early diagnosis of metastatic disease. 
Given the emerging clinical evidence that new melanoma therapeutics, 
particularly ipilimumab, are most effective when deployed in low volume 
metastatic disease, such epigenetic biomarkers are likely to be of value in 
informing the initiation of such agents. 
. 
6.2 Future perspectives 
 
6.2.1 Serum epigenetic biomarkers for detection of metastatic 
disease 
 
The primary aim of this study is to build up a portfolio of epigenetic serum 
biomarkers for the early detection of metastatic disease. My preliminary work has 
shown that TFPI2 and P4HA3 are potential serum epigenetic biomarkers and 
methylation of TFPI2 or P4HA3 in melanoma patients’ sera significantly 
correlates with metastatic disease. Prospective validation in large clinical cohorts 
of these two biomarkers and the new biomarkers I have identified in preliminary 
form by genome-wide methylation screen, is now a priority. Such studies are 
already underway on Tayside. Prospective study is a more appropriate for 
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rigorous validation because melanoma patients enrolled in any prospective study 
can be closely monitored for their outcome and sera are collected, processed 
and stored according to pre-defined protocols and at regular intervals at clinical 
review. There is also less potential for bias in sample selection in prospective 
studies. 
 
Circulating methylated DNA levels will increase in metastasis because increased 
number of tumour cells intravasated into blood vessels undergo necrosis or 
apoptosis and release their DNA into the circulation (Weinberg 2006). Any 
analytical technique with high sensitivity and accuracy such as pyrosequencing is 
applicable for the measurement of these biomarkers in sera, and pyrosequencing 
has provided promising results in this study by revealing methylation of TFPI2 
and P4HA3 in melanoma patients’ sera that correlates with metastatic melanoma. 
All potential diagnostic tests must satisfy criteria of cost-effectiveness in addition 
to sensitivity and specificity. One great advantage of using methylated DNA is 
that its detection is amenable to automation and pyrosequencing, as evidenced 
by the data I present in this thesis, is clearly both sensitive and specific. 
Automation of the assays would undoubtedly improve cost effectiveness. I 
suspect that the definitive serum test for routine clinical use will require a panel of 
biomarkers because a combination of biomarkers is more likely to reach 
sufficient sensitivity and specificity to minimize false negative and false positive 
results. Regarding the optimal application of these biomarkers in routine clinical 
practice, at least two further issues need to be addressed: 
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(i) Is crossing of a threshold level or an increasing level of DNA 
methylation in biomarker genes (or both) required to provide sufficient 
evidence of recurrent/ metastatic disease? To answer this question, it 
will be necessary to rigorously determine either a threshold level of 
methylation or an increased level of DNA methylation for clinical 
surveillance of high-risk patients. Use of such parameters enables 
stratification of melanoma patients into a low risk group, an 
intermediate risk group, and a high risk group. An increase in DNA 
methylation adds risk to tumour progression, therefore, high risk 
melanoma patients defined by such a biomarker test should be 
considered for treatment applicable to metastatic disease. The low 
concentration of DNA present in patients’ sera makes it a challenging 
task to determine the appropriate threshold level/increase level. Using 
a higher DNA methylation threshold level/increase level will improve 
the specificity and reduce the sensitivity, whilst use of lower value will 
improve the sensitivity and reduce the specificity of any employed test. 
Therefore, adjustment of two parameters should be undertaken by 
rigorous statistical analysis in a prospective study. It may also be 
helpful to take multiple blood samples from each patient for the 
purpose of ruling out inconsistencies of DNA methylation from given 
blood samples. A further consideration is whether increasing levels of 
DNA methylation on serial examination of blood samples from the 
same individual is more important for prognosis/outcome than the 
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absolute level of DNA methylation achieved. Only large prospective 
investigation will be able to resolve this question. 
 
(ii) Combination of biomarkers for batch examination. As argued above, a 
panel of biomarkers will be required in order to optimise the clinical 
sensitivity and specificity. Metastatic melanoma is a heterogeneous 
disease and so it is very unlikely that DNA methylation will be present 
in all chosen biomarkers. Whether the final biomarker assay requires 
methylation in certain key biomarkers or if methylation in any 
proportion of the biomarkers is an acceptable indicator of recurrence / 
metastasis can only be answered by prospective validation of 
candidate panels of genes. 
 
Though such rigorous testing may be time consuming, successful establishment 
of a portfolio of serum epigenetic biomarkers will significantly benefit melanoma 
patients by allowing early detection of sub-clinical metastatic disease and 
informing both the initiation and possibly the form (targeted therapy or 
immunomodulatory therapy) of therapeutic intervention. 
 
6.2.2 Epigenetic biomarkers in melanoma tissues 
 
Detection of the aberrant methylation of informative biomarkers not only offers 
the opportunity for early detection of relapsed disease in biofluids but may also 
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afford prognostic value in biopsy specimens. Methylated genes in cancer tissues 
may show better sensitivity as biomarkers due to the high concentration of 
tumour DNA present in the tumour tissue. Furthermore, use of methylated DNA 
as a biomarker may enhance the sensitivity and clinical utility of existing 
modalities, such as sentinel lymph node biopsy (SLNB). One of the major 
limitations of current SLNB protocols is that there is no way to predict from an 
individual positive SLNB the risk of future visceral metastatic disease (and death). 
A subset of patients with positive SLNB are cured by this procedure whereas a 
further subset will ultimately relapse and die from visceral and/or central nervous 
system metastasis. The ability to predict from epigenetic analysis of positive 
sentinel nodes the probability of such life-threatening events would be 
enormously valuable in informing the use of adjuvant therapies post SLNB and in 
identifying the group of patients in whom there is a high risk of metastatic relapse. 
Such patients could then be managed by close clinical follow up (potentially 
including the use of validated serum epigenetic biomarkers) in order to detect 
relapse as early as possible. This subset of patients would also be considered for 
appropriate adjuvant therapy. Conversely, patients whose SLNB epigenetic 
profile indicates a low risk of future visceral/ CNS disease can continue to be 
monitored with low intensity follow-up, reassured about the low risk of recurrence 
and spared the likely side effects of adjuvant therapies (for example the auto-
immune toxicities of ipilimumab).  
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6.2.3 Epigenetic candidates as new therapeutic targets 
 
Data presented within this thesis demonstrate that promoter methylation of TFPI2 
and P4HA3 correlates with poor prognosis, while promoter methylation of NT5E 
and DUSP2 correlates with a good prognosis of melanoma. These results have 
implications for therapeutic strategies aimed at reactivation of transcriptionally 
silenced genes. Global demethylating agents such as 5’-azacytidine and 5’-aza-
2-deoxycytidine show remarkable efficacy in the treatment of haematopoietic 
malignancies (Kantarjian et al. 2007), but may not be suitable for melanoma due 
to the epigenetic heterogeneity of melanoma and, as illustrated by my work, 
dynamic changes in methylation even within a single gene during the natural 
history of an individual patient’s disease. However, it is not unreasonable to 
hypothesise that metastatic melanoma with specific combinations of 
transcriptionally silenced genes such as TFPI2 or P4HA3 might be amenable to 
demethylating agents. In other solid tumours such as non-small cell lung cancer, 
disappointment at initial clinical results with 5’ azacytidine has been replaced with 
optimism that appropriately dosed demethylating agents can show meaningful 
efficacy and acceptable toxicity in some patients, even with large volume 
metastatic disease. The key will be to identify the profile(s) of methylated genes 
which confer individual cancer sensitivity to demethylation. Such studies would 
be of immense interest in melanoma. Inhibitors of NT5E are available and my 
work in this thesis implies that these could be of value in metastatic melanoma in 
which there is over-expression of NT5E. Studies of therapeutic antibodies to 
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NT5E have shown promise in mouse models of cancer (Stagg et al. 2010; Stagg 
et al. 2012) and my data suggests that these merit detailed study as potential 
melanoma therapeutics, particularly given the apparent importance of this protein 
in metastatic disease. 
6.2.4 Summary 
 
The epigenetic biomarkers identified and investigated in this study offer potential 
utility in the early diagnosis of metastatic melanoma via detection of methylated 
DNA in patient serum. The biomarkers may also have prognostic utility in both 
primary and SLNB tissues. Validation of these first generation candidates in large, 
well-annotated patient cohorts is now beginning. Confirmation of my initial data in 
these large scale studies and similar development of the additional candidate 
genes identified in my later work in this thesis will support their introduction into 
the routine clinical management of melanoma and encourage yet further studies 
to determine their utility in informing the adjuvant use of current and emerging 
therapeutics in melanoma. 
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